<?xml version="1.0" encoding="UTF-8" standalone="yes"?><Rowset rowCount='750'><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="3492">levofloxacin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Efficacy and Safety of Modified Anti-tubercular Regimens in Treatment of Tuberculosis in Patients With Underlying Compensated and Decompensated Chronic Liver Disease</ProtocolTitle><Sponsor>Institute of Liver and Biliary Sciences, India</Sponsor><StudyType>Interventional</StudyType><Trial id="90788"/><TrialStartDate>2012-09-30 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="3492">levofloxacin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>TB-TRUST</ProtocolAcronym><ProtocolTitle>Refining MDR-TB Treatment Regimens for Ultra Short Therapy</ProtocolTitle><Sponsor>Huashan Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="372676"/><TrialStartDate>2019-05-01 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="3492">levofloxacin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>InDEX</ProtocolAcronym><ProtocolTitle>The Individualized M(X) Drug-resistant TB Treatment Strategy Study</ProtocolTitle><Sponsor>Centre for the AIDS Program of Research in South Africa</Sponsor><StudyType>Interventional</StudyType><Trial id="307654"/><TrialStartDate>2017-06-14 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="3492">levofloxacin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>NEXT</ProtocolAcronym><ProtocolTitle>An Open-label RCT to Evaluate a New Treatment Regimen for Patients With Multidrug-resistant Tuberculosis</ProtocolTitle><Sponsor>University of Cape Town</Sponsor><StudyType>Interventional</StudyType><Trial id="230529"/><TrialStartDate>2015-10-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="3492">levofloxacin</Drug><Endpoint>Bioequivalence,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Study to assess the bioequivalence of two oral formulations of levofloxacin tablets: FLEVOX (SERRAL, SA de CV), versus TAVANIC (Sanofi-Aventis of Mexico, SA de CV), after administration of a single dose- 500 mg to healthy adult subjects of both genders, in the fasting state</ProtocolTitle><Sponsor>Laboratorios Serral</Sponsor><StudyType>Interventional</StudyType><Trial id="227604"/><TrialStartDate/><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="4229">rifabutin</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>TMC-207 +/- Rifabutin/Rifampin</ProtocolTitle><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><StudyType>Interventional</StudyType><Trial id="76765"/><TrialStartDate>2011-10-21 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Drug id="4229">rifabutin</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>APT</ProtocolAcronym><ProtocolTitle>Assessing PA-824 for Tuberculosis</ProtocolTitle><Sponsor>Johns Hopkins Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="213394"/><TrialStartDate>2015-04-29 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>5</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="4229">rifabutin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>BBA</ProtocolAcronym><ProtocolTitle>Brief Bactericidal Activity of Anti-Tuberculosis Drugs</ProtocolTitle><Sponsor>Centers for Disease Control and Prevention</Sponsor><StudyType>Interventional</StudyType><Trial id="210083"/><TrialStartDate>2015-11-30 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="4229">rifabutin</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>USPHS-23</ProtocolAcronym><ProtocolTitle>Intensive Pharmacokinetics of the Nelfinavir-Rifabutin Interaction in Patients With HIV-Related Tuberculosis Treated With a Rifabutin-Based Regimen</ProtocolTitle><Sponsor>National Institutes of Health</Sponsor><StudyType>Interventional</StudyType><Trial id="10648"/><TrialStartDate>2001-07-02 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="9490">MTB72F vaccine (tuberculosis), GSK/ IAVI</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Safety and Immunogenicity of a Candidate Tuberculosis Vaccine in Healthy HIV Negative Adolescents</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="59304"/><TrialStartDate>2009-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="9490">MTB72F vaccine (tuberculosis), GSK/ IAVI</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine Given to PPD-Negative Adults</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="23067"/><TrialStartDate>2004-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="9490">MTB72F vaccine (tuberculosis), GSK/ IAVI</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Safety and Immunogenicity Study of GSK Biologicals Tuberculosis Vaccines (692342) in Healthy Adults</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="11263"/><TrialStartDate>2008-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="11088">sutezolid</Drug><Endpoint>Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>PK and Bactericidal Activity in Sputum and Blood of PNU-100480 (Sutezolid, U-480) and its Major Metabolite (PNU-101603, U-603) in Patients with Pulmonary TB</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="128346"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Rifapentine-containing tuberculosis treatment shortening regimens (S31/A5349)</ProtocolTitle><Sponsor>Centers for Disease Control and Prevention</Sponsor><StudyType>Interventional</StudyType><Trial id="347338"/><TrialStartDate>2018-07-20 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Multicenter, controlled clinical study of the safety, tolerability and efficacy of clofazimine in the treatment of drug-resistant tuberculosis</ProtocolTitle><Sponsor>Beijing Chest Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="328802"/><TrialStartDate>2009-12-01 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><Endpoint>Bioequivalence,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Open-label, randomized, crossover study of the comparative pharmacokinetics and bioequivalence of drugs moxifloxacin film-coated tablets 400 mg (JSC "Synthesis", Russia) and Avelox tablets, film-coated 400 mg (Bayer Pharma AG, Germany) in healthy volunteers on an empty stomach</ProtocolTitle><Sponsor>Joint Stock Company Kurganskoye medicines and medical products" Synthesis</Sponsor><StudyType>Interventional</StudyType><Trial id="255583"/><TrialStartDate>2016-03-04 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Rifapentine-containing Tuberculosis Treatment Shortening Regimens</ProtocolTitle><Sponsor>Centers for Disease Control and Prevention</Sponsor><StudyType>Interventional</StudyType><Trial id="226815"/><TrialStartDate>2016-01-25 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>5</ArmCount><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>TBRU 10</ProtocolAcronym><ProtocolTitle>Early Bactericidal Activity of Linezolid, Gatifloxacin, Levofloxacin, Isoniazid (INH) and Moxifloxacin in HIV Negative Adults With Initial Episodes of Sputum Smear-Positive Pulmonary Tuberculosis</ProtocolTitle><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><StudyType>Interventional</StudyType><Trial id="10869"/><TrialStartDate>2004-02-29 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="13323">pretomanid</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="PR">Pre-registration</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Evaluating the Safety and Drug Interaction of PA-824, an Investigational Tuberculosis Medication, Together With Efavirenz, Ritonavir-Boosted Lopinavir or Rifampin</ProtocolTitle><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><StudyType>Interventional</StudyType><Trial id="86312"/><TrialStartDate>2012-05-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="13323">pretomanid</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="PR">Pre-registration</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Evaluation of 8 Weeks of Treatment With the Combination of Moxifloxacin, PA-824 and Pyrazinamide in Patients With Drug Sensitive and Multi Drug-Resistant Pulmonary Tuberculosis (TB)</ProtocolTitle><Sponsor>TB Alliance</Sponsor><StudyType>Interventional</StudyType><Trial id="83489"/><TrialStartDate>2012-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="13323">pretomanid</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="PR">Pre-registration</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis</ProtocolTitle><Sponsor>TB Alliance</Sponsor><StudyType>Interventional</StudyType><Trial id="59043"/><TrialStartDate>2009-08-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="13323">pretomanid</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="PR">Pre-registration</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Pharmacokinetics and Safety of PA-824 in Subjects With Mild, Moderate, and Severe Hepatic Impairment to Matched, Non-Hepatically Impaired Subjects</ProtocolTitle><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><StudyType>Interventional</StudyType><Trial id="227410"/><TrialStartDate>2017-12-11 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="13323">pretomanid</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="PR">Pre-registration</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>A Phase III Study Assessing the Safety and Efficacy of Bedaquiline Plus PA-824 Plus Linezolid in Subjects With Drug-Resistant Pulmonary Tuberculosis</ProtocolTitle><Sponsor>TB Alliance</Sponsor><StudyType>Interventional</StudyType><Trial id="219499"/><TrialStartDate>2015-03-31 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="15102">rifapentine</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Efficacy of Weekly Rifapentine and Isoniazid for Tuberculosis Prevention</ProtocolTitle><Sponsor>Huashan Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="228560"/><TrialStartDate>2015-03-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="15102">rifapentine</Drug><Endpoint>Safety</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>A Non-randomized, Uncontrolled, Single-group Study of Short-course Isoniazid plus Rifapentine Directly Observed Therapy for Latent Tuberculosis in Solid-organ Transplant Candidates</ProtocolTitle><Sponsor>University of Washington</Sponsor><StudyType>Interventional</StudyType><Trial id="159244"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>5+</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="16545">delamanid</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>endTB-Q</ProtocolAcronym><ProtocolTitle>Evaluating Newly Approved Drugs in Combination Regimens for Multidrug-Resistant TB With Fluoroquinolone Resistance</ProtocolTitle><Sponsor>Médecins Sans Frontières France</Sponsor><StudyType>Interventional</StudyType><Trial id="375499"/><TrialStartDate>2019-06-30 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="16545">delamanid</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>PHOENIx MDR-TB</ProtocolAcronym><ProtocolTitle>Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients</ProtocolTitle><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><StudyType>Interventional</StudyType><Trial id="344335"/><TrialStartDate>2019-06-03 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="17132">pascolizumab</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Safety and Efficacy of Blocking IL-4 With Pascolizumab in Patients Receiving Standard Therapy for Pulmonary Tuberculosis</ProtocolTitle><Sponsor>National University Hospital (Singapore) Pte Ltd, Syneos Health Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="89066"/><TrialStartDate>2012-06-30 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1A">Phase 1a Clinical</DevStatus><Drug id="31010">SQ-109</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>A phase Ia, Placebo-controlled, Dose-Escalating study to test the Safety, Tolerability and Pharmacokinetics of Single dose of SQ-109 in 62 Healthy Subjects</ProtocolTitle><Sponsor>Sequella Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="8945"/><TrialStartDate>2006-09-30 04:46:54</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="31010">SQ-109</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Evaluation of SQ-109, High-dose Rifampicin, and Moxifloxacin in Adults With Smear-positive Pulmonary TB in a MAMS Design</ProtocolTitle><Sponsor>Ludwig-Maximilians University of Munich</Sponsor><StudyType>Interventional</StudyType><Trial id="109063"/><TrialStartDate>2013-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="51310">bedaquiline</Drug><Endpoint>Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>PANDEMIC</ProtocolAcronym><ProtocolTitle>A study on the uptake, distribution and excretion of bedaquiline, a medicine against tuberculosis, in people with type 2 diabetes</ProtocolTitle><Sponsor>University Medical Center Groningen</Sponsor><StudyType>Interventional</StudyType><Trial id="331962"/><TrialStartDate>2018-06-01 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="51310">bedaquiline</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>TB-PRACTECAL</ProtocolAcronym><ProtocolTitle>Pragmatic Clinical Trial for a More Effective Concise and Less Toxic MDR-TB Treatment Regimen(s)</ProtocolTitle><Sponsor>Medecins Sans Frontieres</Sponsor><StudyType>Interventional</StudyType><Trial id="244304"/><TrialStartDate>2017-01-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="55317">MVA-85A</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Safety Study of Tuberculosis Vaccines AERAS-402 and MVA-85A</ProtocolTitle><Sponsor>University of Oxford</Sponsor><StudyType>Interventional</StudyType><Trial id="91280"/><TrialStartDate>2012-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="55317">MVA-85A</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Safety of Tuberculosis Vaccine, MVA-85A, Administered by the Intramuscular Route and the Intradermal Route</ProtocolTitle><Sponsor>University of Oxford</Sponsor><StudyType>Interventional</StudyType><Trial id="69212"/><TrialStartDate>2010-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="55317">MVA-85A</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>A Study of MVA-85A, in Asymptomatic Volunteers Infected With TB, HIV or Both</ProtocolTitle><Sponsor>University of Oxford</Sponsor><StudyType>Interventional</StudyType><Trial id="14589"/><TrialStartDate>2007-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="55317">MVA-85A</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>A Study of two Doses of a New TB Vaccine, MVA85A, in Healthy Volunteers Previously Vaccinated With BCG</ProtocolTitle><Sponsor>University of Oxford</Sponsor><StudyType>Interventional</StudyType><Trial id="10944"/><TrialStartDate>2005-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1B">Phase 1b Clinical</DevStatus><Drug id="55569">VPM-1002</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Dose-Escalation Study on Safety and Immunogenicity of VPM-1-002 in Comparison to BCG in Healthy Volunteers in South Africa</ProtocolTitle><Sponsor>Vakzine Projekt Management GmbH</Sponsor><StudyType>Interventional</StudyType><Trial id="65984"/><TrialStartDate>2010-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry>European Ancestry</Ancestry><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="55569">VPM-1002</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Dose-Escalation Study on Safety and Immunogenicity of VPM-1-002 in Comparison With BCG in Healthy Male Volunteers</ProtocolTitle><Sponsor>Vakzine Projekt Management GmbH</Sponsor><StudyType>Interventional</StudyType><Trial id="48943"/><TrialStartDate>2008-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Drug id="68617">ID93 vaccine (GLA-SE adjuvant, TB), IDRI/ Quratis</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Phase IIa Clinical Trial of ID93 + GLA-SE Vaccine in BCG-vaccinated Healthy Healthcare Workers</ProtocolTitle><Sponsor>Quratis Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="366580"/><TrialStartDate>2018-05-31 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="70581">GSK-3036656</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>First Time in Human (FTIH) Safety and Pharmacokinetics (PK) Study of GSK-3036656 in Healthy Subjects</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="290705"/><TrialStartDate>2017-04-02 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="70901">BTZ-043</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>A Single Ascending Dose Study Of BTZ-043</ProtocolTitle><Sponsor>Ludwig-Maximilians University of Munich</Sponsor><StudyType>Interventional</StudyType><Trial id="346718"/><TrialStartDate>2018-06-07 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="74849">SSI H56-IC31</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>A Phase II Study of H56:IC31 in Healthy Adolescents</ProtocolTitle><Sponsor>Aeras, Aeras Global TB Vaccine Foundation</Sponsor><StudyType>Interventional</StudyType><Trial id="310653"/><TrialStartDate>2018-06-30 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="74849">SSI H56-IC31</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>A Phase I Study of Safety and Immunogenicity of AERAS-456 in HIV-Negative Adults Treated for Drug-susceptible Pulmonary TB</ProtocolTitle><Sponsor>Aeras</Sponsor><StudyType>Interventional</StudyType><Trial id="223291"/><TrialStartDate>2014-11-21 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="76307">delpazolid</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Phase I study Evaluating the Safety, Tolerability and Pharmacokinetic Characteristics of RMX-2001</ProtocolTitle><Sponsor>Nome West (Shanghai) Pharmaceutical Technology Co., Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="381962"/><TrialStartDate/><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="87251">Perchlozone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>An Open, Prospective, Comparative, Randomized, Controlled Clinical Trial Of Efficacy And Safety Perhlozone Capsules (JSC 'Pharmasyntez', Russia), Used In Doses Of 9.5 And 12.5 mg/kg Night In The Complex Treatment Of Pulmonary Tuberculosis</ProtocolTitle><Sponsor>Pharmasyntez</Sponsor><StudyType>Interventional</StudyType><Trial id="169098"/><TrialStartDate>2013-01-28 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1B">Phase 1b Clinical</DevStatus><Drug id="90085">macozinone</Drug><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Study to Evaluate the Safety, Tolerability and Pharmacokinetics of PBTZ-169 in Multiple Dosing</ProtocolTitle><Sponsor>Innovative Medicines for Tuberculosis</Sponsor><StudyType>Interventional</StudyType><Trial id="363587"/><TrialStartDate>2019-02-21 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="90085">macozinone</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Phase I Study of PBTZ-169</ProtocolTitle><Sponsor>Nearmedic Plus</Sponsor><StudyType>Interventional</StudyType><Trial id="286724"/><TrialStartDate>2016-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="91861">clofazimine (oral, tuberculosis), Novartis</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>TB-PRACTECAL</ProtocolAcronym><ProtocolTitle>Pragmatic Clinical Trial for a More Effective Concise and Less Toxic MDR-TB Treatment Regimen(s)</ProtocolTitle><Sponsor>Medecins Sans Frontieres</Sponsor><StudyType>Interventional</StudyType><Trial id="244304"/><TrialStartDate>2017-01-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Drug id="95442">ESAT-6CFP10</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Phase IIb Clinical Study of Recombinant Mycobacterium Tuberculosis Allergen ESAT-6-CFP-10</ProtocolTitle><Sponsor>Anhui Zhifei Longcom Biopharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="219931"/><TrialStartDate>2014-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>4+</ArmCount><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="104447">OPC-167832</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>A Phase I/II Trial of Multiple Oral Doses of OPC-167832 for Uncomplicated Pulmonary Tuberculosis</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="353987"/><TrialStartDate>2018-10-25 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="14493">tenofovir disoproxil fumarate</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>REFLATE TB</ProtocolAcronym><ProtocolTitle>Efficacy and Safety of Two Raltegravir Doses in Naive HIV-1-Infected Patients Receiving Rifampin for Active Tuberculosis</ProtocolTitle><Sponsor>French National Agency for Research on AIDS and Viral Hepatitis</Sponsor><StudyType>Interventional</StudyType><Trial id="40948"/><TrialStartDate>2009-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="14493">tenofovir disoproxil fumarate</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>IMPAACT4TB</ProtocolAcronym><ProtocolTitle>Safety, Tolerability DDI Short Course Treatment of LTBI Infection With High-dose Rifapentine Isoniazid in HIV+ Patients</ProtocolTitle><Sponsor>Aurum Institute</Sponsor><StudyType>Interventional</StudyType><Trial id="329251"/><TrialStartDate>2018-01-18 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="14681">lopinavir + ritonavir</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>TEMPRANO</ProtocolAcronym><ProtocolTitle>Early Antiretroviral Treatment and/or Early Isoniazid Prophylaxis Against Tuberculosis in HIV-Infected Adults</ProtocolTitle><Sponsor>French National Agency for Research on AIDS and Viral Hepatitis</Sponsor><StudyType>Interventional</StudyType><Trial id="195741"/><TrialStartDate>2008-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="14681">lopinavir + ritonavir</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>An Open-Label, Sequential Non-Randomized Pharmacokinetics Study Comparing Lopinavir Plasma Exposure When Given as Lopinavir Superboosted With Ritonavir (1 : 1 Ratio) in the Presence of Rifampicin or Lopinavir Boosted With Ritonavir (4 : 1 Ratio) in the Absence of Rifampicin in HIV and TB Co-Infected Children in South Africa</ProtocolTitle><Sponsor>Drugs for Neglected Diseases Initiative</Sponsor><StudyType>Interventional</StudyType><Trial id="142540"/><TrialStartDate>2012-12-01 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="8255">nelfinavir</Drug><Endpoint>Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>TBTC-23B</ProtocolAcronym><ProtocolTitle>Intensive PK of the Nelfinavir Rifabutin Interaction in Patients With HIV-TB</ProtocolTitle><Sponsor>Centers for Disease Control and Prevention</Sponsor><StudyType>Interventional</StudyType><Trial id="10656"/><TrialStartDate>2000-02-29 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>1+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="4481">stavudine</Drug><Endpoint>Safety,Efficacy,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Pharmacokinetics of Rifabutin Combined With Antiretroviral Therapy in Patients With TB/HIV co-Infection in South Africa</ProtocolTitle><Sponsor>French National Agency for Research on AIDS and Viral Hepatitis</Sponsor><StudyType>Interventional</StudyType><Trial id="11187"/><TrialStartDate>2009-02-28 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="4481">stavudine</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>A prospective, open-label, pilot study to evaluate the pharmacokinetics (PK)/safety/efficacy of an adjusted dose of indinavir/ritonavir (IDV/r) 600/100 mg plus two nucleoside reverse transcriptase inhibitors (NRTIs) in HIV/TB-coinfected Thais receiving rifampicin-based anti-TB treatment</ProtocolTitle><Sponsor>Thai Red Cross AIDS Research Centre</Sponsor><StudyType>Interventional</StudyType><Trial id="100728"/><TrialStartDate>2012-01-17 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="26574">lamivudine + abacavir + zidovudine, GSK</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>THIRST</ProtocolAcronym><ProtocolTitle>Tuberculosis and HIV Immune Reconstitution Syndrome Trial (THIRST)</ProtocolTitle><Sponsor>Duke University</Sponsor><StudyType>Interventional</StudyType><Trial id="47398"/><TrialStartDate>2004-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="6050">metformin hydrochloride</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Effect of metformin in treatment of non-diabetic pulmonary tuberculosis patients</ProtocolTitle><Sponsor>Veer Surendra Sai Institute of Medical Sciences and Research</Sponsor><StudyType>Interventional</StudyType><Trial id="372893"/><TrialStartDate>2019-03-07 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>6</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="13340">everolimus</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>TBHDT</ProtocolAcronym><ProtocolTitle>TB Host Directed Therapy</ProtocolTitle><Sponsor>Aurum Institute</Sponsor><StudyType>Interventional</StudyType><Trial id="279898"/><TrialStartDate>2016-11-30 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="3474">lamivudine</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Efficacy of Thrice Weekly Directly Observed Treatment, Short-course (DOTS) in HIV-associated Tuberculosis</ProtocolTitle><Sponsor>All India Institute of Medical Sciences</Sponsor><StudyType>Interventional</StudyType><Trial id="161275"/><TrialStartDate>2006-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>4</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="3474">lamivudine</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>N2R</ProtocolAcronym><ProtocolTitle>Efavirenz-Based Versus Nevirapine-Based Antiretroviral Therapy Among HIV-Infected Patients Receiving Rifampin</ProtocolTitle><Sponsor>Bamrasnaradura Infectious Diseases Institute</Sponsor><StudyType>Interventional</StudyType><Trial id="10947"/><TrialStartDate>2007-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="3474">lamivudine</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>A prospective, open-label, pilot study to evaluate the pharmacokinetics (PK)/safety/efficacy of an adjusted dose of indinavir/ritonavir (IDV/r) 600/100 mg plus two nucleoside reverse transcriptase inhibitors (NRTIs) in HIV/TB-coinfected Thais receiving rifampicin-based anti-TB treatment</ProtocolTitle><Sponsor>Thai Red Cross AIDS Research Centre</Sponsor><StudyType>Interventional</StudyType><Trial id="100728"/><TrialStartDate>2012-01-17 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="39069">simeprevir</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>TMC-435350-TiDP16-C105:  Phase I, Three-Way Crossover, Drug-Drug Interaction Between TMC-435350 and Rifampin After Multiple Dosing</ProtocolTitle><Sponsor>Janssen R&amp;D (Ireland)</Sponsor><StudyType>Interventional</StudyType><Trial id="25800"/><TrialStartDate>2008-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="44313">simvastatin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Simvastatin and sputum conversion in pulmonary tuberculosis: a double-blinded, randomized, controlled trial</ProtocolTitle><Sponsor>Khonkaen Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="330023"/><TrialStartDate>2018-04-01 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="44437">verapamil</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Verapamil Dose-finding Study in Adult Patients with Tuberculosis</ProtocolTitle><Sponsor>Indian Government Department of Biotechnology</Sponsor><StudyType>Interventional</StudyType><Trial id="261260"/><TrialStartDate>2016-06-15 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>4</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="4728">emtricitabine</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>STRIDE</ProtocolAcronym><ProtocolTitle>Immediate Versus Deferred Start of Anti-HIV Therapy in HIV Infected Adults Being Treated for Tuberculosis</ProtocolTitle><Sponsor>AIDS Clinical Trials Group</Sponsor><StudyType>Interventional</StudyType><Trial id="10681"/><TrialStartDate>2006-08-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="10774">NeisVac-C</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>BAM</ProtocolAcronym><ProtocolTitle>A Study of the Interaction Between BCG And MenC Immunization</ProtocolTitle><Sponsor>University of Oxford</Sponsor><StudyType>Interventional</StudyType><Trial id="162886"/><TrialStartDate>2014-06-20 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="10172">efavirenz</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Efficacy of Thrice Weekly Directly Observed Treatment, Short-course (DOTS) in HIV-associated Tuberculosis</ProtocolTitle><Sponsor>All India Institute of Medical Sciences</Sponsor><StudyType>Interventional</StudyType><Trial id="161275"/><TrialStartDate>2006-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="10172">efavirenz</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>"NVP"</ProtocolAcronym><ProtocolTitle>Efficacy and Safety of Concomitant Use of Nevirapine and Rifampicin With HIV-TB</ProtocolTitle><Sponsor>All India Institute of Medical Sciences</Sponsor><StudyType>Interventional</StudyType><Trial id="114300"/><TrialStartDate>2007-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="10172">efavirenz</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>USPHS-23</ProtocolAcronym><ProtocolTitle>Intensive Pharmacokinetics of the Nelfinavir-Rifabutin Interaction in Patients With HIV-Related Tuberculosis Treated With a Rifabutin-Based Regimen</ProtocolTitle><Sponsor>National Institutes of Health</Sponsor><StudyType>Interventional</StudyType><Trial id="10648"/><TrialStartDate>2001-07-02 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>4+</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="12135">celecoxib</Drug><Endpoint>Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Evaluating Celecoxib Activity in Mycobacterium Tuberculosis: A Whole Blood Bactericidal Activity Study in Healthy Volunteers</ProtocolTitle><Sponsor>National University Hospital (Singapore) Pte Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="245694"/><TrialStartDate>2015-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="3700">nevirapine</Drug><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Pharmacokinetics of Rifabutin Combined With Antiretroviral Therapy in Patients With TB/HIV Co-Infection in Vietnam</ProtocolTitle><Sponsor>French National Agency for Research on AIDS and Viral Hepatitis</Sponsor><StudyType>Interventional</StudyType><Trial id="11188"/><TrialStartDate>2010-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="3700">nevirapine</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>CARINEMO</ProtocolAcronym><ProtocolTitle>Comparison of Nevirapine and Efavirenz for the Treatment of HIV-TB Co-infected Patients</ProtocolTitle><Sponsor>French National Agency for Research on AIDS and Viral Hepatitis</Sponsor><StudyType>Interventional</StudyType><Trial id="10948"/><TrialStartDate>2007-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="4144">Prevnar</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Safety and Immunogenicity Study of a Candidate Tuberculosis Vaccine in Healthy Infants</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="65639"/><TrialStartDate>2010-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3+</ArmCount><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="2807">atorvastatin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Paradoxical Tuberculosis Immune Reconstitution Inflammatory Syndrome (TB-IRIS) Treatment Trial</ProtocolTitle><Sponsor>University of Minnesota - Clinical and Translational Science Institute</Sponsor><StudyType>Interventional</StudyType><Trial id="199754"/><TrialStartDate>2014-01-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="3517">losartan</Drug><Endpoint>Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>The Influence of Rifampicin Discontinuation on Rifampicin-Induced Cytochrome P450 Enzyme Activity</ProtocolTitle><Sponsor>Hamamatsu University School of Medicine</Sponsor><StudyType>Interventional</StudyType><Trial id="122291"/><TrialStartDate>2010-07-01 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="11036">linezolid</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>ZeNiX</ProtocolAcronym><ProtocolTitle>Safety and Efficacy of Various Doses and Treatment Durations of Linezolid Plus Bedaquiline and Pretomanid in Participants With Pulmonary TB, XDR-TB, Pre-XDR-TB or Non-responsive/Intolerant MDR-TB</ProtocolTitle><Sponsor>TB Alliance</Sponsor><StudyType>Interventional</StudyType><Trial id="293734"/><TrialStartDate>2017-10-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="11036">linezolid</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>endTB</ProtocolAcronym><ProtocolTitle>Evaluating Newly Approved Drugs for Multidrug-resistant TB</ProtocolTitle><Sponsor>Médecins Sans Frontières France</Sponsor><StudyType>Interventional</StudyType><Trial id="259506"/><TrialStartDate>2016-12-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>3+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="59062">dolutegravir</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Evaluating the Safety, Tolerability and Pharmacokinetics of Bedaquiline and Delamanid, Alone and in Combination, For Drug-Resistant Pulmonary Tuberculosis</ProtocolTitle><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><StudyType>Interventional</StudyType><Trial id="243619"/><TrialStartDate>2016-08-31 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Drug id="59062">dolutegravir</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>INSPIRING</ProtocolAcronym><ProtocolTitle>Open-Label Study of Dolutegravir (DTG) or Efavirenz (EFV) for Human Immunodeficiency Virus (HIV)-Tuberculosis (TB) Co-infection</ProtocolTitle><Sponsor>ViiV Healthcare Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="201302"/><TrialStartDate>2015-01-23 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="6306">aldesleukin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>A randomized, placebo-controlled clinical trial to evaluate the safety and efficacy of IL-2 for the treatment of patients with pulmonary tuberculosis</ProtocolTitle><Sponsor>Case Western Reserve University</Sponsor><StudyType>Interventional</StudyType><Trial id="73321"/><TrialStartDate>2002-11-21 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="6229">Infanrix</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>BAM</ProtocolAcronym><ProtocolTitle>A Study of the Interaction Between BCG And MenC Immunization</ProtocolTitle><Sponsor>University of Oxford</Sponsor><StudyType>Interventional</StudyType><Trial id="162886"/><TrialStartDate>2014-06-20 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>1+</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="44316">zidovudine</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Acquired Immunodeficiency Syndrome (AIDS) and Tuberculosis (TB) Co-Infection Treatment Strategies Study of China</ProtocolTitle><Sponsor>Shanghai Public Health Clinical Center</Sponsor><StudyType>Interventional</StudyType><Trial id="76946"/><TrialStartDate>2009-02-28 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="44316">zidovudine</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Efficacy of Thrice Weekly Directly Observed Treatment, Short-course (DOTS) in HIV-associated Tuberculosis</ProtocolTitle><Sponsor>All India Institute of Medical Sciences</Sponsor><StudyType>Interventional</StudyType><Trial id="161275"/><TrialStartDate>2006-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="5321">indinavir</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>The Pharmacokinetics and Safety of indinavir/ritonavir With NRTIs in HIV/TB co-Infected Patients Receiving Rifampicin</ProtocolTitle><Sponsor>The HIV Netherlands Australia Thailand Research Collaboration</Sponsor><StudyType>Interventional</StudyType><Trial id="10871"/><TrialStartDate>2006-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="4492">faropenem</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Phase II Trial to Evaluate the Early Bactericidal Activity, Safety and Tolerability of Meropenem Plus Amoxycillin/CA and Faropenem Plus Amoxycillin/CA in Adult Patients With Newly Diagnosed Pulmonary Tuberculosis</ProtocolTitle><Sponsor>Task Foundation NPC</Sponsor><StudyType>Interventional</StudyType><Trial id="220739"/><TrialStartDate>2014-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="3612">meningococcal C/CRM-197 conjugate vaccine, Chiron</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Safety and Immunogenicity Study of a Candidate Tuberculosis Vaccine in Healthy Infants</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="65639"/><TrialStartDate>2010-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="11457">Priorix</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>BAM</ProtocolAcronym><ProtocolTitle>A Study of the Interaction Between BCG And MenC Immunization</ProtocolTitle><Sponsor>University of Oxford</Sponsor><StudyType>Interventional</StudyType><Trial id="162886"/><TrialStartDate>2014-06-20 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="7310">ritonavir</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>The Pharmacokinetics and Safety of indinavir/ritonavir With NRTIs in HIV/TB co-Infected Patients Receiving Rifampicin</ProtocolTitle><Sponsor>The HIV Netherlands Australia Thailand Research Collaboration</Sponsor><StudyType>Interventional</StudyType><Trial id="10871"/><TrialStartDate>2006-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="3492">levofloxacin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>DAZZLE</ProtocolAcronym><ProtocolTitle>Efficacy and Tolerability of Delamanid, Linezolid, Pyrazinamide and Levofloxacin</ProtocolTitle><Sponsor>Boston University</Sponsor><StudyType>Interventional</StudyType><Trial id="280651"/><TrialStartDate>2017-08-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="3492">levofloxacin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>TB-CHAMP trial</ProtocolAcronym><ProtocolTitle>Tuberculosis child multidrug-resistant preventive therapy</ProtocolTitle><Sponsor>University of Stellenbosch</Sponsor><StudyType>Interventional</StudyType><Trial id="259562"/><TrialStartDate>2016-01-01 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="3492">levofloxacin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>endTB</ProtocolAcronym><ProtocolTitle>Evaluating Newly Approved Drugs for Multidrug-resistant TB</ProtocolTitle><Sponsor>Médecins Sans Frontières France</Sponsor><StudyType>Interventional</StudyType><Trial id="259506"/><TrialStartDate>2016-12-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Drug id="4229">rifabutin</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Rifampin-Based Tuberculosis Treatment Versus Rifabutin-Based Tuberculosis Treatment in Persons With HIV</ProtocolTitle><Sponsor>AIDS Clinical Trials Group</Sponsor><StudyType>Interventional</StudyType><Trial id="87585"/><TrialStartDate>2013-07-13 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="4229">rifabutin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>InDEX</ProtocolAcronym><ProtocolTitle>The Individualized M(X) Drug-resistant TB Treatment Strategy Study</ProtocolTitle><Sponsor>Centre for the AIDS Program of Research in South Africa</Sponsor><StudyType>Interventional</StudyType><Trial id="307654"/><TrialStartDate>2017-06-14 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>1+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="4229">rifabutin</Drug><Endpoint>Safety,Efficacy,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Pharmacokinetics of Rifabutin Combined With Antiretroviral Therapy in Patients With TB/HIV co-Infection in South Africa</ProtocolTitle><Sponsor>French National Agency for Research on AIDS and Viral Hepatitis</Sponsor><StudyType>Interventional</StudyType><Trial id="11187"/><TrialStartDate>2009-02-28 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="4229">rifabutin</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>TBTC-23A</ProtocolAcronym><ProtocolTitle>Pharmacokinetics of Intermittent Isoniazid and Rifabutin in HIV-TB</ProtocolTitle><Sponsor>Centers for Disease Control and Prevention</Sponsor><StudyType>Interventional</StudyType><Trial id="10652"/><TrialStartDate>1999-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="9490">MTB72F vaccine (tuberculosis), GSK/ IAVI</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine in Adults With Tuberculosis (TB) Disease</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="80383"/><TrialStartDate>2011-11-14 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="11115">IMM-201</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>A phase III study to evaluate the safety and efficacy of SRL-172 for the prevention of tuberculosis</ProtocolTitle><Sponsor>Silence Therapeutics plc</Sponsor><StudyType>Interventional</StudyType><Trial id="20002"/><TrialStartDate>1997-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="11115">IMM-201</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>A dose-finding, multicenter, open-label study to investigate the efficacy of SRL-172 vaccine in the treatment of multidrug-resistant pulmonary tuberculosis</ProtocolTitle><Sponsor>Royal Free and University College Medical School</Sponsor><StudyType>Interventional</StudyType><Trial id="110339"/><TrialStartDate>2001-01-09 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With</ProtocolTitle><Sponsor>TB Alliance</Sponsor><StudyType>Interventional</StudyType><Trial id="71107"/><TrialStartDate>2010-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Intensified Treatment Regimens for TB Meningitis: PK, PD and Tolerability Study</ProtocolTitle><Sponsor>Universitas Padjadjaran</Sponsor><StudyType>Interventional</StudyType><Trial id="67996"/><TrialStartDate>2010-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>The Effect of 18-month Regimen Containing Six Anti-tuberculosis Drugs for Patients With MDR-TB</ProtocolTitle><Sponsor>Beijing Chest Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="369109"/><TrialStartDate>2019-03-08 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>endTB</ProtocolAcronym><ProtocolTitle>Evaluating Newly Approved Drugs for Multidrug-resistant TB</ProtocolTitle><Sponsor>Médecins Sans Frontières France</Sponsor><StudyType>Interventional</StudyType><Trial id="259506"/><TrialStartDate>2016-12-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="12978">moxifloxacin</Drug><Endpoint>Bioequivalence,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Open, randomized, crossover study of comparative pharmacokinetics and bioequivalence of drugs Moxifloxacin tablets, film-coated, 400 mg (JSC "Pharmasyntez", Russia) and Avelox tablets, film-coated, 400 mg ("Bayer Pharma AG", Germany)</ProtocolTitle><Sponsor>Pharmasyntez</Sponsor><StudyType>Interventional</StudyType><Trial id="247038"/><TrialStartDate>2015-11-23 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>STAND</ProtocolAcronym><ProtocolTitle>Shortening Treatment by Advancing Novel Drugs</ProtocolTitle><Sponsor>TB Alliance</Sponsor><StudyType>Interventional</StudyType><Trial id="221844"/><TrialStartDate>2015-02-28 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>5</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="12978">moxifloxacin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>BBA</ProtocolAcronym><ProtocolTitle>Brief Bactericidal Activity of Anti-Tuberculosis Drugs</ProtocolTitle><Sponsor>Centers for Disease Control and Prevention</Sponsor><StudyType>Interventional</StudyType><Trial id="210083"/><TrialStartDate>2015-11-30 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Pharmacokinetic Issues of Moxifloxacin Plus Rifapentine</ProtocolTitle><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><StudyType>Interventional</StudyType><Trial id="10943"/><TrialStartDate>2007-06-30 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Evaluation of SQ-109, High-dose Rifampicin, and Moxifloxacin in Adults With Smear-positive Pulmonary TB in a MAMS Design</ProtocolTitle><Sponsor>Ludwig-Maximilians University of Munich</Sponsor><StudyType>Interventional</StudyType><Trial id="109063"/><TrialStartDate>2013-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>5</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><Endpoint>Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>TBTC-27/28 PK</ProtocolAcronym><ProtocolTitle>TBTC Study 27/28 PK: Moxifloxacin Pharmacokinetics During TB Treatment</ProtocolTitle><Sponsor>Centers for Disease Control and Prevention</Sponsor><StudyType>Interventional</StudyType><Trial id="10847"/><TrialStartDate>2004-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>TBTC-27</ProtocolAcronym><ProtocolTitle>TBTC Study 27: Moxifloxacin versus Ethambutol for TB Treatment</ProtocolTitle><Sponsor>Centers for Disease Control and Prevention</Sponsor><StudyType>Interventional</StudyType><Trial id="10684"/><TrialStartDate>2003-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="13323">pretomanid</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="PR">Pre-registration</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>InDEX</ProtocolAcronym><ProtocolTitle>The Individualized M(X) Drug-resistant TB Treatment Strategy Study</ProtocolTitle><Sponsor>Centre for the AIDS Program of Research in South Africa</Sponsor><StudyType>Interventional</StudyType><Trial id="307654"/><TrialStartDate>2017-06-14 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="13323">pretomanid</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="PR">Pre-registration</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>TB-PRACTECAL</ProtocolAcronym><ProtocolTitle>Pragmatic Clinical Trial for a More Effective Concise and Less Toxic MDR-TB Treatment Regimen(s)</ProtocolTitle><Sponsor>Medecins Sans Frontieres</Sponsor><StudyType>Interventional</StudyType><Trial id="244304"/><TrialStartDate>2017-01-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="15102">rifapentine</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>DORIIS</ProtocolAcronym><ProtocolTitle>Doravirine, Rifapentine and Isoniazid Interaction</ProtocolTitle><Sponsor>Thomas Jefferson University</Sponsor><StudyType>Interventional</StudyType><Trial id="374387"/><TrialStartDate>2019-04-30 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="15102">rifapentine</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Tuberculosis Clinical Trials Consortium Study 35</ProtocolTitle><Sponsor>Centers for Disease Control and Prevention</Sponsor><StudyType>Interventional</StudyType><Trial id="359122"/><TrialStartDate>2019-09-30 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="15102">rifapentine</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>A 9-Month Isoniazid versus 3-Month Isoniazid plus Rifapentine for Treatment of Tuberculosis Infection in Rheumatic Patients: a Randomized, Controlled Trial</ProtocolTitle><Sponsor>Peking Union Medical College Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="352748"/><TrialStartDate>2017-09-01 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="15102">rifapentine</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>DOT-LTBI</ProtocolAcronym><ProtocolTitle>Treatment of Latent Tuberculosis in Socially Marginalised Citizens</ProtocolTitle><Sponsor>Aarhus University Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="310930"/><TrialStartDate>2017-10-27 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="15102">rifapentine</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>WHIP3TB</ProtocolAcronym><ProtocolTitle>Evaluation of the Effect of 3HP versus Periodic 3HP versus 6H in HIV-Positive Individuals</ProtocolTitle><Sponsor>Aurum Institute</Sponsor><StudyType>Interventional</StudyType><Trial id="281055"/><TrialStartDate>2016-11-30 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="15102">rifapentine</Drug><Endpoint>Bioavailability</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>A phase II trial of rifapentine in comparision with rifampicin to evaluate bioavailability in treatment of patients with pulmonary tuberculosis</ProtocolTitle><Sponsor>Aventis Pharma AG</Sponsor><StudyType>Interventional</StudyType><Trial id="15342"/><TrialStartDate>1987-12-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="15102">rifapentine</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Pharmacokinetic Issues of Moxifloxacin Plus Rifapentine</ProtocolTitle><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><StudyType>Interventional</StudyType><Trial id="10943"/><TrialStartDate>2007-06-30 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="15102">rifapentine</Drug><Endpoint>Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>TBTC-25</ProtocolAcronym><ProtocolTitle>Intensive Pharmacokinetic Study of Three Doses of Rifapentine and 25-Desacetyl Rifapentine</ProtocolTitle><Sponsor>Centers for Disease Control and Prevention</Sponsor><StudyType>Interventional</StudyType><Trial id="10655"/><TrialStartDate>2000-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>5</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="16545">delamanid</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Safety and Efficacy Trial of Delamanid for 6 Months in Participants With Multidrug Resistant Tuberculosis</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="80386"/><TrialStartDate>2011-09-02 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="16545">delamanid</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>A phase II trial to evaluate delamanid in pediatric patients with multi-drug resistance tuberculosis</ProtocolTitle><Sponsor>Otsuka Holdings Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="341287"/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="16545">delamanid</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>DAZZLE</ProtocolAcronym><ProtocolTitle>Efficacy and Tolerability of Delamanid, Linezolid, Pyrazinamide and Levofloxacin</ProtocolTitle><Sponsor>Boston University</Sponsor><StudyType>Interventional</StudyType><Trial id="280651"/><TrialStartDate>2017-08-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Drug id="16545">delamanid</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>A Placebo-Controlled, Phase II Trial to Evaluate OPC-67683 in Patients With Pulmonary Sputum Culture-Positive, Multidrug-Resistant Tuberculosis (TB)</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="15754"/><TrialStartDate>2008-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry>African Ancestry</Ancestry><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="16755">pafuramidine</Drug><Endpoint>Safety</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="OL">Outlicensed</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Randomized, double-blind, phase I safety and tolerability study of pafuramidine maleate (DB-289) in healthy subjects</ProtocolTitle><Sponsor>Immtech Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="17432"/><TrialStartDate>2007-11-30 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="31010">SQ-109</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Phase Ic Study of Safety and PK of SQ-109 300 mg Daily</ProtocolTitle><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><StudyType>Interventional</StudyType><Trial id="77682"/><TrialStartDate>2010-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="48499">H4:IC31</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>A Study for Safety and Immunogenicity of BCG and AERAS-404 in HIV-negative, TB-negative, BCG-naive Adults</ProtocolTitle><Sponsor>Aeras Global TB Vaccine Foundation</Sponsor><StudyType>Interventional</StudyType><Trial id="227111"/><TrialStartDate>2011-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C1B">Phase 1b Clinical</DevStatus><Drug id="48499">H4:IC31</Drug><Endpoint>Safety,Efficacy,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>A-042</ProtocolAcronym><ProtocolTitle>Phase Ib, Safety and Immunogenicity Trial of BCG Revaccination, H4:IC31 and H56:IC31 in Healthy, HIV-1-Uninfected Adolescents</ProtocolTitle><Sponsor>Aeras</Sponsor><StudyType>Interventional</StudyType><Trial id="223463"/><TrialStartDate>2015-05-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Drug id="51310">bedaquiline</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>TMC207-C202: Study to Evaluate Bactericidal Activity of Multiple Oral Doses of TMC207 in Subjects With Sputum-Smear Positive Tuberculosis</ProtocolTitle><Sponsor>Janssen R&amp;D (Ireland)</Sponsor><StudyType>Interventional</StudyType><Trial id="9315"/><TrialStartDate>2005-05-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="51310">bedaquiline</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With</ProtocolTitle><Sponsor>TB Alliance</Sponsor><StudyType>Interventional</StudyType><Trial id="71107"/><TrialStartDate>2010-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="51310">bedaquiline</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>DRAMATIC</ProtocolAcronym><ProtocolTitle>Efficacy and Tolerability of Bedaquiline, Delamanid, Levofloxacin, Linezolid, and Clofazimine for Treatment of Patients With MDR-TB</ProtocolTitle><Sponsor>Boston University</Sponsor><StudyType>Interventional</StudyType><Trial id="368916"/><TrialStartDate>2020-01-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="51310">bedaquiline</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>ZeNiX</ProtocolAcronym><ProtocolTitle>Safety and Efficacy of Various Doses and Treatment Durations of Linezolid Plus Bedaquiline and Pretomanid in Participants With Pulmonary TB, XDR-TB, Pre-XDR-TB or Non-responsive/Intolerant MDR-TB</ProtocolTitle><Sponsor>TB Alliance</Sponsor><StudyType>Interventional</StudyType><Trial id="293734"/><TrialStartDate>2017-10-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Drug id="51310">bedaquiline</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>An Open-Label Study to Evaluate the Extended Early Bactericidal Activity, Safety, Tolerability and Pharmacokinetics of Multiple Doses (md) of TMC-207 Oral Solution (Os) and Isoniazid (JH), TMC-207 Os and Pyrazinamide (JZ), TMC-207 Os and Rifampin (JR) or TMC-207 Os and Isoniazid and Pyrazinamide (JHZ), Compared to the three Principle Drugs of Standard Anti-Tuberculosis Treatment (HRZ) in Treatment-Naive Subjects With Sputum-Smear Positive Pulmonary Tuberculosis</ProtocolTitle><Sponsor>Janssen R&amp;D (Ireland)</Sponsor><StudyType>Interventional</StudyType><Trial id="131253"/><TrialStartDate>2005-06-25 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="51310">bedaquiline</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>An Open-Label Study to Evaluate the Effects on Mycobacterium Tuberculosis, Safety, Tolerability and Pharmacokinetics of Single Doses of R-207910, in Treatment Naive Patients With Mycobacterium Tuberculosis Infection</ProtocolTitle><Sponsor>Janssen Diagnostics BVBA, Johnson &amp; Johnson</Sponsor><StudyType>Interventional</StudyType><Trial id="129536"/><TrialStartDate>2004-10-18 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="55317">MVA-85A</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>A Phase I Study of the Safety and Immunogenicity of a Recombinant MVA-85A Vaccine in Healthy Volunteers</ProtocolTitle><Sponsor>University of Oxford</Sponsor><StudyType>Interventional</StudyType><Trial id="9320"/><TrialStartDate>2002-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="55317">MVA-85A</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>The Safety and Immunogenicity of a TB Vaccine; MVA85A, in Healthy Volunteers Who Are Infected With HIV</ProtocolTitle><Sponsor>University of Oxford</Sponsor><StudyType>Interventional</StudyType><Trial id="10868"/><TrialStartDate>2006-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="55569">VPM-1002</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>To Study Effect of Two Vaccines in Preventing Spread of Tuberculosis in Persons Living With New Tuberculosis Patients</ProtocolTitle><Sponsor>Indian Council of Medical Research</Sponsor><StudyType>Interventional</StudyType><Trial id="366261"/><TrialStartDate>2019-01-25 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="57308">RUTI</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>RUTISAPH2</ProtocolAcronym><ProtocolTitle>Clinical Trial to Investigate the Safety, Tolerability, and Immunogenicity of the Novel Antituberculous Vaccine RUTI Following 1 Month of Isoniazid Treatment in Subjects With Latent Tuberculosis Infection</ProtocolTitle><Sponsor>Archivel Farma SL</Sponsor><StudyType>Interventional</StudyType><Trial id="67014"/><TrialStartDate>2010-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="69440">rifampicin + isoniazid + piperine (fixed dose combination, tuberculosis), Cadila Pharmaceuticals</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Combination of Two Drugs in Tuberculosis Treatment</ProtocolTitle><Sponsor>SRM University</Sponsor><StudyType>Interventional</StudyType><Trial id="224091"/><TrialStartDate/><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="71742">TBA-354</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>A Multiple Ascending Dose Study With a Dose Formulation Comparison Cohort to Evaluate the Safety, Tolerability, and Pharmacokinetics of TBA-354 in Healthy Adult Subjects</ProtocolTitle><Sponsor>TB Alliance</Sponsor><StudyType>Interventional</StudyType><Trial id="246089"/><TrialStartDate>2015-11-30 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="71742">TBA-354</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>A Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of TBA-354 in Healthy Adult Subjects</ProtocolTitle><Sponsor>TB Alliance</Sponsor><StudyType>Interventional</StudyType><Trial id="215600"/><TrialStartDate>2015-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="74849">SSI H56-IC31</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Study to Evaluate H56:IC31 in Preventing Rate of TB Recurrence</ProtocolTitle><Sponsor>Aeras</Sponsor><StudyType>Interventional</StudyType><Trial id="337957"/><TrialStartDate>2019-01-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="PNA">Phase Not Applicable</DevStatus><Drug id="76307">delpazolid</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>A clinical trial of RMX-2001 in multidrug-resistant tuberculosis (MDR-TB) in China</ProtocolTitle><Sponsor>HaiHe Pharmaceuticals Co Ltd, LegoChem Bioscience Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="370697"/><TrialStartDate/><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>3+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="76307">delpazolid</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>A Phase II Clinical Study of LCB01-0371 to Evaluate the EBA, Safety and PK</ProtocolTitle><Sponsor>LegoChem Bioscience Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="265899"/><TrialStartDate>2016-12-10 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="81264">interferon gamma follow-on biologic, PHARMACLON LLC</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Randomized, comparative, controlled, open-label clinical study of efficacy and safety of Ingaron (recombinant human interferon gamma) production of "NPP" FARMAKLON, Russia in the treatment of patients with pulmonary tuberculosis</ProtocolTitle><Sponsor>PHARMACLON LLC</Sponsor><StudyType>Interventional</StudyType><Trial id="194177"/><TrialStartDate>2014-05-26 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="84564">ChAdOx1-85A</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>EMaBS TB Vaccine Study</ProtocolTitle><Sponsor>University of Oxford</Sponsor><StudyType>Interventional</StudyType><Trial id="354327"/><TrialStartDate>2018-12-01 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="85970">telacebec</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>A phase I, singlecenter, open-label, prospective clinical study to assess safety, tolerability and pharmacokinetics of ascending doses of Q-203 in single use in healthy subjects</ProtocolTitle><Sponsor>Infectex</Sponsor><StudyType>Interventional</StudyType><Trial id="371518"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="89460">rifampicin + isoniazid (fixed dose combination, tuberculosis), Pfizer</Drug><Endpoint>Safety,Bioequivalence,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>A Bioequivalence Study Comparing A Fixed Dose Combination Formulation, RIN-150 And Individual Reference Drugs In Healthy Volunteers</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="164292"/><TrialStartDate>2012-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="91861">clofazimine (oral, tuberculosis), Novartis</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>DRAMATIC</ProtocolAcronym><ProtocolTitle>Efficacy and Tolerability of Bedaquiline, Delamanid, Levofloxacin, Linezolid, and Clofazimine for Treatment of Patients With MDR-TB</ProtocolTitle><Sponsor>Boston University</Sponsor><StudyType>Interventional</StudyType><Trial id="368916"/><TrialStartDate>2020-01-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="91861">clofazimine (oral, tuberculosis), Novartis</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Clofazimine in the Treatment of Pulmonary Mycobacterium Avium Complex (MAC)</ProtocolTitle><Sponsor>Oregon Health Sciences University</Sponsor><StudyType>Interventional</StudyType><Trial id="279727"/><TrialStartDate>2017-04-11 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="95442">ESAT-6CFP10</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Clinical Study of Recombinant Mycobacterium Tuberculosis ESAT-6CFP10 Allergen for Children</ProtocolTitle><Sponsor>Anhui Zhifei Longcom Biopharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="285889"/><TrialStartDate>2016-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Drug id="95442">ESAT-6CFP10</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Phase IIb Clinical Study of Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10 on Healthy People Aged 18 to 65</ProtocolTitle><Sponsor>Anhui Zhifei Longcom Biopharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="224675"/><TrialStartDate>2015-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="104447">OPC-167832</Drug><Endpoint>Safety</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>A phase I, single-ascending-dose study of OPC-167832 for the treatment of Mycobacterium tuberculosis infection</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="327014"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="108779">GC-3107</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>A Study of GC-3107(BCG Vaccine) in Healthy Infants</ProtocolTitle><Sponsor>GC Pharma</Sponsor><StudyType>Interventional</StudyType><Trial id="380364"/><TrialStartDate>2019-06-01 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="14493">tenofovir disoproxil fumarate</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>REFLATE TB2</ProtocolAcronym><ProtocolTitle>Raltegravir Versus Efavirenz in Naive HIV-1-infected Patients Receiving Rifampin for Active Tuberculosis</ProtocolTitle><Sponsor>INSERM</Sponsor><StudyType>Interventional</StudyType><Trial id="214156"/><TrialStartDate>2015-09-30 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Drug id="14681">lopinavir + ritonavir</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Rifampin-Based Tuberculosis Treatment Versus Rifabutin-Based Tuberculosis Treatment in Persons With HIV</ProtocolTitle><Sponsor>AIDS Clinical Trials Group</Sponsor><StudyType>Interventional</StudyType><Trial id="87585"/><TrialStartDate>2013-07-13 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="28379">Glutoxim</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Glutoxim in the Complex Treatment of Tuberculosis</ProtocolTitle><Sponsor>IM Sechenov Moscow Medical Academy</Sponsor><StudyType>Interventional</StudyType><Trial id="149460"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>1+</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="44309">ranitidine</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>SURE</ProtocolAcronym><ProtocolTitle>Short Intensive Treatment For Children With Tuberculous Meningitis</ProtocolTitle><Sponsor>University College London</Sponsor><StudyType>Interventional</StudyType><Trial id="360104"/><TrialStartDate>2018-01-02 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="2829">clarithromycin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>The Effect of 18-month Regimen Containing Six Anti-tuberculosis Drugs for Patients With MDR-TB</ProtocolTitle><Sponsor>Beijing Chest Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="369109"/><TrialStartDate>2019-03-08 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>3+</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="2829">clarithromycin</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>The research of new regimen for multidrug-resistant tuberculosis treatment</ProtocolTitle><Sponsor>Beijing Chest Hospital, Beijing Tuberculosis &amp; Thoracic Tumor Research Institute, Capital Medical University</Sponsor><StudyType>Interventional</StudyType><Trial id="244777"/><TrialStartDate>2008-10-01 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>1+</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="3474">lamivudine</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Acquired Immunodeficiency Syndrome (AIDS) and Tuberculosis (TB) Co-Infection Treatment Strategies Study of China</ProtocolTitle><Sponsor>Shanghai Public Health Clinical Center</Sponsor><StudyType>Interventional</StudyType><Trial id="76946"/><TrialStartDate>2009-02-28 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="3474">lamivudine</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>RRHT</ProtocolAcronym><ProtocolTitle>Rifampicin versus Rifabutin in HIV/AIDS Patients Combined With Tuberculosis</ProtocolTitle><Sponsor>Shanghai Public Health Clinical Center</Sponsor><StudyType>Interventional</StudyType><Trial id="334027"/><TrialStartDate>2018-04-15 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Drug id="4155">pravastatin</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>Stat-TB</ProtocolAcronym><ProtocolTitle>Statin Adjunctive Therapy for TB: A Phase IIb Dose-finding Study of Pravastatin in Adults With Tuberculosis</ProtocolTitle><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><StudyType>Interventional</StudyType><Trial id="374083"/><TrialStartDate>2019-06-15 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>3+</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="4728">emtricitabine</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>RIFART</ProtocolAcronym><ProtocolTitle>RIFART</ProtocolTitle><Sponsor>Azienda Ospedaliera Spedali Civili di Brescia</Sponsor><StudyType>Interventional</StudyType><Trial id="131240"/><TrialStartDate>2005-03-15 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="9354">picroliv</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Evaluation of Hepatoprotective Effect of Picroliv in Patients Receiving Multi Drug Therapy of Tuberculosis</ProtocolTitle><Sponsor>Central Drug Research Institute</Sponsor><StudyType>Interventional</StudyType><Trial id="127798"/><TrialStartDate>2005-03-01 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3+</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7017">gatifloxacin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>OFLOTUB</ProtocolAcronym><ProtocolTitle>A Controlled Trial of a 4-Month Quinolone-Containing Regimen for the Treatment of Pulmonary Tuberculosis</ProtocolTitle><Sponsor>Institut de Recherche pour le Developpement (IRD)</Sponsor><StudyType>Interventional</StudyType><Trial id="10855"/><TrialStartDate>2005-01-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>4</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="10172">efavirenz</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Effectiveness of Directly Observed Therapy in Combined HIV and Tuberculosis Treatment in Resource-Limited Settings</ProtocolTitle><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><StudyType>Interventional</StudyType><Trial id="8820"/><TrialStartDate>2009-08-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>1+</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="10172">efavirenz</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Acquired Immunodeficiency Syndrome (AIDS) and Tuberculosis (TB) Co-Infection Treatment Strategies Study of China</ProtocolTitle><Sponsor>Shanghai Public Health Clinical Center</Sponsor><StudyType>Interventional</StudyType><Trial id="76946"/><TrialStartDate>2009-02-28 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="10172">efavirenz</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>REFLATE TB</ProtocolAcronym><ProtocolTitle>Efficacy and Safety of Two Raltegravir Doses in Naive HIV-1-Infected Patients Receiving Rifampin for Active Tuberculosis</ProtocolTitle><Sponsor>French National Agency for Research on AIDS and Viral Hepatitis</Sponsor><StudyType>Interventional</StudyType><Trial id="40948"/><TrialStartDate>2009-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="10172">efavirenz</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>REFLATE TB2</ProtocolAcronym><ProtocolTitle>Raltegravir Versus Efavirenz in Naive HIV-1-infected Patients Receiving Rifampin for Active Tuberculosis</ProtocolTitle><Sponsor>INSERM</Sponsor><StudyType>Interventional</StudyType><Trial id="214156"/><TrialStartDate>2015-09-30 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="10172">efavirenz</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>SAPIT</ProtocolAcronym><ProtocolTitle>A Study to Compare Three Existing Starting Points of Antiretroviral Therapy (ART) Initiation in HIV/Tuberculosis (TB) Co-infected Patients</ProtocolTitle><Sponsor>Centre for the AIDS Program of Research in South Africa</Sponsor><StudyType>Interventional</StudyType><Trial id="201474"/><TrialStartDate>2005-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="10172">efavirenz</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>Pred-ART</ProtocolAcronym><ProtocolTitle>Preventing TB-IRIS in High-risk Patients: a Randomized, Placebo-controlled Trial of Prednisone</ProtocolTitle><Sponsor>University of Cape Town</Sponsor><StudyType>Interventional</StudyType><Trial id="150793"/><TrialStartDate>2013-08-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>4</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="10172">efavirenz</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>N2R</ProtocolAcronym><ProtocolTitle>Efavirenz-Based Versus Nevirapine-Based Antiretroviral Therapy Among HIV-Infected Patients Receiving Rifampin</ProtocolTitle><Sponsor>Bamrasnaradura Infectious Diseases Institute</Sponsor><StudyType>Interventional</StudyType><Trial id="10947"/><TrialStartDate>2007-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="12862">Tritanrix HB</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Safety and Immunogenicity Study of a Candidate Tuberculosis Vaccine in Healthy Infants</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="65639"/><TrialStartDate>2010-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>1+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="3700">nevirapine</Drug><Endpoint>Safety,Efficacy,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Pharmacokinetics of Rifabutin Combined With Antiretroviral Therapy in Patients With TB/HIV co-Infection in South Africa</ProtocolTitle><Sponsor>French National Agency for Research on AIDS and Viral Hepatitis</Sponsor><StudyType>Interventional</StudyType><Trial id="11187"/><TrialStartDate>2009-02-28 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="3700">nevirapine</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Safety and Efficacy of Two Once Daily Anti Retroviral Treatment Regimens Along With Anti-Tuberculosis Treatment</ProtocolTitle><Sponsor>Tuberculosis Research Centre</Sponsor><StudyType>Interventional</StudyType><Trial id="10863"/><TrialStartDate>2006-06-30 00:00:00</TrialStartDate><TrialStatus>Suspended</TrialStatus></Row><Row><Ancestry/><ArmCount>4+</ArmCount><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="25182">valganciclovir</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>EMPIRICAL</ProtocolAcronym><ProtocolTitle>Empirical Treatment Against Cytomegalovirus and Tuberculosis in HIV-infected Infants With Severe Pneumonia</ProtocolTitle><Sponsor>Hospital Universitario 12 de Octubre</Sponsor><StudyType>Interventional</StudyType><Trial id="377163"/><TrialStartDate>2020-01-01 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="8050">thalidomide, Celgene</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Phase II, Placebo-Controlled Study of Thalidomide in Patients With Mycobacterial and HIV Infections</ProtocolTitle><Sponsor>National Center for Research Resources</Sponsor><StudyType>Interventional</StudyType><Trial id="92426"/><TrialStartDate>1990-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="8050">thalidomide, Celgene</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Adjunctive Thalidomide Therapy of Childhood Tuberculous Meningitis: Possible Anti-Inflammatory Role</ProtocolTitle><Sponsor>University of Stellenbosch</Sponsor><StudyType>Interventional</StudyType><Trial id="150307"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="PNA">Phase Not Applicable</DevStatus><Drug id="30819">tedizolid phosphate</Drug><Endpoint>Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Evaluating Pharmacokinetics and Whole Blood Bactericidal Activity Against Mycobacterium Tuberculosis of Single-Doses of Tedizolid Plus Rifampicin in Healthy Volunteers</ProtocolTitle><Sponsor>National University Hospital (Singapore) Pte Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="331225"/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="3616">meropenem</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>InDEX</ProtocolAcronym><ProtocolTitle>The Individualized M(X) Drug-resistant TB Treatment Strategy Study</ProtocolTitle><Sponsor>Centre for the AIDS Program of Research in South Africa</Sponsor><StudyType>Interventional</StudyType><Trial id="307654"/><TrialStartDate>2017-06-14 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="2587">azithromycin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>ACT-TB</ProtocolAcronym><ProtocolTitle>Accuracy and Consequences of Using Trial-of-antibiotics for TB Diagnosis</ProtocolTitle><Sponsor>London School of Hygiene and Tropical Medicine</Sponsor><StudyType>Interventional</StudyType><Trial id="341686"/><TrialStartDate>2019-02-25 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="2587">azithromycin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>InDEX</ProtocolAcronym><ProtocolTitle>The Individualized M(X) Drug-resistant TB Treatment Strategy Study</ProtocolTitle><Sponsor>Centre for the AIDS Program of Research in South Africa</Sponsor><StudyType>Interventional</StudyType><Trial id="307654"/><TrialStartDate>2017-06-14 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="11036">linezolid</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>ESCALATE</ProtocolAcronym><ProtocolTitle>To observe if administration of drug namely linezolid along with standard four drug regimen in intensive(initial) phase of Tubercular meningitis will help reduce death and disability among patients when compared to standard four drug antitubercular drug therapy alone</ProtocolTitle><Sponsor>All India Institute of Medical Sciences</Sponsor><StudyType>Interventional</StudyType><Trial id="383209"/><TrialStartDate>2019-06-07 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="11036">linezolid</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>PRACTECAL-PRO</ProtocolAcronym><ProtocolTitle>Patient-reported Experiences and Quality of Life Outcomes in the TB-PRACTECAL Clinical Trial</ProtocolTitle><Sponsor>Medecins Sans Frontieres, Netherlands</Sponsor><StudyType>Interventional</StudyType><Trial id="379769"/><TrialStartDate>2019-07-01 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="11036">linezolid</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>The Effect of 18-month Regimen Containing Six Anti-tuberculosis Drugs for Patients With MDR-TB</ProtocolTitle><Sponsor>Beijing Chest Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="369109"/><TrialStartDate>2019-03-08 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="11036">linezolid</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>MDR-END</ProtocolAcronym><ProtocolTitle>Treatment Shortening of MDR-TB Using Existing and New Drugs</ProtocolTitle><Sponsor>Seoul National University Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="247456"/><TrialStartDate>2016-01-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="11036">linezolid</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>A multicenter, randomized controlled study to evaluate the clinical efficacy and safety of linezolid in patients with extensively drug resistant tuberculosis</ProtocolTitle><Sponsor>Tongji University</Sponsor><StudyType>Interventional</StudyType><Trial id="173992"/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="59062">dolutegravir</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>RADIANT-TB</ProtocolAcronym><ProtocolTitle>Standard Versus Double Dose Dolutegravir in Patients With HIV-associated Tuberculosis</ProtocolTitle><Sponsor>University of Cape Town</Sponsor><StudyType>Interventional</StudyType><Trial id="371202"/><TrialStartDate>2019-05-01 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="54488">raltegravir</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>EARNEST Rifabutin Pharmacokinetics (PK) Substudy</ProtocolTitle><Sponsor>Joint Clinical Research Centre, Medical Research Council</Sponsor><StudyType>Interventional</StudyType><Trial id="90175"/><TrialStartDate>2012-05-03 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="44316">zidovudine</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>RRHT</ProtocolAcronym><ProtocolTitle>Rifampicin versus Rifabutin in HIV/AIDS Patients Combined With Tuberculosis</ProtocolTitle><Sponsor>Shanghai Public Health Clinical Center</Sponsor><StudyType>Interventional</StudyType><Trial id="334027"/><TrialStartDate>2018-04-15 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>3+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="4492">faropenem</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Synergistically acting Rifampicin and Faropenem in Tuberculosis</ProtocolTitle><Sponsor>Indian Council of Medical Research</Sponsor><StudyType>Interventional</StudyType><Trial id="377088"/><TrialStartDate>2019-05-31 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7310">ritonavir</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Pharmacokinetic Study of Super-boosted Lopinavir/Ritonavir Given With Rifampin</ProtocolTitle><Sponsor>University of Miami</Sponsor><StudyType>Interventional</StudyType><Trial id="93494"/><TrialStartDate>2016-02-29 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="3492">levofloxacin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Multicenter, controlled clinical study of the safety, tolerability and efficacy of clofazimine in the treatment of drug-resistant tuberculosis</ProtocolTitle><Sponsor>Beijing Chest Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="328802"/><TrialStartDate>2009-12-01 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="3492">levofloxacin</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>STREAM</ProtocolAcronym><ProtocolTitle>The Evaluation of a Standard Treatment Regimen of Anti-Tuberculosis Drugs for Patients With MDR-TB</ProtocolTitle><Sponsor>International Union Against Tuberculosis and Lung Diseases</Sponsor><StudyType>Interventional</StudyType><Trial id="228190"/><TrialStartDate>2016-04-30 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="3492">levofloxacin</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>A open-labeled study to assess the efficacy of levofloxacin in healthy volunteers</ProtocolTitle><Sponsor>Ophthalmic Consultants of Boston</Sponsor><StudyType>Interventional</StudyType><Trial id="113606"/><TrialStartDate>2012-09-30 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>5</ArmCount><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="3492">levofloxacin</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>TBRU 10</ProtocolAcronym><ProtocolTitle>Early Bactericidal Activity of Linezolid, Gatifloxacin, Levofloxacin, Isoniazid (INH) and Moxifloxacin in HIV Negative Adults With Initial Episodes of Sputum Smear-Positive Pulmonary Tuberculosis</ProtocolTitle><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><StudyType>Interventional</StudyType><Trial id="10869"/><TrialStartDate>2004-02-29 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="4229">rifabutin</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>TBTC-23C</ProtocolAcronym><ProtocolTitle>Pharmacokinetics of Intermittent Rifabutin and Isoniazid With Daily Efavirenz</ProtocolTitle><Sponsor>Centers for Disease Control and Prevention</Sponsor><StudyType>Interventional</StudyType><Trial id="10657"/><TrialStartDate>1999-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="4229">rifabutin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>TBTC-23</ProtocolAcronym><ProtocolTitle>Treatment of HIV-Related Tuberculosis Using a Rifabutin-Based Regimen</ProtocolTitle><Sponsor>Centers for Disease Control and Prevention</Sponsor><StudyType>Interventional</StudyType><Trial id="10653"/><TrialStartDate>1999-02-28 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="9490">MTB72F vaccine (tuberculosis), GSK/ IAVI</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Safety and Immunogenicity Study of a Candidate Tuberculosis Vaccine in HIV-positive Adults</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="73200"/><TrialStartDate>2011-01-17 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="9490">MTB72F vaccine (tuberculosis), GSK/ IAVI</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Study to Evaluate the Efficacy of GlaxoSmithKline (GSK) Biologicals' Candidate Tuberculosis (TB) Vaccine in Healthy Adults</ProtocolTitle><Sponsor>GlaxoSmithKline Biologicals, GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="102580"/><TrialStartDate>2014-08-19 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="11088">sutezolid</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Safety, Tolerability And Pharmacokinetics Study Of Single-Doses Of PNU-100480 In Healthy Adults</ProtocolTitle><Sponsor>Sequella Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="50188"/><TrialStartDate>2009-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Drug id="11088">sutezolid</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>SUDOCU</ProtocolAcronym><ProtocolTitle>PanACEA Sutezolid Dose-finding and Combination Evaluation</ProtocolTitle><Sponsor>Ludwig-Maximilians University of Munich</Sponsor><StudyType>Interventional</StudyType><Trial id="381674"/><TrialStartDate>2019-08-31 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="11115">IMM-201</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>A five year study to evaluate the safety and efficacy of SRL-172 in the prevention of tuberculosis in HIV-positive subjects</ProtocolTitle><Sponsor>National Institutes of Health, Silence Therapeutics plc</Sponsor><StudyType>Interventional</StudyType><Trial id="19967"/><TrialStartDate>2001-09-30 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="11115">IMM-201</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>A Randomized, Double-blind, Multicenter, Placebo-controlled Trial to Study the Efficacy of Mycobacterium vaccae Immunotherapy for Tuberculosis in KwaZulu, South Africa, 1991-97</ProtocolTitle><Sponsor>Blandford Medical Centre</Sponsor><StudyType>Interventional</StudyType><Trial id="109626"/><TrialStartDate>2000-10-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="12978">moxifloxacin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Moxifloxacin_QT Study in Chinese Healthy Volunteer</ProtocolTitle><Sponsor>Peking University Third Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="89715"/><TrialStartDate>2012-07-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>A Comparative study of different treatment regimes for brain tuberculosis</ProtocolTitle><Sponsor>Department of Science &amp; Technology</Sponsor><StudyType>Interventional</StudyType><Trial id="382387"/><TrialStartDate>2019-05-27 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>InDEX</ProtocolAcronym><ProtocolTitle>The Individualized M(X) Drug-resistant TB Treatment Strategy Study</ProtocolTitle><Sponsor>Centre for the AIDS Program of Research in South Africa</Sponsor><StudyType>Interventional</StudyType><Trial id="307654"/><TrialStartDate>2017-06-14 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>TB-PRACTECAL</ProtocolAcronym><ProtocolTitle>Pragmatic Clinical Trial for a More Effective Concise and Less Toxic MDR-TB Treatment Regimen(s)</ProtocolTitle><Sponsor>Medecins Sans Frontieres</Sponsor><StudyType>Interventional</StudyType><Trial id="244304"/><TrialStartDate>2017-01-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>A Phase II to Evaluate the Efficacy, Safety and Tolerability of Combinations of Bedaquiline, Moxifloxacin, PA-824 and Pyrazinamide in Adult Subjects With Drug-Sensitive or Multi Drug-Resistant Pulmonary Tuberculosis</ProtocolTitle><Sponsor>TB Alliance</Sponsor><StudyType>Interventional</StudyType><Trial id="210646"/><TrialStartDate>2014-10-23 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Bioavailability, Food Effect and Safety, Tolerability of a New Oral Suspension in Comparison to the Marketed Moxifloxacin Tablet in Healthy Adults</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><Trial id="198748"/><TrialStartDate>2010-05-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="12978">moxifloxacin</Drug><Endpoint>Bioequivalence,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>A randomized, open, balanced, two-component, two-period, crossover, with a single-dose study of comparative pharmacokinetics and bioequivalence of Primflo (moxifloxacin) 400 mg (Dr Reddy's Laboratories Ltd, India) and Avilox  (moxifloxacin) 400 mg (Bayer Healthcare AG, Germany), when taken orally on an empty stomach in healthy adult volunteers</ProtocolTitle><Sponsor>Dr Reddy's Laboratories Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="167750"/><TrialStartDate>2012-10-10 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Thrice-Weekly, 4- Months Moxifloxacin or Gatifloxacin Regimens for Pulmonary TB</ProtocolTitle><Sponsor>Indian Council of Medical Research</Sponsor><StudyType>Interventional</StudyType><Trial id="150332"/><TrialStartDate>2004-05-14 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Drug id="13323">pretomanid</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="PR">Pre-registration</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Phase IIa Evaluation of Early Bactericidal Activity of PA-824 in Pulmonary Tuberculosis</ProtocolTitle><Sponsor>TB Alliance</Sponsor><StudyType>Interventional</StudyType><Trial id="9381"/><TrialStartDate>2007-08-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="13323">pretomanid</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="PR">Pre-registration</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With</ProtocolTitle><Sponsor>TB Alliance</Sponsor><StudyType>Interventional</StudyType><Trial id="71107"/><TrialStartDate>2010-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="13323">pretomanid</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="PR">Pre-registration</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Single-Dose Study to Evaluate the PKs of Pretomanid in Subjects With Renal Impairment Compared to Subjects With Normal Renal Function</ProtocolTitle><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><StudyType>Interventional</StudyType><Trial id="375406"/><TrialStartDate>2019-05-09 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="13323">pretomanid</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="PR">Pre-registration</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>CL-004</ProtocolAcronym><ProtocolTitle>A Study of the Safety, Tolerability, and Absorption, Metabolism, and Excretion of PA-824 in Healthy Adult Male Subjects</ProtocolTitle><Sponsor>TB Alliance</Sponsor><StudyType>Interventional</StudyType><Trial id="303299"/><TrialStartDate>2006-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="13323">pretomanid</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="PR">Pre-registration</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>STAND</ProtocolAcronym><ProtocolTitle>Shortening Treatment by Advancing Novel Drugs</ProtocolTitle><Sponsor>TB Alliance</Sponsor><StudyType>Interventional</StudyType><Trial id="221844"/><TrialStartDate>2015-02-28 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Drug id="13323">pretomanid</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="PR">Pre-registration</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>A Phase II to Evaluate the Efficacy, Safety and Tolerability of Combinations of Bedaquiline, Moxifloxacin, PA-824 and Pyrazinamide in Adult Subjects With Drug-Sensitive or Multi Drug-Resistant Pulmonary Tuberculosis</ProtocolTitle><Sponsor>TB Alliance</Sponsor><StudyType>Interventional</StudyType><Trial id="210646"/><TrialStartDate>2014-10-23 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="15102">rifapentine</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>The safety and efficacy of high dose rifapentine in treatment of tuberculosis</ProtocolTitle><Sponsor>Shanghai Public Health Clinical Center</Sponsor><StudyType>Interventional</StudyType><Trial id="359664"/><TrialStartDate>2019-01-01 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="15102">rifapentine</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Toward a Safe and Reachable Preventive Therapy for LTBI: a Multicenter, Randomized, Controlled Study in Taiwan</ProtocolTitle><Sponsor>National Taiwan University Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="207608"/><TrialStartDate>2014-08-31 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="16545">delamanid</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Safety, Efficacy and Pharmacokinetics of OPC-67683 in Patients With Pulmonary Tuberculosis</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="8842"/><TrialStartDate>2006-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="16545">delamanid</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Evaluating the Pharmacokinetics, Safety and Tolerability of Delamanid in Combination With Optimized Multidrug Background Regimen (OBR) for Multidrug-Resistant Tuberculosis (MDR-TB) in HIV-Infected and HIV-Uninfected Children With MDR-TB</ProtocolTitle><Sponsor>National Institute of Allergy and Infectious Diseases, National Institutes of Health</Sponsor><StudyType>Interventional</StudyType><Trial id="297373"/><TrialStartDate>2018-01-30 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>3+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="16545">delamanid</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Evaluating the Safety, Tolerability and Pharmacokinetics of Bedaquiline and Delamanid, Alone and in Combination, For Drug-Resistant Pulmonary Tuberculosis</ProtocolTitle><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><StudyType>Interventional</StudyType><Trial id="243619"/><TrialStartDate>2016-08-31 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="25023">golotimod</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>A Phase II Trial To Study SCV-07 in Tuberculosis (TB) Patients Receiving Standard Anti-TB Chemotherapy</ProtocolTitle><Sponsor>SciClone Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="9345"/><TrialStartDate>2002-09-28 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Drug id="26493">posizolid</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Phase IIa EBA Trial of AZD-5847</ProtocolTitle><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><StudyType>Interventional</StudyType><Trial id="84246"/><TrialStartDate>2012-12-05 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="26493">posizolid</Drug><Endpoint>Safety,Bioavailability,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>A phase I, double-blind, placebo-controlled, flexible single day ascending dose (SDAD) study to evaluate safety, tolerability and pharmacokinetics (PK) of iv AZD-5847 in healthy subjects</ProtocolTitle><Sponsor>AstraZeneca plc</Sponsor><StudyType>Interventional</StudyType><Trial id="82840"/><TrialStartDate>2011-09-20 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Drug id="31010">SQ-109</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>SQ109EBA</ProtocolAcronym><ProtocolTitle>EBA of SQ-109 in Adult Subjects with Pulmonary TB</ProtocolTitle><Sponsor>Ludwig-Maximilians University of Munich</Sponsor><StudyType>Interventional</StudyType><Trial id="71188"/><TrialStartDate>2010-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="31010">SQ-109</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>A phase IIb/III, international, multicenter, prospective, randomized, double-blind, placebo-controlled study to evaluate the efficacy and tolerability of chemotherapy regimens, including drug SQ-109 in patients with pulmonary multidrug-resistant mycobacterium tuberculosis</ProtocolTitle><Sponsor>Infectex</Sponsor><StudyType>Interventional</StudyType><Trial id="168785"/><TrialStartDate>2012-06-27 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="51310">bedaquiline</Drug><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>A Study to Determine the Relative Oral Bioavailability of Single Dose Administration of TMC207, Under Fed and Fasted Conditions in Healthy Participants</ProtocolTitle><Sponsor>Janssen Diagnostics BVBA</Sponsor><StudyType>Interventional</StudyType><Trial id="59134"/><TrialStartDate>2009-08-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="51310">bedaquiline</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>To Evaluate the Safety, Tolerability, and Efficacy of TMC-207 as Part of an Individualized Multi-Drug Resistant Tuberculosis (MDR-TB) Treatment Regimen in Participants With Sputum Smear-Positive Pulmonary MDR-TB</ProtocolTitle><Sponsor>Johnson &amp; Johnson</Sponsor><StudyType>Interventional</StudyType><Trial id="56974"/><TrialStartDate>2009-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="51310">bedaquiline</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>endTB</ProtocolAcronym><ProtocolTitle>Evaluating Newly Approved Drugs for Multidrug-resistant TB</ProtocolTitle><Sponsor>Médecins Sans Frontières France</Sponsor><StudyType>Interventional</StudyType><Trial id="259506"/><TrialStartDate>2016-12-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="51310">bedaquiline</Drug><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>A Study to Assess the Relative Bioavailability of TMC-207 Following Single-dose Administrations of Two Pediatric Formulations in Healthy Adult Participants</ProtocolTitle><Sponsor>Janssen Research &amp; Development LLC</Sponsor><StudyType>Interventional</StudyType><Trial id="114087"/><TrialStartDate>2013-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="55317">MVA-85A</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>A Study of MVA-85A in Healthy Infants</ProtocolTitle><Sponsor>Aeras Global TB Vaccine Foundation</Sponsor><StudyType>Interventional</StudyType><Trial id="59405"/><TrialStartDate>2009-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="55317">MVA-85A</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>EMaBS TB Vaccine Study</ProtocolTitle><Sponsor>University of Oxford</Sponsor><StudyType>Interventional</StudyType><Trial id="354327"/><TrialStartDate>2018-12-01 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="55317">MVA-85A</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>A Phase I Study of the Safety and Immunogenicity of a Recombinant MVA Vaccine Encoding a Secreted Antigen From M Tuberculosis, Antigen 85A, Delivered Intradermally by a Needle Injection in Healthy Volunteers Who Have Previously Received BCG</ProtocolTitle><Sponsor>University of Oxford</Sponsor><StudyType>Interventional</StudyType><Trial id="10874"/><TrialStartDate>2003-05-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="55569">VPM-1002</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Study to Evaluate Safety and Immunogenicity of VPM-1-002 in Comparison With BCG in Newborn Infants in South Africa</ProtocolTitle><Sponsor>Vakzine Projekt Management GmbH</Sponsor><StudyType>Interventional</StudyType><Trial id="82764"/><TrialStartDate>2011-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="55569">VPM-1002</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Study to Check the Efficacy and Safety of Recombinant BCG Vaccine in Prevention of TB Recurrence in India</ProtocolTitle><Sponsor>Serum Institute of India Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="298671"/><TrialStartDate>2017-12-15 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="55569">VPM-1002</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Study to Evaluate the Safety and Immunogenicity of VPM-1002 in Comparison With BCG in HIV-exposed/-Unexposed Newborn Infants in South Africa</ProtocolTitle><Sponsor>Serum Institute of India Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="224781"/><TrialStartDate>2015-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="81363">AEC/BC02</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="PR">Pre-registration</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>A Phase III trial of recombinant tuberculosis vaccine AEC/BC02 in patients with tuberculosis</ProtocolTitle><Sponsor>Chongqing Zhifei Biological Products Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="352354"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="81363">AEC/BC02</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="PR">Pre-registration</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>A Phase I Study of the Recombinant Mycobacterium Tuberculosis Vaccine Freeze-dried</ProtocolTitle><Sponsor>Anhui Zhifei Longcom Biopharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="285854"/><TrialStartDate>2018-04-16 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="90231">DAR-901</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>DAR-PIA</ProtocolAcronym><ProtocolTitle>DAR-901 TB Booster Vaccine to Prevent TB in Adolescents</ProtocolTitle><Sponsor>Dartmouth-Hitchcock Medical Center</Sponsor><StudyType>Interventional</StudyType><Trial id="256110"/><TrialStartDate>2016-03-31 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="91861">clofazimine (oral, tuberculosis), Novartis</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>endTB</ProtocolAcronym><ProtocolTitle>Evaluating Newly Approved Drugs for Multidrug-resistant TB</ProtocolTitle><Sponsor>Médecins Sans Frontières France</Sponsor><StudyType>Interventional</StudyType><Trial id="259506"/><TrialStartDate>2016-12-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>3+</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="14493">tenofovir disoproxil fumarate</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>RIFART</ProtocolAcronym><ProtocolTitle>RIFART</ProtocolTitle><Sponsor>Azienda Ospedaliera Spedali Civili di Brescia</Sponsor><StudyType>Interventional</StudyType><Trial id="131240"/><TrialStartDate>2005-03-15 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="14681">lopinavir + ritonavir</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Pharmacokinetics and Safety of Rifabutin 150 mg qd Versus Rifabutin 300 mg tiw</ProtocolTitle><Sponsor>The HIV Netherlands Australia Thailand Research Collaboration</Sponsor><StudyType>Interventional</StudyType><Trial id="226826"/><TrialStartDate>2015-06-30 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>3+</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="14681">lopinavir + ritonavir</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>RIFART</ProtocolAcronym><ProtocolTitle>RIFART</ProtocolTitle><Sponsor>Azienda Ospedaliera Spedali Civili di Brescia</Sponsor><StudyType>Interventional</StudyType><Trial id="131240"/><TrialStartDate>2005-03-15 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="14681">lopinavir + ritonavir</Drug><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Pharmacokinetics of Rifabutin Combined With Antiretroviral Therapy in Patients With TB/HIV Co-Infection in Vietnam</ProtocolTitle><Sponsor>French National Agency for Research on AIDS and Viral Hepatitis</Sponsor><StudyType>Interventional</StudyType><Trial id="11188"/><TrialStartDate>2010-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>1+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="14681">lopinavir + ritonavir</Drug><Endpoint>Safety,Efficacy,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Pharmacokinetics of Rifabutin Combined With Antiretroviral Therapy in Patients With TB/HIV co-Infection in South Africa</ProtocolTitle><Sponsor>French National Agency for Research on AIDS and Viral Hepatitis</Sponsor><StudyType>Interventional</StudyType><Trial id="11187"/><TrialStartDate>2009-02-28 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>1+</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="4481">stavudine</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Acquired Immunodeficiency Syndrome (AIDS) and Tuberculosis (TB) Co-Infection Treatment Strategies Study of China</ProtocolTitle><Sponsor>Shanghai Public Health Clinical Center</Sponsor><StudyType>Interventional</StudyType><Trial id="76946"/><TrialStartDate>2009-02-28 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="69974">cabotegravir</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Effect of Rifabutin on the Pharmacokinetics of Oral Cabotegravir in Healthy Subjects</ProtocolTitle><Sponsor>ViiV Healthcare Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="298711"/><TrialStartDate>2017-06-06 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>8</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="3412">ivermectin</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>TB-LION</ProtocolAcronym><ProtocolTitle>Tuberculosis - Learning the Impact of Nutrition</ProtocolTitle><Sponsor>Boston Medical Center Corp</Sponsor><StudyType>Interventional</StudyType><Trial id="347635"/><TrialStartDate>2019-06-30 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="2829">clarithromycin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Optimization of MDR-TB Treatment Regimen Based on the Molecular Drug Susceptibility Results of Pyrazinamide</ProtocolTitle><Sponsor>Huashan Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="183613"/><TrialStartDate>2014-04-30 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="2829">clarithromycin</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Drug Interaction Study Between Linezolid and Clarithromycin in Tuberculosis Patients</ProtocolTitle><Sponsor>University Medical Center Groningen</Sponsor><StudyType>Interventional</StudyType><Trial id="182646"/><TrialStartDate>2011-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>4</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="3474">lamivudine</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Effectiveness of Directly Observed Therapy in Combined HIV and Tuberculosis Treatment in Resource-Limited Settings</ProtocolTitle><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><StudyType>Interventional</StudyType><Trial id="8820"/><TrialStartDate>2009-08-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C0">Phase 0 Clinical</DevStatus><Drug id="3474">lamivudine</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>TasP in Correctional Facilities</ProtocolTitle><Sponsor>University of North Carolina</Sponsor><StudyType>Interventional</StudyType><Trial id="280225"/><TrialStartDate>2016-02-01 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="3474">lamivudine</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>ANRS 1295 CAMELIA</ProtocolAcronym><ProtocolTitle>Early versus Late Introduction of Antiretroviral Therapy in HIV-infected Patients With Tuberculosis</ProtocolTitle><Sponsor>French National Agency for Research on AIDS and Viral Hepatitis</Sponsor><StudyType>Interventional</StudyType><Trial id="145651"/><TrialStartDate>2006-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="3474">lamivudine</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>CARINEMO</ProtocolAcronym><ProtocolTitle>Comparison of Nevirapine and Efavirenz for the Treatment of HIV-TB Co-infected Patients</ProtocolTitle><Sponsor>French National Agency for Research on AIDS and Viral Hepatitis</Sponsor><StudyType>Interventional</StudyType><Trial id="10948"/><TrialStartDate>2007-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="3474">lamivudine</Drug><Endpoint>Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Effectiveness of Anti-HIV Therapy (HAART) in HIV-Infected Patients With Tuberculosis</ProtocolTitle><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><StudyType>Interventional</StudyType><Trial id="10646"/><TrialStartDate>2000-02-25 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="10172">efavirenz</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Pharmacokinetics of Efavirenz in the Presence of Rifampicin and Isoniazid</ProtocolTitle><Sponsor>St Stephens Aids Trust</Sponsor><StudyType>Interventional</StudyType><Trial id="265766"/><TrialStartDate>2016-10-21 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="10172">efavirenz</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>ANRS 12154 PECAN</ProtocolAcronym><ProtocolTitle>Pharmacokinetics of efavirenz in combination of rimfampin in HIV-infected adults</ProtocolTitle><Sponsor>INSERM, Institut Pasteur Du Cambodge</Sponsor><StudyType>Interventional</StudyType><Trial id="145595"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="10172">efavirenz</Drug><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Pharmacokinetics of Rifabutin Combined With Antiretroviral Therapy in Patients With TB/HIV Co-Infection in Vietnam</ProtocolTitle><Sponsor>French National Agency for Research on AIDS and Viral Hepatitis</Sponsor><StudyType>Interventional</StudyType><Trial id="11188"/><TrialStartDate>2010-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>1+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="10172">efavirenz</Drug><Endpoint>Safety,Efficacy,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Pharmacokinetics of Rifabutin Combined With Antiretroviral Therapy in Patients With TB/HIV co-Infection in South Africa</ProtocolTitle><Sponsor>French National Agency for Research on AIDS and Viral Hepatitis</Sponsor><StudyType>Interventional</StudyType><Trial id="11187"/><TrialStartDate>2009-02-28 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="10172">efavirenz</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>OPTI-NNRTI</ProtocolAcronym><ProtocolTitle>A Study to Determine the Best Dose of Antivirals in Patients With Both TB and HIV</ProtocolTitle><Sponsor>Stanford University</Sponsor><StudyType>Interventional</StudyType><Trial id="11177"/><TrialStartDate>2007-07-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="3700">nevirapine</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>TMC207-TiDP13-C117: Interaction Study in Human Immunodeficiency Virus-type 1 (HIV-1) Infected Patients With Nevirapine (NVP)</ProtocolTitle><Sponsor>Janssen Diagnostics BVBA, Johnson &amp; Johnson</Sponsor><StudyType>Interventional</StudyType><Trial id="56959"/><TrialStartDate>2009-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="3700">nevirapine</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Efficacy Safety Study Comparing two Doses of NVP After Initiating Rifampin-Containing TB Therapy</ProtocolTitle><Sponsor>The HIV Netherlands Australia Thailand Research Collaboration</Sponsor><StudyType>Interventional</StudyType><Trial id="10946"/><TrialStartDate>2005-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Drug id="44284">amoxicillin + clavulanate potassium, GSK</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Early Bactericidal Activity of Rifampin + Meropenem + Amoxicillin/Clavulanate in Adults With Pulmonary TB</ProtocolTitle><Sponsor>Johns Hopkins University</Sponsor><StudyType>Interventional</StudyType><Trial id="300655"/><TrialStartDate>2017-08-23 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Drug id="46927">doxycycline hyclate</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>Map2Co</ProtocolAcronym><ProtocolTitle>Concomitant Infections of Mansonella Perstans in Tuberculosis and Buruli Ulcer Disease Patients From Ghana</ProtocolTitle><Sponsor>kwame Nkrumah University of Science and Technology</Sponsor><StudyType>Interventional</StudyType><Trial id="214864"/><TrialStartDate>2014-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="44279">amoxicillin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>ACT-TB</ProtocolAcronym><ProtocolTitle>Accuracy and Consequences of Using Trial-of-antibiotics for TB Diagnosis</ProtocolTitle><Sponsor>London School of Hygiene and Tropical Medicine</Sponsor><StudyType>Interventional</StudyType><Trial id="341686"/><TrialStartDate>2019-02-25 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="11036">linezolid</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>SIMPLE</ProtocolAcronym><ProtocolTitle>Pharmacokinetic Study of Linezolid for TB Meningitis</ProtocolTitle><Sponsor>Universitas Padjadjaran</Sponsor><StudyType>Interventional</StudyType><Trial id="340851"/><TrialStartDate>2019-06-30 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>3+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="11036">linezolid</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>A Phase II Clinical Study of LCB01-0371 to Evaluate the EBA, Safety and PK</ProtocolTitle><Sponsor>LegoChem Bioscience Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="265899"/><TrialStartDate>2016-12-10 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Drug id="11036">linezolid</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Linezolid to Treat Extensively-Drug Resistant Tuberculosis</ProtocolTitle><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><StudyType>Interventional</StudyType><Trial id="23143"/><TrialStartDate>2008-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Drug id="59062">dolutegravir</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>SAEFRIF</ProtocolAcronym><ProtocolTitle>Safety and Efficacy of High Dose Rifampicin in Tuberculosis (TB)-HIV Co-infected Patients on Efavirenz- or Dolutegravir-based Antiretroviral Therapy</ProtocolTitle><Sponsor>Makerere University</Sponsor><StudyType>Interventional</StudyType><Trial id="384080"/><TrialStartDate>2019-04-30 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>3</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="59062">dolutegravir</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Efficacy, Safety and Pharmacokinetics of DTG With RIF</ProtocolTitle><Sponsor>The HIV Netherlands Australia Thailand Research Collaboration</Sponsor><StudyType>Interventional</StudyType><Trial id="359086"/><TrialStartDate>2019-03-01 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="54488">raltegravir</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Raltegravir + ABC/3TC in HIV/TB Co-Infected Patients</ProtocolTitle><Sponsor>Central Research Institute of Epidemiology</Sponsor><StudyType>Interventional</StudyType><Trial id="63729"/><TrialStartDate>2010-10-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="54488">raltegravir</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Evaluating the Safety, Tolerance, and Pharmacokinetics of a Raltegravir-containing Antiretroviral Therapy (ART) Regimen in Infants and Children Infected With HIV and TB</ProtocolTitle><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><StudyType>Interventional</StudyType><Trial id="102102"/><TrialStartDate>2014-05-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="74480">doravirine</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>DORIIS</ProtocolAcronym><ProtocolTitle>Doravirine, Rifapentine and Isoniazid Interaction</ProtocolTitle><Sponsor>Thomas Jefferson University</Sponsor><StudyType>Interventional</StudyType><Trial id="374387"/><TrialStartDate>2019-04-30 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="44316">zidovudine</Drug><Endpoint>Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Effectiveness of Anti-HIV Therapy (HAART) in HIV-Infected Patients With Tuberculosis</ProtocolTitle><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><StudyType>Interventional</StudyType><Trial id="10646"/><TrialStartDate>2000-02-25 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="5321">indinavir</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>A prospective, open-label, pilot study to evaluate the pharmacokinetics (PK)/safety/efficacy of an adjusted dose of indinavir/ritonavir (IDV/r) 600/100 mg plus two nucleoside reverse transcriptase inhibitors (NRTIs) in HIV/TB-coinfected Thais receiving rifampicin-based anti-TB treatment</ProtocolTitle><Sponsor>Thai Red Cross AIDS Research Centre</Sponsor><StudyType>Interventional</StudyType><Trial id="100728"/><TrialStartDate>2012-01-17 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="4492">faropenem</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Trial of faropenem and cefadroxil (in combination with amoxicillin/clavulanic acid and standard TB drugs) in patients with pulmonary tuberculosis: measurement of early bactericidal activity and effects on novel biomarkers</ProtocolTitle><Sponsor>National University Hospital (Singapore) Pte Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="360329"/><TrialStartDate>2018-11-30 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="3492">levofloxacin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>LEVOF</ProtocolAcronym><ProtocolTitle>MDR TB, Levofloxacin, Multi-Drug-Resistant Pulmonary Tuberculosis</ProtocolTitle><Sponsor>Sanofi SA</Sponsor><StudyType>Interventional</StudyType><Trial id="8644"/><TrialStartDate>2007-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>1+</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="3492">levofloxacin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>SURE</ProtocolAcronym><ProtocolTitle>Short Intensive Treatment For Children With Tuberculous Meningitis</ProtocolTitle><Sponsor>University College London</Sponsor><StudyType>Interventional</StudyType><Trial id="360104"/><TrialStartDate>2018-01-02 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="3492">levofloxacin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>LAST ACT</ProtocolAcronym><ProtocolTitle>Leukotriene A4 Hydrolase Stratified Trial of Adjunctive Corticosteroids for HIV-uninfected Adults With Tuberculous Meningitis</ProtocolTitle><Sponsor>Oxford University Clinical Research Unit, Vietnam</Sponsor><StudyType>Interventional</StudyType><Trial id="293087"/><TrialStartDate>2018-02-08 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="3492">levofloxacin</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>TBM-KIDS</ProtocolAcronym><ProtocolTitle>Optimizing Treatment to Improve TBM Outcomes in Children</ProtocolTitle><Sponsor>Johns Hopkins University</Sponsor><StudyType>Interventional</StudyType><Trial id="278847"/><TrialStartDate>2017-02-22 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="4229">rifabutin</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Effect of Rifabutin on the Pharmacokinetics of Oral Cabotegravir in Healthy Subjects</ProtocolTitle><Sponsor>ViiV Healthcare Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="298711"/><TrialStartDate>2017-06-06 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="4229">rifabutin</Drug><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>A Bioavailability Study of Rifabutin and Lopinavir/Ritonavir in Healthy Adult Subjects</ProtocolTitle><Sponsor>Abbott Laboratories</Sponsor><StudyType>Interventional</StudyType><Trial id="25327"/><TrialStartDate>2008-08-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="4229">rifabutin</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Pharmacokinetics and Safety of Rifabutin 150 mg qd Versus Rifabutin 300 mg tiw</ProtocolTitle><Sponsor>The HIV Netherlands Australia Thailand Research Collaboration</Sponsor><StudyType>Interventional</StudyType><Trial id="226826"/><TrialStartDate>2015-06-30 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="4229">rifabutin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>An open-label, comparative, multicenter trial to evaluate long-term tolerance and effectiveness of moxifloxacin therapy for tuberculosis</ProtocolTitle><Sponsor>Ospedale Ninetto Melli</Sponsor><StudyType>Interventional</StudyType><Trial id="113726"/><TrialStartDate>2003-02-28 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="4229">rifabutin</Drug><Endpoint>Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Effectiveness of Anti-HIV Therapy (HAART) in HIV-Infected Patients With Tuberculosis</ProtocolTitle><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><StudyType>Interventional</StudyType><Trial id="10646"/><TrialStartDate>2000-02-25 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="9490">MTB72F vaccine (tuberculosis), GSK/ IAVI</Drug><Endpoint>Safety</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>A phase I study to evaluate the safety and immunogenicity of a novel, proprietary prophylactic vaccine MTB72F to induce protection against tuberculosis (TB)</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="9554"/><TrialStartDate>2004-03-08 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="9490">MTB72F vaccine (tuberculosis), GSK/ IAVI</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Safety and Immunogenicity of GSK Biological's Candidate Tuberculosis Vaccine Mtb72F/AS02 in Healthy PPD-Negative Adults</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="9540"/><TrialStartDate>2004-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Essentiality of INH in TB Therapy</ProtocolTitle><Sponsor>AIDS Clinical Trials Group</Sponsor><StudyType>Interventional</StudyType><Trial id="87091"/><TrialStartDate>2015-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>PRACTECAL-PRO</ProtocolAcronym><ProtocolTitle>Patient-reported Experiences and Quality of Life Outcomes in the TB-PRACTECAL Clinical Trial</ProtocolTitle><Sponsor>Medecins Sans Frontieres, Netherlands</Sponsor><StudyType>Interventional</StudyType><Trial id="379769"/><TrialStartDate>2019-07-01 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Rifapentine Plus Moxifloxacin for Treatment of Pulmonary Tuberculosis</ProtocolTitle><Sponsor>Johns Hopkins University</Sponsor><StudyType>Interventional</StudyType><Trial id="23035"/><TrialStartDate>2009-11-30 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><Endpoint>Bioequivalence</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Bioequivalency Study of Moxifloxacin Tablets, 400 mg Under Fasting Conditions</ProtocolTitle><Sponsor>Dr Reddy's Laboratories Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="218651"/><TrialStartDate>2012-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>IMPRESS</ProtocolAcronym><ProtocolTitle>Improving Retreatment Success</ProtocolTitle><Sponsor>Centre for the AIDS Program of Research in South Africa</Sponsor><StudyType>Interventional</StudyType><Trial id="182040"/><TrialStartDate>2013-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><Endpoint>Safety,Efficacy,Bioequivalence,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>TBTC/UITB Study 28</ProtocolAcronym><ProtocolTitle>Evaluation of a Moxifloxacin-Based, Isoniazid-Sparing Regimen for Tuberculosis Treatment TBTC/UITB Study 28</ProtocolTitle><Sponsor>Tuberculosis Investigation Unit of Barcelona</Sponsor><StudyType>Interventional</StudyType><Trial id="155451"/><TrialStartDate>2006-05-01 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="13323">pretomanid</Drug><Endpoint>Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="PR">Pre-registration</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>A phase I, controlled study to evaluate the pharmacokinetics and efficacy of PA-824 in patients with tuberculosis</ProtocolTitle><Sponsor>Chiron PathoGenesis</Sponsor><StudyType>Interventional</StudyType><Trial id="70963"/><TrialStartDate>2010-09-13 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="13323">pretomanid</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="PR">Pre-registration</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>PRACTECAL-PRO</ProtocolAcronym><ProtocolTitle>Patient-reported Experiences and Quality of Life Outcomes in the TB-PRACTECAL Clinical Trial</ProtocolTitle><Sponsor>Medecins Sans Frontieres, Netherlands</Sponsor><StudyType>Interventional</StudyType><Trial id="379769"/><TrialStartDate>2019-07-01 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="13323">pretomanid</Drug><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="PR">Pre-registration</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Food Effect Study on the Bioavailability and PK of PA-824 Tablets in Healthy Adult Subjects</ProtocolTitle><Sponsor>TB Alliance</Sponsor><StudyType>Interventional</StudyType><Trial id="120522"/><TrialStartDate>2007-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="15102">rifapentine</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Tuberculosis Prevention for HIV Infected Adults</ProtocolTitle><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><StudyType>Interventional</StudyType><Trial id="8790"/><TrialStartDate>2002-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="15102">rifapentine</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>ASTEROID</ProtocolAcronym><ProtocolTitle>Assessment of the Safety, Tolerability, and Effectiveness of Rifapentine Given Daily for LTBI</ProtocolTitle><Sponsor>Centers for Disease Control and Prevention</Sponsor><StudyType>Interventional</StudyType><Trial id="333384"/><TrialStartDate>2019-07-31 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="15102">rifapentine</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Impact of Once-Weekly Rifapentine and Isoniazid on the Steady State Pharmacokinetics of Dolutegravir and Darunavir Boosted With Cobicistat in Healthy Volunteers</ProtocolTitle><Sponsor>National Institutes of Health Clinical Center</Sponsor><StudyType>Interventional</StudyType><Trial id="260814"/><TrialStartDate>2016-06-03 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="15102">rifapentine</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>iAdhere</ProtocolAcronym><ProtocolTitle>Adherence to Latent Tuberculosis Infection Treatment 3HP SAT Versus 3HP DOT</ProtocolTitle><Sponsor>Centers for Disease Control and Prevention, Tuberculosis Investigation Unit of Barcelona</Sponsor><StudyType>Interventional</StudyType><Trial id="177457"/><TrialStartDate>2012-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="15102">rifapentine</Drug><Endpoint>Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>TBTC-26 PK</ProtocolAcronym><ProtocolTitle>Rifapentine Pharmacokinetics in Children During Treatment of Latent TB Infection</ProtocolTitle><Sponsor>Centers for Disease Control and Prevention</Sponsor><StudyType>Interventional</StudyType><Trial id="10687"/><TrialStartDate>2005-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="15102">rifapentine</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>PREVENT TB</ProtocolAcronym><ProtocolTitle>A 3 Months of Weekly Rifapentine and Isoniazid for M Tuberculosis Infection</ProtocolTitle><Sponsor>Centers for Disease Control and Prevention</Sponsor><StudyType>Interventional</StudyType><Trial id="10659"/><TrialStartDate>2001-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="16545">delamanid</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>DRAMATIC</ProtocolAcronym><ProtocolTitle>Efficacy and Tolerability of Bedaquiline, Delamanid, Levofloxacin, Linezolid, and Clofazimine for Treatment of Patients With MDR-TB</ProtocolTitle><Sponsor>Boston University</Sponsor><StudyType>Interventional</StudyType><Trial id="368916"/><TrialStartDate>2020-01-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="48499">H4:IC31</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>A Randomized, Placebo-Controlled, Partially-Blinded, Phase II Study to Evaluate Safety, Immunogenicity, and Prevention of Infection With Mycobacterium Tuberculosis of AERAS-404 and BCG Revaccination in Healthy Adolescents</ProtocolTitle><Sponsor>Aeras Global TB Vaccine Foundation</Sponsor><StudyType>Interventional</StudyType><Trial id="176219"/><TrialStartDate>2014-02-28 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Drug id="49162">LL-3858</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>A phase IIa clinical trial for a novel molecule (LL-3858) developed by Lupin Limited which has the potential of treating the Pulmonary tuberculosis patients effectively</ProtocolTitle><Sponsor>Lupin Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="103573"/><TrialStartDate>2009-12-02 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Drug id="51310">bedaquiline</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Anti-bacterial Activity, Safety, and Tolerability of TMC-207 in Participants With Multi-drug Resistant Mycobacterium Tuberculosis (MDR-TB)</ProtocolTitle><Sponsor>Janssen R&amp;D (Ireland)</Sponsor><StudyType>Interventional</StudyType><Trial id="9302"/><TrialStartDate>2007-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="51310">bedaquiline</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>TMC-207 +/- Rifabutin/Rifampin</ProtocolTitle><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><StudyType>Interventional</StudyType><Trial id="76765"/><TrialStartDate>2011-10-21 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Drug id="51310">bedaquiline</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>SUDOCU</ProtocolAcronym><ProtocolTitle>PanACEA Sutezolid Dose-finding and Combination Evaluation</ProtocolTitle><Sponsor>Ludwig-Maximilians University of Munich</Sponsor><StudyType>Interventional</StudyType><Trial id="381674"/><TrialStartDate>2019-08-31 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="51310">bedaquiline</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>A prospective, unblinded, non-randomized, single-center study to evaluate outcomes of bedaquiline-included regimens in multidrug-resistance/extensively drug-resistant (MDR/XDR) tuberculosis patients after 24 months and to identify factors predisposing the long-term treatment success</ProtocolTitle><Sponsor>Moscow City Research Center For Tuberculosis Department Of Healthcare</Sponsor><StudyType>Interventional</StudyType><Trial id="361163"/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>3+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="51310">bedaquiline</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Evaluating the Safety, Tolerability and Pharmacokinetics of Bedaquiline and Delamanid, Alone and in Combination, For Drug-Resistant Pulmonary Tuberculosis</ProtocolTitle><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><StudyType>Interventional</StudyType><Trial id="243619"/><TrialStartDate>2016-08-31 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="51310">bedaquiline</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>STREAM</ProtocolAcronym><ProtocolTitle>The Evaluation of a Standard Treatment Regimen of Anti-Tuberculosis Drugs for Patients With MDR-TB</ProtocolTitle><Sponsor>International Union Against Tuberculosis and Lung Diseases</Sponsor><StudyType>Interventional</StudyType><Trial id="228190"/><TrialStartDate>2016-04-30 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Drug id="51310">bedaquiline</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>A Phase II to Evaluate the Efficacy, Safety and Tolerability of Combinations of Bedaquiline, Moxifloxacin, PA-824 and Pyrazinamide in Adult Subjects With Drug-Sensitive or Multi Drug-Resistant Pulmonary Tuberculosis</ProtocolTitle><Sponsor>TB Alliance</Sponsor><StudyType>Interventional</StudyType><Trial id="210646"/><TrialStartDate>2014-10-23 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="53975">AERAS-402</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>A phase I, double-blind, randomized, placebo-controlled, safety and immunogenicity study of AERAS-402, a potential vaccine for Mycobacterium tuberculosis infection</ProtocolTitle><Sponsor>Crucell NV</Sponsor><StudyType>Interventional</StudyType><Trial id="8499"/><TrialStartDate>2007-12-21 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="53975">AERAS-402</Drug><Endpoint>Safety</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>A phase I study to test the safety of AERAS-402 in healthy infants previously vaccinated with the Bacille Calmette-Guerin (BCG) vaccine</ProtocolTitle><Sponsor>Aeras Global TB Vaccine Foundation, Crucell NV</Sponsor><StudyType>Interventional</StudyType><Trial id="53622"/><TrialStartDate>2009-04-28 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="53975">AERAS-402</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>A Study to Evaluate Safety and Immunogenicity of AERAS-402 Administered in HIV-negative, BCG-vaccinated, QFT (+) and (-) Adults Without Evidence of TB</ProtocolTitle><Sponsor>Aeras Global TB Vaccine Foundation</Sponsor><StudyType>Interventional</StudyType><Trial id="228651"/><TrialStartDate>2008-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="55317">MVA-85A</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Safety of Tuberculosis Vaccine, MVA-85A, Administered by the Aerosol Route and the Intradermal Route</ProtocolTitle><Sponsor>University of Oxford</Sponsor><StudyType>Interventional</StudyType><Trial id="83464"/><TrialStartDate>2011-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="55317">MVA-85A</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>TB036</ProtocolAcronym><ProtocolTitle>Trial to Investigate the Effect of Schistosoma Mansoni Infection on the Response to Vaccination With MVA-85A in BCG-vaccinated African Adolescents</ProtocolTitle><Sponsor>University of Oxford</Sponsor><StudyType>Interventional</StudyType><Trial id="201409"/><TrialStartDate>2014-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="55317">MVA-85A</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Phase I Trial Evaluating Safety and Immunogenicity of MVA-85A-IMX3-13 Compared to MVA-85A in BCG Vaccinated Adults</ProtocolTitle><Sponsor>University of Oxford</Sponsor><StudyType>Interventional</StudyType><Trial id="142322"/><TrialStartDate>2013-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="55317">MVA-85A</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>A Phase I Study of the Safety and Immunogenicity of MVA85A in Healthy Gambian Volunteers</ProtocolTitle><Sponsor>University of Oxford</Sponsor><StudyType>Interventional</StudyType><Trial id="10872"/><TrialStartDate>2003-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>6</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="59386">CC-11050</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>TBHDT</ProtocolAcronym><ProtocolTitle>TB Host Directed Therapy</ProtocolTitle><Sponsor>Aurum Institute</Sponsor><StudyType>Interventional</StudyType><Trial id="279898"/><TrialStartDate>2016-11-30 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1B">Phase 1b Clinical</DevStatus><Drug id="68617">ID93 vaccine (GLA-SE adjuvant, TB), IDRI/ Quratis</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Phase I, ID93 + GLA-SE Vaccine Trial in BCG-vaccinated Healthy Adult Volunteers</ProtocolTitle><Sponsor>Infectious Disease Research Institute</Sponsor><StudyType>Interventional</StudyType><Trial id="151743"/><TrialStartDate>2013-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="69440">rifampicin + isoniazid + piperine (fixed dose combination, tuberculosis), Cadila Pharmaceuticals</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Clinical Trial for Comparing Safety and Efficacy of Bio-enhanced Rifampicin (Risorine) Capsule in newly diagnosed Pulmonary Tuberculosis in Adult Patients</ProtocolTitle><Sponsor>All India Institute of Medical Sciences</Sponsor><StudyType>Interventional</StudyType><Trial id="295037"/><TrialStartDate>2017-04-17 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="69440">rifampicin + isoniazid + piperine (fixed dose combination, tuberculosis), Cadila Pharmaceuticals</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>A Risorine Study in Sputum Positive Patients After 8 Weeks of Conventional Treatment</ProtocolTitle><Sponsor>Cadila Pharmaceuticals Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="138715"/><TrialStartDate>2012-06-10 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="69440">rifampicin + isoniazid + piperine (fixed dose combination, tuberculosis), Cadila Pharmaceuticals</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Comparative Evaluation of the Effect of Risorine in Patients With Newly Diagnosed Sputum Smear Positive Pulmonary Tuberculosis</ProtocolTitle><Sponsor>Cadila Pharmaceuticals Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="118547"/><TrialStartDate>2011-02-10 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="74849">SSI H56-IC31</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Safety and Immunogenicity Study of AERAS-456 Vaccine for Tuberculosis</ProtocolTitle><Sponsor>Aeras Global TB Vaccine Foundation</Sponsor><StudyType>Interventional</StudyType><Trial id="158535"/><TrialStartDate>2011-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="74849">SSI H56-IC31</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>A Phase I/IIa Safety And Immunogenicity of AERAS-456 in HIV-Negative Adults With And Without Latent Tuberculosis Infection</ProtocolTitle><Sponsor>Aeras Global TB Vaccine Foundation</Sponsor><StudyType>Interventional</StudyType><Trial id="136263"/><TrialStartDate>2013-08-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="87251">Perchlozone</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>An open, phase I study to study the pharmacokinetics, safety and tolerability of Perhlozone (400 mg capsules) in healthy volunteers after a single dose</ProtocolTitle><Sponsor>Pharmasyntez</Sponsor><StudyType>Interventional</StudyType><Trial id="167779"/><TrialStartDate>2012-03-20 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="89744">MTBVAC</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>MTBVAC-Ph1b</ProtocolAcronym><ProtocolTitle>Dose-escalation, Safety and Immunogenicity Study to Compare MTBVAC to BCG in Newborns With a Safety Arm in Adults</ProtocolTitle><Sponsor>Biofabri SL</Sponsor><StudyType>Interventional</StudyType><Trial id="257534"/><TrialStartDate>2015-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Drug id="90085">macozinone</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Phase IIa Study of PBTZ-169</ProtocolTitle><Sponsor>Nearmedic Plus</Sponsor><StudyType>Interventional</StudyType><Trial id="318771"/><TrialStartDate>2016-12-16 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Drug id="90085">macozinone</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>International, multicenter, double-blind, placebo-controlled, randomized trial to evaluate the efficacy, safety and pharmacokinetics of PBTZ-169 when used in combination therapy in patients with tuberculosis of respiratory organs with bacterial excretion and drug resistance</ProtocolTitle><Sponsor>Nearmedic Plus</Sponsor><StudyType>Interventional</StudyType><Trial id="316145"/><TrialStartDate>2017-08-17 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="91861">clofazimine (oral, tuberculosis), Novartis</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>CORTAIL</ProtocolAcronym><ProtocolTitle>Evaluation of clofazimine as a part of TB treatment in order to shorten the duration of treatment</ProtocolTitle><Sponsor>Indian Council of Medical Research</Sponsor><StudyType>Interventional</StudyType><Trial id="373668"/><TrialStartDate>2019-04-01 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="91861">clofazimine (oral, tuberculosis), Novartis</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>A randomized, multicenter, controlled trial for clofazimine-containing protocol in the treatment of newly diagnosed multidrug-resistant tuberculosis</ProtocolTitle><Sponsor>Beijing Chest Hospital, Capital Medical University</Sponsor><StudyType>Interventional</StudyType><Trial id="365020"/><TrialStartDate>2012-12-01 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="91861">clofazimine (oral, tuberculosis), Novartis</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Multicenter, controlled clinical study of the safety, tolerability and efficacy of clofazimine in the treatment of drug-resistant tuberculosis</ProtocolTitle><Sponsor>Beijing Chest Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="328802"/><TrialStartDate>2009-12-01 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="95442">ESAT-6CFP10</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Recombinant Mycobacterium tuberculosis allergen ESAT6-CFP10 for 18 to 65 years old healthy people: randomized, blinded, parallel-group phase III clinical trial</ProtocolTitle><Sponsor>Jiangsu Provincial Academy Of Environmental Science</Sponsor><StudyType>Interventional</StudyType><Trial id="252783"/><TrialStartDate>2016-02-17 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="98373">TB/FLU-04L</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Reactogenicity, Safety and Immunogenicity of a TB/FLU-04L Tuberculosis Vaccine</ProtocolTitle><Sponsor>National Center for Biotechnology of the Republic of Kazakhstan</Sponsor><StudyType>Interventional</StudyType><Trial id="235054"/><TrialStartDate>2013-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="22216">etoricoxib</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>TBCOX2</ProtocolAcronym><ProtocolTitle>Therapeutic Vaccination and Immune Modulation - New Treatment Strategies for the MDR Tuberculosis Pandemic</ProtocolTitle><Sponsor>Oslo University Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="235355"/><TrialStartDate>2015-11-30 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="14681">lopinavir + ritonavir</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Evaluating the Safety and Drug Interaction of PA-824, an Investigational Tuberculosis Medication, Together With Efavirenz, Ritonavir-Boosted Lopinavir or Rifampin</ProtocolTitle><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><StudyType>Interventional</StudyType><Trial id="86312"/><TrialStartDate>2012-05-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="6748">Recombivax HB</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>ELVIS</ProtocolAcronym><ProtocolTitle>A Trial Investigating the Influence of BCG and Hepatitis B Immunization at Birth on Neonatal Immune Responses: The Early Life Vaccines and Immunity Study</ProtocolTitle><Sponsor>Murdoch Childrens Research Institute</Sponsor><StudyType>Interventional</StudyType><Trial id="229498"/><TrialStartDate>2015-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="2935">didanosine</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Safety and Efficacy of Two Once Daily Anti Retroviral Treatment Regimens Along With Anti-Tuberculosis Treatment</ProtocolTitle><Sponsor>Tuberculosis Research Centre</Sponsor><StudyType>Interventional</StudyType><Trial id="10863"/><TrialStartDate>2006-06-30 00:00:00</TrialStartDate><TrialStatus>Suspended</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="44363">trimethoprim + sulphamethoxazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Daily Isoniazid to Prevent Tuberculosis in Infants Born to Mothers With HIV</ProtocolTitle><Sponsor>International Maternal Pediatric Adolescent AIDS Clinical Trials Group</Sponsor><StudyType>Interventional</StudyType><Trial id="187839"/><TrialStartDate>2004-02-29 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="3474">lamivudine</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Raltegravir + ABC/3TC in HIV/TB Co-Infected Patients</ProtocolTitle><Sponsor>Central Research Institute of Epidemiology</Sponsor><StudyType>Interventional</StudyType><Trial id="63729"/><TrialStartDate>2010-10-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="3474">lamivudine</Drug><Endpoint>Safety</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>TIME</ProtocolAcronym><ProtocolTitle>Appropriate Timing of HAART in Co-infected HIV/TB Patients</ProtocolTitle><Sponsor>Bamrasnaradura Infectious Diseases Institute</Sponsor><StudyType>Interventional</StudyType><Trial id="61991"/><TrialStartDate>2009-10-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="3474">lamivudine</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>Pred-ART</ProtocolAcronym><ProtocolTitle>Preventing TB-IRIS in High-risk Patients: a Randomized, Placebo-controlled Trial of Prednisone</ProtocolTitle><Sponsor>University of Cape Town</Sponsor><StudyType>Interventional</StudyType><Trial id="150793"/><TrialStartDate>2013-08-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>4+</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="3474">lamivudine</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Once-Daily Dose of Nevirapine (400 mg) Versus Twice Daily Dose (200 mg) of Nevirapine in HIV and Tuberculosis Infection</ProtocolTitle><Sponsor>National AIDS Control Organization</Sponsor><StudyType>Interventional</StudyType><Trial id="126486"/><TrialStartDate>2012-09-01 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>1+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="3474">lamivudine</Drug><Endpoint>Safety,Efficacy,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Pharmacokinetics of Rifabutin Combined With Antiretroviral Therapy in Patients With TB/HIV co-Infection in South Africa</ProtocolTitle><Sponsor>French National Agency for Research on AIDS and Viral Hepatitis</Sponsor><StudyType>Interventional</StudyType><Trial id="11187"/><TrialStartDate>2009-02-28 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="3474">lamivudine</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Safety and Efficacy of Two Once Daily Anti Retroviral Treatment Regimens Along With Anti-Tuberculosis Treatment</ProtocolTitle><Sponsor>Tuberculosis Research Centre</Sponsor><StudyType>Interventional</StudyType><Trial id="10863"/><TrialStartDate>2006-06-30 00:00:00</TrialStartDate><TrialStatus>Suspended</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="4155">pravastatin</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>StAT-TB</ProtocolAcronym><ProtocolTitle>Statin Adjunctive Therapy for TB</ProtocolTitle><Sponsor>Johns Hopkins University</Sponsor><StudyType>Interventional</StudyType><Trial id="331728"/><TrialStartDate>2019-08-15 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="11089">nitazoxanide</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>A 14-Day Early Bactericidal Activity Study of Nitazoxanide for the Treatment of Tuberculosis</ProtocolTitle><Sponsor>Weill Medical College of Cornell University</Sponsor><StudyType>Interventional</StudyType><Trial id="253491"/><TrialStartDate>2016-02-29 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="49219">tenofovir disoproxil fumarate + emtricitabine (fixed dose), Gilead Sciences</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Pharmacokinetics of Efavirenz in the Presence of Rifampicin and Isoniazid</ProtocolTitle><Sponsor>St Stephens Aids Trust</Sponsor><StudyType>Interventional</StudyType><Trial id="265766"/><TrialStartDate>2016-10-21 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="49219">tenofovir disoproxil fumarate + emtricitabine (fixed dose), Gilead Sciences</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Simultaneous Versus Sequential Antiretroviral Therapy (ARV) Therapy and Mycobacterium Tuberculosis (MTB) Treatment</ProtocolTitle><Sponsor>Instituto Nacional de Enfermedades Respiratorias</Sponsor><StudyType>Interventional</StudyType><Trial id="169697"/><TrialStartDate>2008-03-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>5</ArmCount><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="7017">gatifloxacin</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>TBRU 10</ProtocolAcronym><ProtocolTitle>Early Bactericidal Activity of Linezolid, Gatifloxacin, Levofloxacin, Isoniazid (INH) and Moxifloxacin in HIV Negative Adults With Initial Episodes of Sputum Smear-Positive Pulmonary Tuberculosis</ProtocolTitle><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><StudyType>Interventional</StudyType><Trial id="10869"/><TrialStartDate>2004-02-29 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C0">Phase 0 Clinical</DevStatus><Drug id="13624">BCG vaccine, Organon</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Leukapheresis Sampling for Immune Responses After BCG Vaccination in BCG-naive Healthy Adults in the US</ProtocolTitle><Sponsor>Aeras Global TB Vaccine Foundation</Sponsor><StudyType>Interventional</StudyType><Trial id="227341"/><TrialStartDate>2015-05-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="10172">efavirenz</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>TEMPRANO</ProtocolAcronym><ProtocolTitle>Early Antiretroviral Treatment and/or Early Isoniazid Prophylaxis Against Tuberculosis in HIV-Infected Adults</ProtocolTitle><Sponsor>French National Agency for Research on AIDS and Viral Hepatitis</Sponsor><StudyType>Interventional</StudyType><Trial id="195741"/><TrialStartDate>2008-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="10172">efavirenz</Drug><Endpoint>Safety,Efficacy,Bioavailability</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>PK-TB-HAART</ProtocolAcronym><ProtocolTitle>Bioavailability of the Fixed Dose Formulation Rifafour Containing Isoniazid, Rifampicin, Pyrazinamide, Ethambutol and the World Health Organization (WHO) Recommended First Line Antiretroviral Drugs Zidovudine, Lamivudine, Efavirenz Administered to New Tuberculosis (TB) Patients at Different Levels of Immunosuppression</ProtocolTitle><Sponsor>World Health Organization</Sponsor><StudyType>Interventional</StudyType><Trial id="136052"/><TrialStartDate>2006-05-29 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="4718">zileuton</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Optimization of Clinical Treatment Schemes for Multidrug - Resistant Pulmonary Tuberculosis Based on Host - Mediate</ProtocolTitle><Sponsor>Shanghai Public Health Clinical Center</Sponsor><StudyType>Interventional</StudyType><Trial id="276708"/><TrialStartDate>2016-10-20 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="3700">nevirapine</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>"NVP"</ProtocolAcronym><ProtocolTitle>Efficacy and Safety of Concomitant Use of Nevirapine and Rifampicin With HIV-TB</ProtocolTitle><Sponsor>All India Institute of Medical Sciences</Sponsor><StudyType>Interventional</StudyType><Trial id="114300"/><TrialStartDate>2007-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="3700">nevirapine</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>OPTI-NNRTI</ProtocolAcronym><ProtocolTitle>A Study to Determine the Best Dose of Antivirals in Patients With Both TB and HIV</ProtocolTitle><Sponsor>Stanford University</Sponsor><StudyType>Interventional</StudyType><Trial id="11177"/><TrialStartDate>2007-07-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>4</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="3700">nevirapine</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>N2R</ProtocolAcronym><ProtocolTitle>Efavirenz-Based Versus Nevirapine-Based Antiretroviral Therapy Among HIV-Infected Patients Receiving Rifampin</ProtocolTitle><Sponsor>Bamrasnaradura Infectious Diseases Institute</Sponsor><StudyType>Interventional</StudyType><Trial id="10947"/><TrialStartDate>2007-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="44284">amoxicillin + clavulanate potassium, GSK</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Phase II Trial to Evaluate the Early Bactericidal Activity, Safety and Tolerability of Meropenem Plus Amoxycillin/CA and Faropenem Plus Amoxycillin/CA in Adult Patients With Newly Diagnosed Pulmonary Tuberculosis</ProtocolTitle><Sponsor>Task Foundation NPC</Sponsor><StudyType>Interventional</StudyType><Trial id="220739"/><TrialStartDate>2014-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="6242">abacavir</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Raltegravir + ABC/3TC in HIV/TB Co-Infected Patients</ProtocolTitle><Sponsor>Central Research Institute of Epidemiology</Sponsor><StudyType>Interventional</StudyType><Trial id="63729"/><TrialStartDate>2010-10-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="44303">midazolam hydrochloride</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>A Phase I Study to Evaluate Safety, Tolerability, PK, and PK Interactions of TBA-7371</ProtocolTitle><Sponsor>TB Alliance</Sponsor><StudyType>Interventional</StudyType><Trial id="303756"/><TrialStartDate>2017-08-29 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="52139">ofloxacin</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>A Comparative Study of the Bactericidal and Sterilising Activity of Three Fluoroquinolones: Gatifloxacin, Moxifloxacin and Ofloxacin Substituted for Ethambutol in the Two Month Initial Phase of the Standard Anti-Tuberculosis Treatment Regimen Also Containing Rifampicin, Isoniazid and Pyrazinamide (South Africa)</ProtocolTitle><Sponsor>United Nations International Children's Fund</Sponsor><StudyType>Interventional</StudyType><Trial id="152200"/><TrialStartDate>2004-11-25 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="44305">omeprazole</Drug><Endpoint>Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>The Influence of Rifampicin Discontinuation on Rifampicin-Induced Cytochrome P450 Enzyme Activity</ProtocolTitle><Sponsor>Hamamatsu University School of Medicine</Sponsor><StudyType>Interventional</StudyType><Trial id="122291"/><TrialStartDate>2010-07-01 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="11036">linezolid</Drug><Endpoint>Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>S30PK</ProtocolAcronym><ProtocolTitle>Linezolid Pharmacokinetics (PK) in Multi-Drug Resistant (MDR)/Extensively-Drug Resistant (XDR) Tuberculosis (TB)</ProtocolTitle><Sponsor>Centers for Disease Control and Prevention</Sponsor><StudyType>Interventional</StudyType><Trial id="48035"/><TrialStartDate>2009-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>4+</ArmCount><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Drug id="11036">linezolid</Drug><Endpoint>Safety,Efficacy,Bioequivalence,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>LASER-TBM</ProtocolAcronym><ProtocolTitle>Linezolid, Aspirin and Enhanced Dose Rifampicin in HIV-TBM</ProtocolTitle><Sponsor>University of Cape Town</Sponsor><StudyType>Interventional</StudyType><Trial id="378146"/><TrialStartDate>2019-06-01 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="11036">linezolid</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>TB-TRUST</ProtocolAcronym><ProtocolTitle>Refining MDR-TB Treatment Regimens for Ultra Short Therapy</ProtocolTitle><Sponsor>Huashan Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="372676"/><TrialStartDate>2019-05-01 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="11036">linezolid</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Study on Tuberculosis Resistant to Treatment</ProtocolTitle><Sponsor>Indian Council of Medical Research, Tuberculosis Research Centre</Sponsor><StudyType>Interventional</StudyType><Trial id="369747"/><TrialStartDate>2019-02-01 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="11036">linezolid</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>GRACE-TB</ProtocolAcronym><ProtocolTitle>NGS-Guided(G) Regimens(R) of Anti-tuberculosis(A) Drugs for the Control(C) and Eradication(E) of MDR-TB</ProtocolTitle><Sponsor>Huashan Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="348056"/><TrialStartDate>2018-08-05 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="11036">linezolid</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>InDEX</ProtocolAcronym><ProtocolTitle>The Individualized M(X) Drug-resistant TB Treatment Strategy Study</ProtocolTitle><Sponsor>Centre for the AIDS Program of Research in South Africa</Sponsor><StudyType>Interventional</StudyType><Trial id="307654"/><TrialStartDate>2017-06-14 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="11036">linezolid</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>A study to investigate the safety and efficacy of bedaquiline and linezolid chemotherapy for extensively drug-resistant pulmonary tuberculosis within 6 months period</ProtocolTitle><Sponsor>Russian Academy of Sciences</Sponsor><StudyType>Interventional</StudyType><Trial id="280303"/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="11036">linezolid</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>TB-PRACTECAL</ProtocolAcronym><ProtocolTitle>Pragmatic Clinical Trial for a More Effective Concise and Less Toxic MDR-TB Treatment Regimen(s)</ProtocolTitle><Sponsor>Medecins Sans Frontieres</Sponsor><StudyType>Interventional</StudyType><Trial id="244304"/><TrialStartDate>2017-01-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="11036">linezolid</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>A hospital-based retrospective study to assess the clinical outcomes of linezolid treatment for extensively drug-resistant tuberculosis in Beijing, China</ProtocolTitle><Sponsor>309th Hospital of Chinese People's Liberation Army</Sponsor><StudyType>Interventional</StudyType><Trial id="234062"/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="11036">linezolid</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>NEXT</ProtocolAcronym><ProtocolTitle>An Open-label RCT to Evaluate a New Treatment Regimen for Patients With Multidrug-resistant Tuberculosis</ProtocolTitle><Sponsor>University of Cape Town</Sponsor><StudyType>Interventional</StudyType><Trial id="230529"/><TrialStartDate>2015-10-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>2+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="11036">linezolid</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>An Exploratory Study of TMC-207 in Japanese Participants with Pulmonary Multi-Drug Resistant Tuberculosis (MDR-TB)</ProtocolTitle><Sponsor>Janssen Pharmaceutical KK</Sponsor><StudyType>Interventional</StudyType><Trial id="222400"/><TrialStartDate>2015-02-18 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="44409">Fluzone</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>TIV_HIV_TB</ProtocolAcronym><ProtocolTitle>Effect of HIV and/or Active Tuberculosis on the Immune Responses to Trivalent Influenza Vaccine (TIV) in Adults</ProtocolTitle><Sponsor>University of Witwatersrand</Sponsor><StudyType>Interventional</StudyType><Trial id="116439"/><TrialStartDate>2014-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="59062">dolutegravir</Drug><Endpoint>Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>RADIO</ProtocolAcronym><ProtocolTitle>A Clinical Study Investigating Rifampicin and Dolutegravir in Combination in Healthy Volunteers</ProtocolTitle><Sponsor>ST STEPHEN'S CLINICAL RESEARCH LIMITED</Sponsor><StudyType>Interventional</StudyType><Trial id="303292"/><TrialStartDate>2017-10-31 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="59062">dolutegravir</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Impact of Once-Weekly Rifapentine and Isoniazid on the Steady State Pharmacokinetics of Dolutegravir and Darunavir Boosted With Cobicistat in Healthy Volunteers</ProtocolTitle><Sponsor>National Institutes of Health Clinical Center</Sponsor><StudyType>Interventional</StudyType><Trial id="260814"/><TrialStartDate>2016-06-03 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="15298">Pentacel</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>BAM</ProtocolAcronym><ProtocolTitle>A Study of the Interaction Between BCG And MenC Immunization</ProtocolTitle><Sponsor>University of Oxford</Sponsor><StudyType>Interventional</StudyType><Trial id="162886"/><TrialStartDate>2014-06-20 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry>African Ancestry</Ancestry><ArmCount>1+</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="53041">artesunate + amodiaquine combination tablet (malaria), DNDi/sanofi-aventis</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>ARTEM-TB STUDY</ProtocolAcronym><ProtocolTitle>Evaluating Pharmacokinetic Interactions Between Artemisinin-Based Therapies and Rifampacin-Based Tuberculosis Treatment in African Patients</ProtocolTitle><Sponsor>Infectious Diseases Institute of Makerer University</Sponsor><StudyType>Interventional</StudyType><Trial id="142485"/><TrialStartDate>2013-01-31 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="4492">faropenem</Drug><Endpoint>Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Whole Blood Bactericidal Activity (WBA) Against Mycobacterium Tuberculosis of Faropenem Plus Amoxicillin/Clavulanic Acid in Healthy Volunteers</ProtocolTitle><Sponsor>National University Hospital (Singapore) Pte Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="224811"/><TrialStartDate>2015-02-28 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="3492">levofloxacin</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>Opti-Q</ProtocolAcronym><ProtocolTitle>Efficacy and Safety of Levofloxacin for the Treatment of MDR-TB</ProtocolTitle><Sponsor>Boston University</Sponsor><StudyType>Interventional</StudyType><Trial id="149562"/><TrialStartDate>2015-01-31 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="3492">levofloxacin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>The Treatment of Tuberculosis in HIV-Infected Patients</ProtocolTitle><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><StudyType>Interventional</StudyType><Trial id="10643"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>1+</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="4229">rifabutin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Acquired Immunodeficiency Syndrome (AIDS) and Tuberculosis (TB) Co-Infection Treatment Strategies Study of China</ProtocolTitle><Sponsor>Shanghai Public Health Clinical Center</Sponsor><StudyType>Interventional</StudyType><Trial id="76946"/><TrialStartDate>2009-02-28 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="4229">rifabutin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Research on New Regimens for Retreatment Pulmonary Tuberculosis</ProtocolTitle><Sponsor>Shanghai Pulmonary Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="220243"/><TrialStartDate>2013-06-30 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry>African Ancestry</Ancestry><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="4229">rifabutin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>A single-blind, randomized, safety study comparing rifabutin with rifampicin in the treatment of HIV-1-associated tuberculosis</ProtocolTitle><Sponsor>Pharmacia &amp; Upjohn AB</Sponsor><StudyType>Interventional</StudyType><Trial id="15878"/><TrialStartDate>1995-12-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>5</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="4229">rifabutin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>A multicenter, randomized, 6-month study to compare the efficacy, tolerability and toxicity of two different regimens of rifabutin with that of rifampicin</ProtocolTitle><Sponsor>Pharmacia &amp; Upjohn AB</Sponsor><StudyType>Interventional</StudyType><Trial id="15869"/><TrialStartDate>1994-12-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="4229">rifabutin</Drug><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Pharmacokinetics of Rifabutin Combined With Antiretroviral Therapy in Patients With TB/HIV Co-Infection in Vietnam</ProtocolTitle><Sponsor>French National Agency for Research on AIDS and Viral Hepatitis</Sponsor><StudyType>Interventional</StudyType><Trial id="11188"/><TrialStartDate>2010-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="9490">MTB72F vaccine (tuberculosis), GSK/ IAVI</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Safety and Immunogenicity of Two Formulations of Tuberculosis Vaccines GSK-692342 Given at 0, 1 Months to Healthy Adults</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="9520"/><TrialStartDate>2006-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="9490">MTB72F vaccine (tuberculosis), GSK/ IAVI</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Study in Healthy Adults to Evaluate Gene Activation After Vaccination With GlaxoSmithKline (GSK) Biologicals Candidate Tuberculosis (TB) Vaccine GSK-692342</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="90314"/><TrialStartDate>2012-08-21 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="11088">sutezolid</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>InDEX</ProtocolAcronym><ProtocolTitle>The Individualized M(X) Drug-resistant TB Treatment Strategy Study</ProtocolTitle><Sponsor>Centre for the AIDS Program of Research in South Africa</Sponsor><StudyType>Interventional</StudyType><Trial id="307654"/><TrialStartDate>2017-06-14 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="11115">IMM-201</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>A phase I, randomized, study to evaluate the efficacy of SRL-172 on cell-mediated immunity of patients with pulmonary tuberculosis</ProtocolTitle><Sponsor>Silence Therapeutics plc</Sponsor><StudyType>Interventional</StudyType><Trial id="17288"/><TrialStartDate>1999-12-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Moxifloxacin As Part of a Multi-Drug Regimen For Tuberculosis</ProtocolTitle><Sponsor>Food and Drug Administration, Johns Hopkins University</Sponsor><StudyType>Interventional</StudyType><Trial id="8791"/><TrialStartDate>2004-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Comparison of the Effect Between Levofloxacin and Moxifloxacin Among MDR-TB Patients</ProtocolTitle><Sponsor>Seoul National University Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="63801"/><TrialStartDate>2010-03-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>SIMPLICITB</ProtocolAcronym><ProtocolTitle>Trial to Evaluate the Efficacy, Safety and Tolerability of BPaMZ in Drug-Sensitive (DS-TB) Adult Patients and Drug-Resistant (DR-TB) Adult Patients</ProtocolTitle><Sponsor>PPD Pharmaceutical Development Philippines Corporation, TB Alliance</Sponsor><StudyType>Interventional</StudyType><Trial id="319125"/><TrialStartDate>2018-07-30 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>S31PK/PD</ProtocolAcronym><ProtocolTitle>Pharmacokinetic and Pharmacodynamic Study of High-Dose Rifapentine and Moxifloxacin for Treatment of Tuberculosis</ProtocolTitle><Sponsor>Centers for Disease Control and Prevention</Sponsor><StudyType>Interventional</StudyType><Trial id="242269"/><TrialStartDate>2016-05-30 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>6+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>NexGen EBA Radiological and Immunological Biomarkers of Sterilizing Drug Activity in Tuberculosis</ProtocolTitle><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><StudyType>Interventional</StudyType><Trial id="222933"/><TrialStartDate>2015-02-25 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Research on New Regimens for Retreatment Pulmonary Tuberculosis</ProtocolTitle><Sponsor>Shanghai Pulmonary Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="220243"/><TrialStartDate>2013-06-30 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Measurement of Anti-TB Drugs in Lung Tissue From Patients Having Surgery to Treat Tuberculosis</ProtocolTitle><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><StudyType>Interventional</StudyType><Trial id="192117"/><TrialStartDate>2008-12-29 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>TBTC Study 28: Moxifloxacin Versus Isoniazid for TB Treatment</ProtocolTitle><Sponsor>Centers for Disease Control and Prevention</Sponsor><StudyType>Interventional</StudyType><Trial id="10685"/><TrialStartDate>2006-02-28 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="13323">pretomanid</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="PR">Pre-registration</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>A phase I trial to evaluate the safety, tolerability, pharmacokinetics of a single dose of PA-824</ProtocolTitle><Sponsor>TB Alliance</Sponsor><StudyType>Interventional</StudyType><Trial id="9416"/><TrialStartDate>2005-06-14 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="13323">pretomanid</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="PR">Pre-registration</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>SIMPLICITB</ProtocolAcronym><ProtocolTitle>Trial to Evaluate the Efficacy, Safety and Tolerability of BPaMZ in Drug-Sensitive (DS-TB) Adult Patients and Drug-Resistant (DR-TB) Adult Patients</ProtocolTitle><Sponsor>PPD Pharmaceutical Development Philippines Corporation, TB Alliance</Sponsor><StudyType>Interventional</StudyType><Trial id="319125"/><TrialStartDate>2018-07-30 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="15102">rifapentine</Drug><Endpoint>Safety</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>TBTC Study 25</ProtocolAcronym><ProtocolTitle>TBTC Study 25: Study of the Tolerability of Higher Doses of Rifapentine in the Treatment of Tuberculosis</ProtocolTitle><Sponsor>Centers for Disease Control and Prevention</Sponsor><StudyType>Interventional</StudyType><Trial id="8751"/><TrialStartDate>1999-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="15102">rifapentine</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Evaluating the Pharmacokinetics of High-Dose Rifapentine When Given as a Single-Dose or in Divided Doses to Healthy Adults</ProtocolTitle><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><StudyType>Interventional</StudyType><Trial id="86389"/><TrialStartDate>2012-06-30 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="15102">rifapentine</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>TBTC-29PK</ProtocolAcronym><ProtocolTitle>High-Dose Rifapentine Pharmacokinetics, Tolerability and Safety Dosage Rifapentine for Treatment of Tuberculosis</ProtocolTitle><Sponsor>Centers for Disease Control and Prevention</Sponsor><StudyType>Interventional</StudyType><Trial id="63261"/><TrialStartDate>2009-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="15102">rifapentine</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Study for latent tuberculosis infection intervention among close contacts of pulmonary tuberculosis patients</ProtocolTitle><Sponsor>The Chinese Centre for Disease Control and Prevention</Sponsor><StudyType>Interventional</StudyType><Trial id="361821"/><TrialStartDate>2018-06-10 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="15102">rifapentine</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Evaluating the Pharmacokinetics, Tolerability, and Safety of Once-Weekly Rifapentine and Isoniazid in HIV-1-Infected and HIV-1-Uninfected Pregnant and Postpartum Women With Latent Tuberculosis Infection</ProtocolTitle><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><StudyType>Interventional</StudyType><Trial id="250483"/><TrialStartDate>2017-02-15 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>4+</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="15102">rifapentine</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Pharmacokinetic Interaction Between Rifapentine or Rifampicin and a Single-dose of TMC-207 in Healthy Subjects</ProtocolTitle><Sponsor>TB Alliance</Sponsor><StudyType>Interventional</StudyType><Trial id="208141"/><TrialStartDate>2010-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="16545">delamanid</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Study on Tuberculosis Resistant to Treatment</ProtocolTitle><Sponsor>Indian Council of Medical Research, Tuberculosis Research Centre</Sponsor><StudyType>Interventional</StudyType><Trial id="369747"/><TrialStartDate>2019-02-01 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="16545">delamanid</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>A phase III study of delamanid in multidrug-resistant tuberculosis patients</ProtocolTitle><Sponsor>Otsuka Holdings Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="323086"/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="19980">HE-2000</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>A phase II pilot, placebo-controlled study to evaluate the efficacy of HE-2000 on opportunistic infections such as tuberculosis (TB) in late-stage AIDS patients</ProtocolTitle><Sponsor>Harbor Therapeutics Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="9820"/><TrialStartDate>2002-02-04 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="48499">H4:IC31</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Phase I/II, Safety and Immunogenicity Study of AERAS-404 in BCG-Primed Infants</ProtocolTitle><Sponsor>Aeras Global TB Vaccine Foundation</Sponsor><StudyType>Interventional</StudyType><Trial id="134374"/><TrialStartDate>2013-07-01 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="51310">bedaquiline</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>PRACTECAL-PRO</ProtocolAcronym><ProtocolTitle>Patient-reported Experiences and Quality of Life Outcomes in the TB-PRACTECAL Clinical Trial</ProtocolTitle><Sponsor>Medecins Sans Frontieres, Netherlands</Sponsor><StudyType>Interventional</StudyType><Trial id="379769"/><TrialStartDate>2019-07-01 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="51310">bedaquiline</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Evaluating the Pharmacokinetics, Safety, and Tolerability of Bedaquiline in HIV-Infected and HIV-Uninfected Infants, Children, and Adolescents With Multidrug-Resistant Tuberculosis</ProtocolTitle><Sponsor>B. J. Medical College, Pune, National Institute of Allergy and Infectious Diseases</Sponsor><StudyType>Interventional</StudyType><Trial id="272021"/><TrialStartDate>2017-08-18 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="51310">bedaquiline</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>A Phase III Study Assessing the Safety and Efficacy of Bedaquiline Plus PA-824 Plus Linezolid in Subjects With Drug-Resistant Pulmonary Tuberculosis</ProtocolTitle><Sponsor>TB Alliance</Sponsor><StudyType>Interventional</StudyType><Trial id="219499"/><TrialStartDate>2015-03-31 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="51310">bedaquiline</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>A randomized, double-blinded, dose-ranging study to assess the 14-day early bactericidal activity of bedaquiline (TMC-207) in patients with sputum microscopy smear-positive pulmonary tuberculosis</ProtocolTitle><Sponsor>University of Stellenbosch</Sponsor><StudyType>Interventional</StudyType><Trial id="139369"/><TrialStartDate>2013-03-04 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="53784">Ag85B-ESAT-6 vaccine (IC31 adjuvant, tuberculosis), SSI/ Valneva</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>THYB-02</ProtocolAcronym><ProtocolTitle>A Safety and Immunogenicity Trial With an Adjuvanted Tuberculosis (TB) Subunit Vaccine in Purified Protein Derivative (PPD) Positive Volunteers</ProtocolTitle><Sponsor>Statens Serum Institut</Sponsor><StudyType>Interventional</StudyType><Trial id="58503"/><TrialStartDate>2007-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="53975">AERAS-402</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>A Study to Evaluate Safety and Immunogenicity of AERAS-402</ProtocolTitle><Sponsor>Aeras Global TB Vaccine Foundation</Sponsor><StudyType>Interventional</StudyType><Trial id="78482"/><TrialStartDate>2011-02-28 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="53975">AERAS-402</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>A Study to Evaluate the Safety of AERAS-402 in Adults Recently Treated for Pulmonary TB</ProtocolTitle><Sponsor>Aeras Global TB Vaccine Foundation</Sponsor><StudyType>Interventional</StudyType><Trial id="226801"/><TrialStartDate>2008-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="55173">cadi-05</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Efficacy and Safety Study of Immunomodulator as an Adjunct Therapy in Pulmonary Tuberculosis (TB) Retreatment Patients</ProtocolTitle><Sponsor>Indian Government Department of Biotechnology</Sponsor><StudyType>Interventional</StudyType><Trial id="10057"/><TrialStartDate>2005-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="55317">MVA-85A</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>T−Cell Turnover Following Vaccination With MVA-85A</ProtocolTitle><Sponsor>University of Oxford</Sponsor><StudyType>Interventional</StudyType><Trial id="11182"/><TrialStartDate>2007-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="55317">MVA-85A</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Safety and Immunogenicity of MVA85A in Volunteers Latently Infected With TB</ProtocolTitle><Sponsor>University of Oxford</Sponsor><StudyType>Interventional</StudyType><Trial id="10941"/><TrialStartDate>2005-08-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="55317">MVA-85A</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>A Phase I Study of the Safety and Immunogenicity of a Recombinant MVA Vaccine Encoding a Secreted Antigen From M Tuberculosis, Antigen 85A, Delivered Intradermally by a Needle Injection in Healthy Volunteers Who Have Received BCG Immunisation 1 Month Previously</ProtocolTitle><Sponsor>University of Oxford</Sponsor><StudyType>Interventional</StudyType><Trial id="10873"/><TrialStartDate>2003-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="55521">golotimod (oral), SciClone/Verta</Drug><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Phase I Trial to Compare Oral Formulation of Golotimod Versus that of Subcutaneous and Sublingual Formulations of Golotimod in Healthy Volunteers for the treatment of Tuberculosis (TB)</ProtocolTitle><Sponsor>SciClone Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="8932"/><TrialStartDate>2006-05-25 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="66409">IMX-461</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Phase I Trial Evaluating Safety and Immunogenicity of MVA-85A-IMX3-13 Compared to MVA-85A in BCG Vaccinated Adults</ProtocolTitle><Sponsor>University of Oxford</Sponsor><StudyType>Interventional</StudyType><Trial id="142322"/><TrialStartDate>2013-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="81037">Wei Ka</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Phase III Clinical Study of Efficacy and Safety of Vaccae to Prevent Tuberculosis</ProtocolTitle><Sponsor>Anhui Zhifei Longcom Biopharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="160177"/><TrialStartDate>2013-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="82062">ethambutol hydrochloride (250 mg) + pyrazinamide (400 mg) + rifampicin (120 mg) + isoniazid (120 mg) (fixed dose combination, tuberculosis), Shenyang Hongqi Pharmaceutical</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>The Efficacy and Safety of Early Double J Stent Placement in Treatment of Renal Tuberculosis: A Novel Renal Function Protective Strategy</ProtocolTitle><Sponsor>Shanghai Changzheng Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="132105"/><TrialStartDate>2012-06-06 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="84564">ChAdOx1-85A</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Safety Study of ChAdOx1-85A Vaccination With and Without MVA-85A Boost in Healthy Adults</ProtocolTitle><Sponsor>University of Oxford</Sponsor><StudyType>Interventional</StudyType><Trial id="120744"/><TrialStartDate>2013-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="87251">Perchlozone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>An international, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy and safety of Perchlozone in the treatment of patients with pulmonary tuberculosis with MDR-TB, including HIV</ProtocolTitle><Sponsor>Pharmasyntez</Sponsor><StudyType>Interventional</StudyType><Trial id="291547"/><TrialStartDate>2017-03-10 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Drug id="89744">MTBVAC</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Dose-Defining Safety and Immunogenicity Study of MTBVAC in South African Neonates</ProtocolTitle><Sponsor>Biofabri SL</Sponsor><StudyType>Interventional</StudyType><Trial id="340636"/><TrialStartDate>2019-02-11 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="89744">MTBVAC</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>MTBVAC Study in Adults With and Without Latent Tuberculosis Infection in South Africa</ProtocolTitle><Sponsor>International AIDS Vaccine Initiative</Sponsor><StudyType>Interventional</StudyType><Trial id="275657"/><TrialStartDate>2019-01-24 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Drug id="98373">TB/FLU-04L</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>A randomized, double-blind, placebo-controlled, phase II clinical trial of TB/FLU-04L TB vaccine in adult volunteers with signs of latent tuberculosis infection</ProtocolTitle><Sponsor>National Center for Biotechnology of the Republic of Kazakhstan</Sponsor><StudyType>Interventional</StudyType><Trial id="301908"/><TrialStartDate>2017-06-05 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="108779">GC-3107</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Study to Investigate the Safety and Efficacy of GC-3107 (BCG Vaccine) in Healthy Adults</ProtocolTitle><Sponsor>GC Pharma</Sponsor><StudyType>Interventional</StudyType><Trial id="321760"/><TrialStartDate>2017-12-14 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="14493">tenofovir disoproxil fumarate</Drug><Endpoint>Safety</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>TIME</ProtocolAcronym><ProtocolTitle>Appropriate Timing of HAART in Co-infected HIV/TB Patients</ProtocolTitle><Sponsor>Bamrasnaradura Infectious Diseases Institute</Sponsor><StudyType>Interventional</StudyType><Trial id="61991"/><TrialStartDate>2009-10-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C0">Phase 0 Clinical</DevStatus><Drug id="14493">tenofovir disoproxil fumarate</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>TasP in Correctional Facilities</ProtocolTitle><Sponsor>University of North Carolina</Sponsor><StudyType>Interventional</StudyType><Trial id="280225"/><TrialStartDate>2016-02-01 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="14681">lopinavir + ritonavir</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Pharmacokinetics (PK) and Safety of Two Different Doses of Lopinavir/Ritonavir in HIV/Tuberculosis (TB) Co-Infected Patients Receiving Rifampicin Containing Anti-Tuberculosis Therapy</ProtocolTitle><Sponsor>The HIV Netherlands Australia Thailand Research Collaboration</Sponsor><StudyType>Interventional</StudyType><Trial id="67098"/><TrialStartDate>2010-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="14681">lopinavir + ritonavir</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>An Evaluation of the Pharmacological Interaction of Lopinavir/ritonavir and Rifampin</ProtocolTitle><Sponsor>Fundacao Oswaldo Cruz (Fiocruz)</Sponsor><StudyType>Interventional</StudyType><Trial id="171009"/><TrialStartDate>2008-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="14681">lopinavir + ritonavir</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>RIFLOPI</ProtocolAcronym><ProtocolTitle>Rifabutin With Lopinavir/ritonavir in Patients Coinfected With Tuberculosis and HIV in Burkina Faso</ProtocolTitle><Sponsor>Institut de Recherche en Sciences de la Sante (IRSS), Burkina Faso</Sponsor><StudyType>Interventional</StudyType><Trial id="161441"/><TrialStartDate>2013-11-28 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="26574">lamivudine + abacavir + zidovudine, GSK</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Anti-HIV Drugs for Ugandan Patients With HIV and Tuberculosis</ProtocolTitle><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><StudyType>Interventional</StudyType><Trial id="8801"/><TrialStartDate>2004-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="6050">metformin hydrochloride</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Effect of metformin on sputum smear conversion in pulmonary tuberculosis with type 2 diabetes mellitus</ProtocolTitle><Sponsor>Khonkaen Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="370128"/><TrialStartDate>2019-03-01 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="3474">lamivudine</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>SAPIT</ProtocolAcronym><ProtocolTitle>A Study to Compare Three Existing Starting Points of Antiretroviral Therapy (ART) Initiation in HIV/Tuberculosis (TB) Co-infected Patients</ProtocolTitle><Sponsor>Centre for the AIDS Program of Research in South Africa</Sponsor><StudyType>Interventional</StudyType><Trial id="201474"/><TrialStartDate>2005-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>4</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="49219">tenofovir disoproxil fumarate + emtricitabine (fixed dose), Gilead Sciences</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>STRIDE</ProtocolAcronym><ProtocolTitle>Immediate Versus Deferred Start of Anti-HIV Therapy in HIV Infected Adults Being Treated for Tuberculosis</ProtocolTitle><Sponsor>AIDS Clinical Trials Group</Sponsor><StudyType>Interventional</StudyType><Trial id="10681"/><TrialStartDate>2006-08-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="50038">tenofovir disoproxil fumarate + emtricitabine + efavirenz, Gilead/BMS/Merck &amp; Co</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>PETE</ProtocolAcronym><ProtocolTitle>Pharmacokinetics of Emtricitabine/Tenofovir + Efavirenz in HIV-Infected Patients With Tuberculosis</ProtocolTitle><Sponsor>Poverty Related Infection Oriented Research</Sponsor><StudyType>Interventional</StudyType><Trial id="10945"/><TrialStartDate>2008-11-30 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7017">gatifloxacin</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>A Comparative Study of the Bactericidal and Sterilising Activity of Three Fluoroquinolones: Gatifloxacin, Moxifloxacin and Ofloxacin Substituted for Ethambutol in the Two Month Initial Phase of the Standard Anti-Tuberculosis Treatment Regimen Also Containing Rifampicin, Isoniazid and Pyrazinamide (South Africa)</ProtocolTitle><Sponsor>United Nations International Children's Fund</Sponsor><StudyType>Interventional</StudyType><Trial id="152200"/><TrialStartDate>2004-11-25 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="13624">BCG vaccine, Organon</Drug><Endpoint>Safety</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>AERAS 422</ProtocolAcronym><ProtocolTitle>Study of AERAS-422 in Healthy Adults</ProtocolTitle><Sponsor>Aeras Global TB Vaccine Foundation</Sponsor><StudyType>Interventional</StudyType><Trial id="76756"/><TrialStartDate>2010-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="10172">efavirenz</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>PRIDE-HT</ProtocolAcronym><ProtocolTitle>PK Study of Rifampicin Interactions With DMPA and Efaviranz in TB</ProtocolTitle><Sponsor>AIDS Clinical Trials Group</Sponsor><StudyType>Interventional</StudyType><Trial id="227340"/><TrialStartDate>2015-11-03 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="10172">efavirenz</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>CARINEMO</ProtocolAcronym><ProtocolTitle>Comparison of Nevirapine and Efavirenz for the Treatment of HIV-TB Co-infected Patients</ProtocolTitle><Sponsor>French National Agency for Research on AIDS and Viral Hepatitis</Sponsor><StudyType>Interventional</StudyType><Trial id="10948"/><TrialStartDate>2007-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>6</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="3700">nevirapine</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>DATiC</ProtocolAcronym><ProtocolTitle>Optimal Dosing of First-Line Antituberculosis and Antiretroviral Drugs in Children (a Pharmacokinetic Study)</ProtocolTitle><Sponsor>University of Cape Town</Sponsor><StudyType>Interventional</StudyType><Trial id="89135"/><TrialStartDate>2012-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>4+</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="3700">nevirapine</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Once-Daily Dose of Nevirapine (400 mg) Versus Twice Daily Dose (200 mg) of Nevirapine in HIV and Tuberculosis Infection</ProtocolTitle><Sponsor>National AIDS Control Organization</Sponsor><StudyType>Interventional</StudyType><Trial id="126486"/><TrialStartDate>2012-09-01 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="3610">meloxicam</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>TB-IRIS NSAID Cox-2 Inhibitor Prevention Trial</ProtocolTitle><Sponsor>University of Stellenbosch</Sponsor><StudyType>Interventional</StudyType><Trial id="172626"/><TrialStartDate>2014-04-30 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="46927">doxycycline hyclate</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>Doxy-TB</ProtocolAcronym><ProtocolTitle>Doxycycline in Human Pulmonary Tuberculosis</ProtocolTitle><Sponsor>National University Hospital (Singapore) Pte Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="261320"/><TrialStartDate>2015-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="44303">midazolam hydrochloride</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>TBTC S29B</ProtocolAcronym><ProtocolTitle>Pharmacokinetics, Safety and Tolerability of Escalating Rifapentine Doses in Healthy Volunteers</ProtocolTitle><Sponsor>Johns Hopkins University</Sponsor><StudyType>Interventional</StudyType><Trial id="68204"/><TrialStartDate>2010-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Drug id="44303">midazolam hydrochloride</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>SUDOCU</ProtocolAcronym><ProtocolTitle>PanACEA Sutezolid Dose-finding and Combination Evaluation</ProtocolTitle><Sponsor>Ludwig-Maximilians University of Munich</Sponsor><StudyType>Interventional</StudyType><Trial id="381674"/><TrialStartDate>2019-08-31 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="44279">amoxicillin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Trial of faropenem and cefadroxil (in combination with amoxicillin/clavulanic acid and standard TB drugs) in patients with pulmonary tuberculosis: measurement of early bactericidal activity and effects on novel biomarkers</ProtocolTitle><Sponsor>National University Hospital (Singapore) Pte Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="360329"/><TrialStartDate>2018-11-30 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="15954">bortezomib</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Evaluating Whole Blood Bactericidal Activity of Bortezomib Against Mycobacterium Tuberculosis in Healthy Volunteers</ProtocolTitle><Sponsor>National University Hospital (Singapore) Pte Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="263359"/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="46931">cefadroxil</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Trial of faropenem and cefadroxil (in combination with amoxicillin/clavulanic acid and standard TB drugs) in patients with pulmonary tuberculosis: measurement of early bactericidal activity and effects on novel biomarkers</ProtocolTitle><Sponsor>National University Hospital (Singapore) Pte Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="360329"/><TrialStartDate>2018-11-30 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="2587">azithromycin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>A Study to Evaluate the Safety and Efficacy of Azithromycin in Individual Patients With Serious Nontuberculous Mycobacterial Disease Who Are Failing or Intolerant of Other Available Therapy</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="8647"/><TrialStartDate>1999-11-02 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="11036">linezolid</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>A Phase II Trial to Evaluate the Efficacy and Safety of Linezolid in Tuberculosis Patients</ProtocolTitle><Sponsor>TB Alliance</Sponsor><StudyType>Interventional</StudyType><Trial id="215072"/><TrialStartDate>2014-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="11036">linezolid</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>A Multicenter, Prospective, Randomized, Controlled Trial to Assess  the Efficacy and Safety of Linezolid for the Treatment of Extensively Drug Resistant Tuberculosis in China</ProtocolTitle><Sponsor>Liu, Shanghai Pulmonary Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="183541"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Drug id="54488">raltegravir</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Rifampin-Based Tuberculosis Treatment Versus Rifabutin-Based Tuberculosis Treatment in Persons With HIV</ProtocolTitle><Sponsor>AIDS Clinical Trials Group</Sponsor><StudyType>Interventional</StudyType><Trial id="87585"/><TrialStartDate>2013-07-13 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="54488">raltegravir</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>REFLATE TB</ProtocolAcronym><ProtocolTitle>Efficacy and Safety of Two Raltegravir Doses in Naive HIV-1-Infected Patients Receiving Rifampin for Active Tuberculosis</ProtocolTitle><Sponsor>French National Agency for Research on AIDS and Viral Hepatitis</Sponsor><StudyType>Interventional</StudyType><Trial id="40948"/><TrialStartDate>2009-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="44316">zidovudine</Drug><Endpoint>Safety,Efficacy,Bioavailability</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>PK-TB-HAART</ProtocolAcronym><ProtocolTitle>Bioavailability of the Fixed Dose Formulation Rifafour Containing Isoniazid, Rifampicin, Pyrazinamide, Ethambutol and the World Health Organization (WHO) Recommended First Line Antiretroviral Drugs Zidovudine, Lamivudine, Efavirenz Administered to New Tuberculosis (TB) Patients at Different Levels of Immunosuppression</ProtocolTitle><Sponsor>World Health Organization</Sponsor><StudyType>Interventional</StudyType><Trial id="136052"/><TrialStartDate>2006-05-29 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="44316">zidovudine</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>IPEC-EFV</ProtocolAcronym><ProtocolTitle>Randomized Clinical Trial to Assess the Efficacy and Safety of Concomitant Use of Rifampicin and Efavirenz 600 X  800 mg</ProtocolTitle><Sponsor>Fundacao Oswaldo Cruz (Fiocruz)</Sponsor><StudyType>Interventional</StudyType><Trial id="11181"/><TrialStartDate>2007-01-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="3492">levofloxacin</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Comparison of the Effect Between Levofloxacin and Moxifloxacin Among MDR-TB Patients</ProtocolTitle><Sponsor>Seoul National University Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="63801"/><TrialStartDate>2010-03-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="3492">levofloxacin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>TriDoRe</ProtocolAcronym><ProtocolTitle>Novel Triple-Dose Tuberculosis Retreatment Regimens: How to Overcome Resistance Without Creating More</ProtocolTitle><Sponsor>Institute of Tropical Medicine, Belgium</Sponsor><StudyType>Interventional</StudyType><Trial id="372353"/><TrialStartDate>2019-09-30 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="3492">levofloxacin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>DRAMATIC</ProtocolAcronym><ProtocolTitle>Efficacy and Tolerability of Bedaquiline, Delamanid, Levofloxacin, Linezolid, and Clofazimine for Treatment of Patients With MDR-TB</ProtocolTitle><Sponsor>Boston University</Sponsor><StudyType>Interventional</StudyType><Trial id="368916"/><TrialStartDate>2020-01-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="3492">levofloxacin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>The V-QUIN MDR Trial</ProtocolAcronym><ProtocolTitle>A randomized, controlled trial of 6 months of daily levofloxacin for the prevention of tuberculosis among household contacts of patients with multi-drug resistant tuberculosis</ProtocolTitle><Sponsor>University of Sydney</Sponsor><StudyType>Interventional</StudyType><Trial id="269403"/><TrialStartDate>2016-03-14 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="3492">levofloxacin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>MDR-END</ProtocolAcronym><ProtocolTitle>Treatment Shortening of MDR-TB Using Existing and New Drugs</ProtocolTitle><Sponsor>Seoul National University Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="247456"/><TrialStartDate>2016-01-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>3+</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="3492">levofloxacin</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>The research of new regimen for multidrug-resistant tuberculosis treatment</ProtocolTitle><Sponsor>Beijing Chest Hospital, Beijing Tuberculosis &amp; Thoracic Tumor Research Institute, Capital Medical University</Sponsor><StudyType>Interventional</StudyType><Trial id="244777"/><TrialStartDate>2008-10-01 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>2+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="3492">levofloxacin</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>An Exploratory Study of TMC-207 in Japanese Participants with Pulmonary Multi-Drug Resistant Tuberculosis (MDR-TB)</ProtocolTitle><Sponsor>Janssen Pharmaceutical KK</Sponsor><StudyType>Interventional</StudyType><Trial id="222400"/><TrialStartDate>2015-02-18 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="4229">rifabutin</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>RIFLOPI</ProtocolAcronym><ProtocolTitle>Rifabutin With Lopinavir/ritonavir in Patients Coinfected With Tuberculosis and HIV in Burkina Faso</ProtocolTitle><Sponsor>Institut de Recherche en Sciences de la Sante (IRSS), Burkina Faso</Sponsor><StudyType>Interventional</StudyType><Trial id="161441"/><TrialStartDate>2013-11-28 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>3+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="9490">MTB72F vaccine (tuberculosis), GSK/ IAVI</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Safety and Immunogenicity Study of a Candidate Tuberculosis Vaccine in Healthy Infants</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="65639"/><TrialStartDate>2010-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Drug id="9490">MTB72F vaccine (tuberculosis), GSK/ IAVI</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Phase IIb Clinical Study of new GSK Vaccine Candidate</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="137219"/><TrialStartDate>2013-01-01 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="11088">sutezolid</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Safety, Tolerability, Pharmacokinetics And Measurement Of Whole Blood Activity (WBA) Of PNU-100480 After Multiple Oral Doses In Healthy Adult Volunteers</ProtocolTitle><Sponsor>Sequella Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="60906"/><TrialStartDate>2009-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="11115">IMM-201</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>A phase II/III study to evaluate the safety and efficacy of SRL-172 for the treatment of tuberculosis</ProtocolTitle><Sponsor>Silence Therapeutics plc</Sponsor><StudyType>Interventional</StudyType><Trial id="19996"/><TrialStartDate>1997-12-31 00:00:00</TrialStartDate><TrialStatus>Suspended</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>GRACE-TB</ProtocolAcronym><ProtocolTitle>NGS-Guided(G) Regimens(R) of Anti-tuberculosis(A) Drugs for the Control(C) and Eradication(E) of MDR-TB</ProtocolTitle><Sponsor>Huashan Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="348056"/><TrialStartDate>2018-08-05 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>A clinical trial to study the effects of moxifloxacin with regular anti-tuberculosis drugs in Tuberculosis patients</ProtocolTitle><Sponsor>Vels University</Sponsor><StudyType>Interventional</StudyType><Trial id="255644"/><TrialStartDate>2015-09-09 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>3+</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="12978">moxifloxacin</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>The research of new regimen for multidrug-resistant tuberculosis treatment</ProtocolTitle><Sponsor>Beijing Chest Hospital, Beijing Tuberculosis &amp; Thoracic Tumor Research Institute, Capital Medical University</Sponsor><StudyType>Interventional</StudyType><Trial id="244777"/><TrialStartDate>2008-10-01 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="12978">moxifloxacin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>A study to evaluate the safety and efficacy of moxifloxacin in comparision with cephalexin in patients being treated for uncomplicated skin and soft tissue infections</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><Trial id="16244"/><TrialStartDate>1999-12-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>RIFAQUIN</ProtocolAcronym><ProtocolTitle>An International, Multicenter, Controlled Clinical Trial to Evaluate High-Dose Rifapentine and a Quinolone in the Treatment of Pulmonary Tuberculosis</ProtocolTitle><Sponsor>St Georges University of London</Sponsor><StudyType>Interventional</StudyType><Trial id="153990"/><TrialStartDate>2008-08-15 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>1</ArmCount><DevStatus id="PNA">Phase Not Applicable</DevStatus><Drug id="12978">moxifloxacin</Drug><Endpoint>Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>The Effect of Ethnic on Moxifloxacin Induced QT Interval Prolongation in Korean and Japanese Healthy Subjects</ProtocolTitle><Sponsor>Inje University</Sponsor><StudyType>Interventional</StudyType><Trial id="139433"/><TrialStartDate>2011-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="15102">rifapentine</Drug><Endpoint>Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Pharmacokinetics of rifapentine and isoniazid and NAT2 and SLCO1B1 polymorphisms in pediatric Thai patients with latent tuberculosis infection</ProtocolTitle><Sponsor>Chulalongkorn University</Sponsor><StudyType>Interventional</StudyType><Trial id="379095"/><TrialStartDate>2019-06-01 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="15102">rifapentine</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Tuberculosis Preventive Therapy Among Latent Tuberculosis Infection in HIV-infected Individuals</ProtocolTitle><Sponsor>The HIV Netherlands Australia Thailand Research Collaboration</Sponsor><StudyType>Interventional</StudyType><Trial id="364544"/><TrialStartDate>2019-03-31 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="15102">rifapentine</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Latent Mycobacterium tuberculosis infection treatment among individuals with a history of prior tuberculosis: a randomized, controlled trial</ProtocolTitle><Sponsor>Chinese Academy of Medical Sciences &amp; Peking Union Medical College</Sponsor><StudyType>Interventional</StudyType><Trial id="352729"/><TrialStartDate>2018-09-01 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="15102">rifapentine</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>TRUNCATE-TB</ProtocolAcronym><ProtocolTitle>A 2 Month Regimens Using Novel Combinations to Augment Treatment Effectiveness for Drug-Sensitive Tuberculosis</ProtocolTitle><Sponsor>Syneos Health Inc, University College London</Sponsor><StudyType>Interventional</StudyType><Trial id="333435"/><TrialStartDate>2018-03-21 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>4</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="15102">rifapentine</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>HARAPAN II</ProtocolAcronym><ProtocolTitle>Addiction, HIV and Tuberculosis in Malaysian Criminal Justice Settings</ProtocolTitle><Sponsor>National Institutes of Health, Yale University</Sponsor><StudyType>Interventional</StudyType><Trial id="294801"/><TrialStartDate>2017-08-21 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="15102">rifapentine</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>CORTIS</ProtocolAcronym><ProtocolTitle>The Correlate of Risk Targeted Intervention Study</ProtocolTitle><Sponsor>University of Cape Town</Sponsor><StudyType>Interventional</StudyType><Trial id="258043"/><TrialStartDate>2016-09-20 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="15102">rifapentine</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>S31PK/PD</ProtocolAcronym><ProtocolTitle>Pharmacokinetic and Pharmacodynamic Study of High-Dose Rifapentine and Moxifloxacin for Treatment of Tuberculosis</ProtocolTitle><Sponsor>Centers for Disease Control and Prevention</Sponsor><StudyType>Interventional</StudyType><Trial id="242269"/><TrialStartDate>2016-05-30 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="15102">rifapentine</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Rifapentine Plus Moxifloxacin for Treatment of Pulmonary Tuberculosis</ProtocolTitle><Sponsor>Johns Hopkins University</Sponsor><StudyType>Interventional</StudyType><Trial id="23035"/><TrialStartDate>2009-11-30 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="15102">rifapentine</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>TBTC Study 29</ProtocolAcronym><ProtocolTitle>Rifapentine During Intensive Phase Tuberculosis (TB) Treatment</ProtocolTitle><Sponsor>Centers for Disease Control and Prevention, Tuberculosis Investigation Unit of Barcelona</Sponsor><StudyType>Interventional</StudyType><Trial id="17237"/><TrialStartDate>2008-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="15102">rifapentine</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Randomized, Open-label, Comparative Study to Evaluate the Rifapentine in the Treatment of Patients Newly Diagnosed with Pulmonary Tuberculosis Negative and Smear-with Preserved Sensitivity of Mycobacteria</ProtocolTitle><Sponsor>S.P.Inkomed Pvt. Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="168261"/><TrialStartDate>2011-09-27 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="15102">rifapentine</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>RIFAQUIN</ProtocolAcronym><ProtocolTitle>An International, Multicenter, Controlled Clinical Trial to Evaluate High-Dose Rifapentine and a Quinolone in the Treatment of Pulmonary Tuberculosis</ProtocolTitle><Sponsor>St Georges University of London</Sponsor><StudyType>Interventional</StudyType><Trial id="153990"/><TrialStartDate>2008-08-15 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>4+</ArmCount><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="16545">delamanid</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>A Phase I/II Trial of Multiple Oral Doses of OPC-167832 for Uncomplicated Pulmonary Tuberculosis</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="353987"/><TrialStartDate>2018-10-25 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="16545">delamanid</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>endTB</ProtocolAcronym><ProtocolTitle>Evaluating Newly Approved Drugs for Multidrug-resistant TB</ProtocolTitle><Sponsor>Médecins Sans Frontières France</Sponsor><StudyType>Interventional</StudyType><Trial id="259506"/><TrialStartDate>2016-12-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="16545">delamanid</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>A Phase II, Multicenter, Uncontrolled, Open-label Trial to Evaluate Safety, Tolerability, and Efficacy of Orally Administered OPC-67683</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="242789"/><TrialStartDate>2009-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="25023">golotimod</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Phase II Trial of SCV-07 in TB</ProtocolTitle><Sponsor>SciClone Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="144312"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="51310">bedaquiline</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>The Effect of 18-month Regimen Containing Six Anti-tuberculosis Drugs for Patients With MDR-TB</ProtocolTitle><Sponsor>Beijing Chest Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="369109"/><TrialStartDate>2019-03-08 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="51310">bedaquiline</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>TRUNCATE-TB</ProtocolAcronym><ProtocolTitle>A 2 Month Regimens Using Novel Combinations to Augment Treatment Effectiveness for Drug-Sensitive Tuberculosis</ProtocolTitle><Sponsor>Syneos Health Inc, University College London</Sponsor><StudyType>Interventional</StudyType><Trial id="333435"/><TrialStartDate>2018-03-21 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="51310">bedaquiline</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>SIMPLICITB</ProtocolAcronym><ProtocolTitle>Trial to Evaluate the Efficacy, Safety and Tolerability of BPaMZ in Drug-Sensitive (DS-TB) Adult Patients and Drug-Resistant (DR-TB) Adult Patients</ProtocolTitle><Sponsor>PPD Pharmaceutical Development Philippines Corporation, TB Alliance</Sponsor><StudyType>Interventional</StudyType><Trial id="319125"/><TrialStartDate>2018-07-30 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="51310">bedaquiline</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Pharmacokinetic Study to Evaluate Anti-Mycobacterial Activity of TMC-207 in Combination With Background Regimen (BR) of Multidrug Resistant Tuberculosis (MDR-TB) Medications for Treatment of Children/Adolescents Pulmonary MDR-TB</ProtocolTitle><Sponsor>Janssen Research &amp; Development LLC, Janssen-Cilag International NV (BE), Quintiles Philippines, Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="221523"/><TrialStartDate>2016-05-03 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="51310">bedaquiline</Drug><Endpoint>Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>A Bioavailability Study of Two New Formulations of Bedaquiline on Pediatric Populaion</ProtocolTitle><Sponsor>Janssen Pharmaceutical KK</Sponsor><StudyType>Interventional</StudyType><Trial id="163991"/><TrialStartDate>2013-12-14 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="53975">AERAS-402</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>A double-blind, randomized, placebo-controlled, phase I study of AERAS-402, a potential vaccine for Mycobacterium tuberculosis infection</ProtocolTitle><Sponsor>Crucell NV</Sponsor><StudyType>Interventional</StudyType><Trial id="8498"/><TrialStartDate>2007-05-11 10:47:27</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="53975">AERAS-402</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>An open-label, phase I trial to evaluate the safety, tolerability and immunogenicity of AERAS-402, a potential vaccine for Mycobacterium tuberculosis infection</ProtocolTitle><Sponsor>Aeras Global TB Vaccine Foundation, Crucell NV</Sponsor><StudyType>Interventional</StudyType><Trial id="8497"/><TrialStartDate>2006-10-25 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="53975">AERAS-402</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Study of AERAS-402 in Healthy Infants</ProtocolTitle><Sponsor>Aeras Global TB Vaccine Foundation</Sponsor><StudyType>Interventional</StudyType><Trial id="70158"/><TrialStartDate>2010-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="55317">MVA-85A</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>MVA(TB)029</ProtocolAcronym><ProtocolTitle>Safety and Immunogenicity of MVA-85A Prime and Bacille Calmette-Guerin Boost Vaccination</ProtocolTitle><Sponsor>University of Cape Town</Sponsor><StudyType>Interventional</StudyType><Trial id="89833"/><TrialStartDate>2012-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Drug id="55317">MVA-85A</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>A phase IIa, open-label, safety and immunogenicity study of MVA-85A in HIV- and/or Mycobacterium tuberculosis-infected adults</ProtocolTitle><Sponsor>European Commission, National Institutes of Health, TB-VAC, University of Cape Town, Wellcome Trust</Sponsor><StudyType>Interventional</StudyType><Trial id="86807"/><TrialStartDate>2011-08-26 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry>African Ancestry</Ancestry><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="55317">MVA-85A</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>A phase I study of a new tuberculosis (TB) vaccine, MVA-85A, in healthy volunteers with HIV</ProtocolTitle><Sponsor>University of Oxford</Sponsor><StudyType>Interventional</StudyType><Trial id="23059"/><TrialStartDate>2008-08-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry>European Ancestry</Ancestry><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="57308">RUTI</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Clinical Trial to Study Four Different Doses of the Vaccine RUTI in Healthy Volunteers</ProtocolTitle><Sponsor>Germans Trias i Pujol Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="8888"/><TrialStartDate>2007-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="61340">S-004992</Drug><Endpoint>Safety</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>A phase I trial of S-004992 for the potential treatment of drug-resistant tuberculosis</ProtocolTitle><Sponsor>Shionogi &amp; Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="334482"/><TrialStartDate/><TrialStatus>Planned</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="62397">AERAS-407 rBCG</Drug><Endpoint>Safety</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>AERAS 422</ProtocolAcronym><ProtocolTitle>Study of AERAS-422 in Healthy Adults</ProtocolTitle><Sponsor>Aeras Global TB Vaccine Foundation</Sponsor><StudyType>Interventional</StudyType><Trial id="76756"/><TrialStartDate>2010-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="68617">ID93 vaccine (GLA-SE adjuvant, TB), IDRI/ Quratis</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Phase I ID-93 + GLA-SE Vaccine Trial in Healthy Adult Volunteers</ProtocolTitle><Sponsor>Infectious Disease Research Institute</Sponsor><StudyType>Interventional</StudyType><Trial id="87507"/><TrialStartDate>2012-08-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="68617">ID93 vaccine (GLA-SE adjuvant, TB), IDRI/ Quratis</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Safety, Tolerability and Immunogenicity of the Vaccine Candidates ID-93 + AP10-602 and ID-93 + GLA-SE Administered Intramuscularly in Healthy Adult Subjects</ProtocolTitle><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><StudyType>Interventional</StudyType><Trial id="235751"/><TrialStartDate>2015-10-22 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="69440">rifampicin + isoniazid + piperine (fixed dose combination, tuberculosis), Cadila Pharmaceuticals</Drug><Endpoint>Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Comparison of Sputum Conversion Rates, Plasma Rifampicin Levels and Cyp 450 Activity Pulmonary Tuberculosis Patients Have Received 8 Weeks of Intensive Phase Therapy With Standard Dose Regimen Versus Risorine Kit</ProtocolTitle><Sponsor>Cadila Pharmaceuticals Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="142231"/><TrialStartDate>2012-06-10 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="74849">SSI H56-IC31</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>TBCOX2</ProtocolAcronym><ProtocolTitle>Therapeutic Vaccination and Immune Modulation - New Treatment Strategies for the MDR Tuberculosis Pandemic</ProtocolTitle><Sponsor>Oslo University Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="235355"/><TrialStartDate>2015-11-30 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C1B">Phase 1b Clinical</DevStatus><Drug id="74849">SSI H56-IC31</Drug><Endpoint>Safety,Efficacy,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>A-042</ProtocolAcronym><ProtocolTitle>Phase Ib, Safety and Immunogenicity Trial of BCG Revaccination, H4:IC31 and H56:IC31 in Healthy, HIV-1-Uninfected Adolescents</ProtocolTitle><Sponsor>Aeras</Sponsor><StudyType>Interventional</StudyType><Trial id="223463"/><TrialStartDate>2015-05-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="81363">AEC/BC02</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="PR">Pre-registration</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Clinical study of freeze - dried recombinant tuberculosis vaccine (AEC/BC02)</ProtocolTitle><Sponsor>Chongqing Zhifei Biological Products Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="291253"/><TrialStartDate/><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Drug id="85970">telacebec</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>A Phase II Study to Evaluate Early Bactericidal Activity, Safety, Tolerability, and Pharmacokinetics of Multiple Oral Doses of Telacebec (Q-203)</ProtocolTitle><Sponsor>Qurient Therapeutics</Sponsor><StudyType>Interventional</StudyType><Trial id="343604"/><TrialStartDate>2018-07-23 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="89460">rifampicin + isoniazid (fixed dose combination, tuberculosis), Pfizer</Drug><Endpoint>Safety,Bioequivalence,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Bioequivalence Study Comparing Rifampicin In A Fixed-dose Combination (Rifampicin + Isoniazid, Myrin 2) And The Reference Drug (Rifampicin, Rimactane)</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="164313"/><TrialStartDate>2011-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="89744">MTBVAC</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>MTBVAC</ProtocolAcronym><ProtocolTitle>Dose-Escalation Study to Evaluate the Safety and Immunogenicity of MTBVAC Vaccine in Comparison With BCG Vaccine</ProtocolTitle><Sponsor>Biofabri SL</Sponsor><StudyType>Interventional</StudyType><Trial id="164024"/><TrialStartDate>2013-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1A">Phase 1a Clinical</DevStatus><Drug id="90085">macozinone</Drug><Endpoint>Safety,Efficacy,Bioavailability,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Ex-vivo Antitubercular Activity of PBTZ-169 Formulation</ProtocolTitle><Sponsor>Innovative Medicines for Tuberculosis</Sponsor><StudyType>Interventional</StudyType><Trial id="328144"/><TrialStartDate>2017-12-05 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="91861">clofazimine (oral, tuberculosis), Novartis</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>STREAM</ProtocolAcronym><ProtocolTitle>The Evaluation of a Standard Treatment Regimen of Anti-Tuberculosis Drugs for Patients With MDR-TB</ProtocolTitle><Sponsor>International Union Against Tuberculosis and Lung Diseases</Sponsor><StudyType>Interventional</StudyType><Trial id="228190"/><TrialStartDate>2016-04-30 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="95442">ESAT-6CFP10</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Phase I Clinical Human Tolerability Study of Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10</ProtocolTitle><Sponsor>Anhui Zhifei Longcom Biopharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="163196"/><TrialStartDate>2013-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1A">Phase 1a Clinical</DevStatus><Drug id="101474">small molecule therapeutic, Beijing Union Pharmaceutical Factory/Institute of Materia Medica</Drug><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="CU">Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>The phase Ia clinical trial of pyrifazimine</ProtocolTitle><Sponsor>Beijing Union Pharmaceutical Factory, Xiyuan Hospital China Academy Of Chinese Medical Sciences</Sponsor><StudyType>Interventional</StudyType><Trial id="356451"/><TrialStartDate>2018-10-01 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="104087">FS-1</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="R">Registered</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>FS-1</ProtocolAcronym><ProtocolTitle>FS-1 Drug for Treatment of Multiple Drug-resistant Tuberculosis</ProtocolTitle><Sponsor>Scientific Center for Anti-infectious Drugs, Kazakhstan</Sponsor><StudyType>Interventional</StudyType><Trial id="246553"/><TrialStartDate>2013-12-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="107010">TBI-223</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>A Phase 1 Study to Evaluate Safety, Tolerability, and PK of TBI-223 in Healthy Adults</ProtocolTitle><Sponsor>TB Alliance</Sponsor><StudyType>Interventional</StudyType><Trial id="362067"/><TrialStartDate>2019-01-16 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="107523">TBA-7371</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>A Phase I Study to Evaluate Safety, Tolerability, PK, and PK Interactions of TBA-7371</ProtocolTitle><Sponsor>TB Alliance</Sponsor><StudyType>Interventional</StudyType><Trial id="303756"/><TrialStartDate>2017-08-29 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="14493">tenofovir disoproxil fumarate</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>Pred-ART</ProtocolAcronym><ProtocolTitle>Preventing TB-IRIS in High-risk Patients: a Randomized, Placebo-controlled Trial of Prednisone</ProtocolTitle><Sponsor>University of Cape Town</Sponsor><StudyType>Interventional</StudyType><Trial id="150793"/><TrialStartDate>2013-08-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>4</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="14493">tenofovir disoproxil fumarate</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>STRIDE</ProtocolAcronym><ProtocolTitle>Immediate Versus Deferred Start of Anti-HIV Therapy in HIV Infected Adults Being Treated for Tuberculosis</ProtocolTitle><Sponsor>AIDS Clinical Trials Group</Sponsor><StudyType>Interventional</StudyType><Trial id="10681"/><TrialStartDate>2006-08-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="14681">lopinavir + ritonavir</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Pharmacokinetic Study of Super-boosted Lopinavir/Ritonavir Given With Rifampin</ProtocolTitle><Sponsor>University of Miami</Sponsor><StudyType>Interventional</StudyType><Trial id="93494"/><TrialStartDate>2016-02-29 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="14681">lopinavir + ritonavir</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>TMC207-TiDP13-C110: Interaction Study With Lopinavir/Ritonavir in Healthy Volunteer</ProtocolTitle><Sponsor>Janssen Diagnostics BVBA</Sponsor><StudyType>Interventional</StudyType><Trial id="42128"/><TrialStartDate>2009-02-28 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="105321">superboosted lopinavir + ritonavir (pediatric oral formulation, HIV infection), DNDi</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Pharmacokinetics of Lopinavir/Ritonavir Superboosting in Infants and Young Children Co-infected With HIV and TB</ProtocolTitle><Sponsor>Drugs for Neglected Diseases Initiative</Sponsor><StudyType>Interventional</StudyType><Trial id="220686"/><TrialStartDate>2013-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="8255">nelfinavir</Drug><Endpoint>Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Effectiveness of Anti-HIV Therapy (HAART) in HIV-Infected Patients With Tuberculosis</ProtocolTitle><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><StudyType>Interventional</StudyType><Trial id="10646"/><TrialStartDate>2000-02-25 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="4481">stavudine</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>CARINEMO</ProtocolAcronym><ProtocolTitle>Comparison of Nevirapine and Efavirenz for the Treatment of HIV-TB Co-infected Patients</ProtocolTitle><Sponsor>French National Agency for Research on AIDS and Viral Hepatitis</Sponsor><StudyType>Interventional</StudyType><Trial id="10948"/><TrialStartDate>2007-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3+</ArmCount><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="12013">once-daily naproxen (oral controlled release, pain), Alvogen</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Paradoxical Tuberculosis Immune Reconstitution Inflammatory Syndrome (TB-IRIS) Treatment Trial</ProtocolTitle><Sponsor>University of Minnesota - Clinical and Translational Science Institute</Sponsor><StudyType>Interventional</StudyType><Trial id="199754"/><TrialStartDate>2014-01-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Drug id="6050">metformin hydrochloride</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Metformin in tuberculosis</ProtocolTitle><Sponsor>Open Source Pharma Foundation, Tuberculosis Research Centre</Sponsor><StudyType>Interventional</StudyType><Trial id="325158"/><TrialStartDate>2018-11-01 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>4</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="2935">didanosine</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Effectiveness of Directly Observed Therapy in Combined HIV and Tuberculosis Treatment in Resource-Limited Settings</ProtocolTitle><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><StudyType>Interventional</StudyType><Trial id="8820"/><TrialStartDate>2009-08-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="2829">clarithromycin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>InDEX</ProtocolAcronym><ProtocolTitle>The Individualized M(X) Drug-resistant TB Treatment Strategy Study</ProtocolTitle><Sponsor>Centre for the AIDS Program of Research in South Africa</Sponsor><StudyType>Interventional</StudyType><Trial id="307654"/><TrialStartDate>2017-06-14 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="44363">trimethoprim + sulphamethoxazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>SAPIT</ProtocolAcronym><ProtocolTitle>A Study to Compare Three Existing Starting Points of Antiretroviral Therapy (ART) Initiation in HIV/Tuberculosis (TB) Co-infected Patients</ProtocolTitle><Sponsor>Centre for the AIDS Program of Research in South Africa</Sponsor><StudyType>Interventional</StudyType><Trial id="201474"/><TrialStartDate>2005-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="3411">itraconazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>A Comparative Study of Itraconazole in Various Doses Schedule in the Treatment of Pulmonary Aspergilloma in Treated  with the Patients of Pulmonary Tuberculosis</ProtocolTitle><Sponsor>Sawai ManSingh Medical College</Sponsor><StudyType>Interventional</StudyType><Trial id="131456"/><TrialStartDate>2012-07-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Drug id="48140">doxycycline (once-daily, oral controlled release), CollaGenex</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>Map2Co</ProtocolAcronym><ProtocolTitle>Concomitant Infections of Mansonella Perstans in Tuberculosis and Buruli Ulcer Disease Patients From Ghana</ProtocolTitle><Sponsor>kwame Nkrumah University of Science and Technology</Sponsor><StudyType>Interventional</StudyType><Trial id="214864"/><TrialStartDate>2014-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7017">gatifloxacin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>InDEX</ProtocolAcronym><ProtocolTitle>The Individualized M(X) Drug-resistant TB Treatment Strategy Study</ProtocolTitle><Sponsor>Centre for the AIDS Program of Research in South Africa</Sponsor><StudyType>Interventional</StudyType><Trial id="307654"/><TrialStartDate>2017-06-14 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="13624">BCG vaccine, Organon</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Challenge Model for Assessment of Human TB Immunity</ProtocolTitle><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><StudyType>Interventional</StudyType><Trial id="149358"/><TrialStartDate>2014-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="10172">efavirenz</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Evaluating the Safety and Drug Interaction of PA-824, an Investigational Tuberculosis Medication, Together With Efavirenz, Ritonavir-Boosted Lopinavir or Rifampin</ProtocolTitle><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><StudyType>Interventional</StudyType><Trial id="86312"/><TrialStartDate>2012-05-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Drug id="10172">efavirenz</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>SAEFRIF</ProtocolAcronym><ProtocolTitle>Safety and Efficacy of High Dose Rifampicin in Tuberculosis (TB)-HIV Co-infected Patients on Efavirenz- or Dolutegravir-based Antiretroviral Therapy</ProtocolTitle><Sponsor>Makerere University</Sponsor><StudyType>Interventional</StudyType><Trial id="384080"/><TrialStartDate>2019-04-30 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="10172">efavirenz</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Efavirenz (EFV) in HIV-Infected and HIV/Tuberculosis (TB) Coinfected Children</ProtocolTitle><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><StudyType>Interventional</StudyType><Trial id="37985"/><TrialStartDate>2009-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="10172">efavirenz</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>RRHT</ProtocolAcronym><ProtocolTitle>Rifampicin versus Rifabutin in HIV/AIDS Patients Combined With Tuberculosis</ProtocolTitle><Sponsor>Shanghai Public Health Clinical Center</Sponsor><StudyType>Interventional</StudyType><Trial id="334027"/><TrialStartDate>2018-04-15 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Drug id="10172">efavirenz</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>INSPIRING</ProtocolAcronym><ProtocolTitle>Open-Label Study of Dolutegravir (DTG) or Efavirenz (EFV) for Human Immunodeficiency Virus (HIV)-Tuberculosis (TB) Co-infection</ProtocolTitle><Sponsor>ViiV Healthcare Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="201302"/><TrialStartDate>2015-01-23 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="10172">efavirenz</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Simultaneous Versus Sequential Antiretroviral Therapy (ARV) Therapy and Mycobacterium Tuberculosis (MTB) Treatment</ProtocolTitle><Sponsor>Instituto Nacional de Enfermedades Respiratorias</Sponsor><StudyType>Interventional</StudyType><Trial id="169697"/><TrialStartDate>2008-03-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>3+</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="10172">efavirenz</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>RIFART</ProtocolAcronym><ProtocolTitle>RIFART</ProtocolTitle><Sponsor>Azienda Ospedaliera Spedali Civili di Brescia</Sponsor><StudyType>Interventional</StudyType><Trial id="131240"/><TrialStartDate>2005-03-15 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="10172">efavirenz</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>IPEC-EFV</ProtocolAcronym><ProtocolTitle>Randomized Clinical Trial to Assess the Efficacy and Safety of Concomitant Use of Rifampicin and Efavirenz 600 X  800 mg</ProtocolTitle><Sponsor>Fundacao Oswaldo Cruz (Fiocruz)</Sponsor><StudyType>Interventional</StudyType><Trial id="11181"/><TrialStartDate>2007-01-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="10172">efavirenz</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Safety and Efficacy of Two Once Daily Anti Retroviral Treatment Regimens Along With Anti-Tuberculosis Treatment</ProtocolTitle><Sponsor>Tuberculosis Research Centre</Sponsor><StudyType>Interventional</StudyType><Trial id="10863"/><TrialStartDate>2006-06-30 00:00:00</TrialStartDate><TrialStatus>Suspended</TrialStatus></Row><Row><Ancestry/><ArmCount>4</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="10172">efavirenz</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>STRIDE</ProtocolAcronym><ProtocolTitle>Immediate Versus Deferred Start of Anti-HIV Therapy in HIV Infected Adults Being Treated for Tuberculosis</ProtocolTitle><Sponsor>AIDS Clinical Trials Group</Sponsor><StudyType>Interventional</StudyType><Trial id="10681"/><TrialStartDate>2006-08-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="10172">efavirenz</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>TBTC-23C</ProtocolAcronym><ProtocolTitle>Pharmacokinetics of Intermittent Rifabutin and Isoniazid With Daily Efavirenz</ProtocolTitle><Sponsor>Centers for Disease Control and Prevention</Sponsor><StudyType>Interventional</StudyType><Trial id="10657"/><TrialStartDate>1999-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="72148">darunavir + cobicistat (fixed dose, HIV infection), Janssen R&amp;D/ Gilead</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Impact of Once-Weekly Rifapentine and Isoniazid on the Steady State Pharmacokinetics of Dolutegravir and Darunavir Boosted With Cobicistat in Healthy Volunteers</ProtocolTitle><Sponsor>National Institutes of Health Clinical Center</Sponsor><StudyType>Interventional</StudyType><Trial id="260814"/><TrialStartDate>2016-06-03 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="44303">midazolam hydrochloride</Drug><Endpoint>Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>The Influence of Rifampicin Discontinuation on Rifampicin-Induced Cytochrome P450 Enzyme Activity</ProtocolTitle><Sponsor>Hamamatsu University School of Medicine</Sponsor><StudyType>Interventional</StudyType><Trial id="122291"/><TrialStartDate>2010-07-01 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="52139">ofloxacin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>InDEX</ProtocolAcronym><ProtocolTitle>The Individualized M(X) Drug-resistant TB Treatment Strategy Study</ProtocolTitle><Sponsor>Centre for the AIDS Program of Research in South Africa</Sponsor><StudyType>Interventional</StudyType><Trial id="307654"/><TrialStartDate>2017-06-14 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>5+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="46931">cefadroxil</Drug><Endpoint>Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Trial of Faropenem and Cefadroxil (in Combination With Amoxicillin/Clavulanic Acid and Standard TB Drugs) in Patients With Pulmonary Tuberculosis: Measurement of Early Bactericidal Activity and Effects on Novel Biomarkers</ProtocolTitle><Sponsor>National University Hospital (Singapore) Pte Ltd, Syneos Health Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="224111"/><TrialStartDate>2018-12-31 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>5</ArmCount><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="11036">linezolid</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>TBRU 10</ProtocolAcronym><ProtocolTitle>Early Bactericidal Activity of Linezolid, Gatifloxacin, Levofloxacin, Isoniazid (INH) and Moxifloxacin in HIV Negative Adults With Initial Episodes of Sputum Smear-Positive Pulmonary Tuberculosis</ProtocolTitle><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><StudyType>Interventional</StudyType><Trial id="10869"/><TrialStartDate>2004-02-29 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="59062">dolutegravir</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>IMPAACT4TB</ProtocolAcronym><ProtocolTitle>Safety, Tolerability DDI Short Course Treatment of LTBI Infection With High-dose Rifapentine Isoniazid in HIV+ Patients</ProtocolTitle><Sponsor>Aurum Institute</Sponsor><StudyType>Interventional</StudyType><Trial id="329251"/><TrialStartDate>2018-01-18 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="54488">raltegravir</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>RIFRAL</ProtocolAcronym><ProtocolTitle>The Effect of Intermittent Rifampicin on Raltegravir</ProtocolTitle><Sponsor>The University of Liverpool</Sponsor><StudyType>Interventional</StudyType><Trial id="80394"/><TrialStartDate>2012-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>4</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="12014">VP-101</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Clinical Trial of Phenylbutyrate and Vitamin D in Tuberculosis (TB)</ProtocolTitle><Sponsor>International Centre For Diarrhoeal Disease Research, Bangladesh</Sponsor><StudyType>Interventional</StudyType><Trial id="142323"/><TrialStartDate>2010-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="4492">faropenem</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Prospective, Randomized Control, Non-inferiority Study of the Use of Faropenem for Patients with etiology Positive Pulmonary Tuberculosis</ProtocolTitle><Sponsor>Zhejiang University</Sponsor><StudyType>Interventional</StudyType><Trial id="338648"/><TrialStartDate>2018-05-15 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="3492">levofloxacin</Drug><Endpoint>Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>A Pilot Study of Methodology to Rapidly Evaluate Drugs for Bactericidal Activity, Tolerance and Pharmacokinetics in the Treatment of Pulmonary Tuberculosis Using Isoniazid and Levofloxacin</ProtocolTitle><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><StudyType>Interventional</StudyType><Trial id="8780"/><TrialStartDate>1999-11-01 18:30:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="3492">levofloxacin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>05TB</ProtocolAcronym><ProtocolTitle>A randomized, double-blind, placebo-controlled trial to investigate the effect of intensified treatment with high dose rifampicin and levofloxacin for adult patients with tuberculous meningitis</ProtocolTitle><Sponsor>University of Oxford</Sponsor><StudyType>Interventional</StudyType><Trial id="75317"/><TrialStartDate>2011-04-18 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="3492">levofloxacin</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Pharmacokinetic study and safety of levofloxacin in pediatric tuberculosis treatment</ProtocolTitle><Sponsor>Center of Excellence for Pediatric Infectious Diseases and Vaccines</Sponsor><StudyType>Interventional</StudyType><Trial id="381490"/><TrialStartDate>2019-05-12 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>1+</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="3492">levofloxacin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>SURE</ProtocolAcronym><ProtocolTitle>Short Intensive Treatment For Children With Tuberculous Meningitis</ProtocolTitle><Sponsor>University College London</Sponsor><StudyType>Interventional</StudyType><Trial id="360104"/><TrialStartDate>2018-01-02 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="3492">levofloxacin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Shortened Regimens for Drug-susceptible Pulmonary Tuberculosis</ProtocolTitle><Sponsor>Beijing Chest Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="271641"/><TrialStartDate>2016-08-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="4229">rifabutin</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>RRHT</ProtocolAcronym><ProtocolTitle>Rifampicin versus Rifabutin in HIV/AIDS Patients Combined With Tuberculosis</ProtocolTitle><Sponsor>Shanghai Public Health Clinical Center</Sponsor><StudyType>Interventional</StudyType><Trial id="334027"/><TrialStartDate>2018-04-15 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>3+</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="4229">rifabutin</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>The research of new regimen for multidrug-resistant tuberculosis treatment</ProtocolTitle><Sponsor>Beijing Chest Hospital, Beijing Tuberculosis &amp; Thoracic Tumor Research Institute, Capital Medical University</Sponsor><StudyType>Interventional</StudyType><Trial id="244777"/><TrialStartDate>2008-10-01 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="4229">rifabutin</Drug><Endpoint>Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>TBTC-23B</ProtocolAcronym><ProtocolTitle>Intensive PK of the Nelfinavir Rifabutin Interaction in Patients With HIV-TB</ProtocolTitle><Sponsor>Centers for Disease Control and Prevention</Sponsor><StudyType>Interventional</StudyType><Trial id="10656"/><TrialStartDate>2000-02-29 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="9490">MTB72F vaccine (tuberculosis), GSK/ IAVI</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine in HIV-Positive Adults</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="19230"/><TrialStartDate>2008-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Drug id="11088">sutezolid</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>PNU-100480 In Newly Diagnosed, Treatment Sensitive Patients With Pulmonary TB; Early Bactericidal Activity; Whole Blood Assay</ProtocolTitle><Sponsor>Sequella Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="71511"/><TrialStartDate>2011-08-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="11088">sutezolid</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Sutezolid</ProtocolTitle><Sponsor>TB Alliance</Sponsor><StudyType>Interventional</StudyType><Trial id="303595"/><TrialStartDate>2017-09-26 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Effect of PA-824 and of PA-824 Plus Moxifloxacin on the QTc Interval in Healthy Volunteers</ProtocolTitle><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><StudyType>Interventional</StudyType><Trial id="90512"/><TrialStartDate>2012-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Evaluation of 8 Weeks of Treatment With the Combination of Moxifloxacin, PA-824 and Pyrazinamide in Patients With Drug Sensitive and Multi Drug-Resistant Pulmonary Tuberculosis (TB)</ProtocolTitle><Sponsor>TB Alliance</Sponsor><StudyType>Interventional</StudyType><Trial id="83489"/><TrialStartDate>2012-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Pharmacokinetics and Safety of Moxifloxacin</ProtocolTitle><Sponsor>University Medical Center Groningen</Sponsor><StudyType>Interventional</StudyType><Trial id="76086"/><TrialStartDate>2011-05-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Latency in Pulmonary Tuberculosis</ProtocolTitle><Sponsor>Tuberculosis Research Centre</Sponsor><StudyType>Interventional</StudyType><Trial id="67984"/><TrialStartDate>2010-02-28 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>REMoxTB</ProtocolAcronym><ProtocolTitle>Controlled Comparison of Two Moxifloxacin Containing Treatment Shortening Regimens in Pulmonary Tuberculosis</ProtocolTitle><Sponsor>TB Alliance</Sponsor><StudyType>Interventional</StudyType><Trial id="49258"/><TrialStartDate>2008-01-01 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>SUDOCU</ProtocolAcronym><ProtocolTitle>PanACEA Sutezolid Dose-finding and Combination Evaluation</ProtocolTitle><Sponsor>Ludwig-Maximilians University of Munich</Sponsor><StudyType>Interventional</StudyType><Trial id="381674"/><TrialStartDate>2019-08-31 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>A study to evaluate the efficacy of moxifloxacin instead of ethambutol in the intensive phase of therapy in patients with newly diagnosed pulmonary tuberculosis</ProtocolTitle><Sponsor>Academy of Medical Sciences of the Ukraine</Sponsor><StudyType>Interventional</StudyType><Trial id="280029"/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>NEXT</ProtocolAcronym><ProtocolTitle>An Open-label RCT to Evaluate a New Treatment Regimen for Patients With Multidrug-resistant Tuberculosis</ProtocolTitle><Sponsor>University of Cape Town</Sponsor><StudyType>Interventional</StudyType><Trial id="230529"/><TrialStartDate>2015-10-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="12978">moxifloxacin</Drug><Endpoint>Bioequivalence,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>An Open-Label, Randomized, Crossover Study of Comparative Pharmacokinetics and Bioequivalence of Haynemoks, 400 mg (Hayglans Laboratories Pvt. Ltd., India) and Avelox, 400 mg (Bayer Healthcare AG, Germany) in Healthy Volunteers</ProtocolTitle><Sponsor>HiGlance Laboratories Pvt ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="168898"/><TrialStartDate>2012-10-29 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>1</ArmCount><DevStatus id="PNA">Phase Not Applicable</DevStatus><Drug id="12978">moxifloxacin</Drug><Endpoint>Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>The Effect of Ethnic on Moxifloxacin Induced QT Interval Prolongation in Korean and Japanese Healthy Subjects</ProtocolTitle><Sponsor>Inje University</Sponsor><StudyType>Interventional</StudyType><Trial id="139433"/><TrialStartDate>2011-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>A Clinical Trial to Study the Effectiveness and Safety of 3- and 4-Month Regimens as Compared to the Standard 6-Month Regimen for the Treatment of Infectious Pulmonary Tuberculosis Patients</ProtocolTitle><Sponsor>Indian Council of Medical Research</Sponsor><StudyType>Interventional</StudyType><Trial id="121916"/><TrialStartDate>2007-05-30 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="12978">moxifloxacin</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>A comparative, open-labeled, randomized study to evaluate the bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis</ProtocolTitle><Sponsor>Royal Free and University College Medical School</Sponsor><StudyType>Interventional</StudyType><Trial id="114922"/><TrialStartDate>2003-12-01 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><Endpoint>Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Pharmacokinetic Interaction Study in Indonesian Tuberculosis Patients Indonesia</ProtocolTitle><Sponsor>Radboud University</Sponsor><StudyType>Interventional</StudyType><Trial id="10860"/><TrialStartDate>2006-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>4+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="13323">pretomanid</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="PR">Pre-registration</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>NC-003</ProtocolAcronym><ProtocolTitle>Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With Clofazimine (C)-TMC-207 (J)-PA-824 (Pa)-Pyrazinamide (Z)</ProtocolTitle><Sponsor>TB Alliance</Sponsor><StudyType>Interventional</StudyType><Trial id="92275"/><TrialStartDate>2012-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="13323">pretomanid</Drug><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="PR">Pre-registration</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Phase I clinical trial of single-dose of PA-824</ProtocolTitle><Sponsor>Shanghai Fosun Pharmaceutical (Group) Co Ltd, Shanghai Fosun Pharmaceutical Industry Development Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="362102"/><TrialStartDate>2018-03-14 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Drug id="13323">pretomanid</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="PR">Pre-registration</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>APT</ProtocolAcronym><ProtocolTitle>Assessing PA-824 for Tuberculosis</ProtocolTitle><Sponsor>Johns Hopkins Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="213394"/><TrialStartDate>2015-04-29 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>3+</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="15102">rifapentine</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>BRIEF TB</ProtocolAcronym><ProtocolTitle>Brief Rifapentine-Isoniazid Evaluation for TB Prevention</ProtocolTitle><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><StudyType>Interventional</StudyType><Trial id="79741"/><TrialStartDate>2012-05-23 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="15102">rifapentine</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>SCRIPT-TB</ProtocolAcronym><ProtocolTitle>Short Course Rifapentine and Isoniazid for the Preventive Treatment of Tuberculosis</ProtocolTitle><Sponsor>Huashan Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="375813"/><TrialStartDate>2018-12-01 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="15102">rifapentine</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>IMPAACT4TB</ProtocolAcronym><ProtocolTitle>Safety, Tolerability DDI Short Course Treatment of LTBI Infection With High-dose Rifapentine Isoniazid in HIV+ Patients</ProtocolTitle><Sponsor>Aurum Institute</Sponsor><StudyType>Interventional</StudyType><Trial id="329251"/><TrialStartDate>2018-01-18 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="15102">rifapentine</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>An open-label, active control trial of rifapentine to evaluate efficacy, in patients with pulmonary tuberculosis</ProtocolTitle><Sponsor>Aventis Pharma AG</Sponsor><StudyType>Interventional</StudyType><Trial id="15328"/><TrialStartDate>1998-12-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="16545">delamanid</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Safety and Pharmacokinetics (PK) in Multidrug-Resistant (MDR) Refractive Tuberculosis</ProtocolTitle><Sponsor>Otsuka Holdings Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="66735"/><TrialStartDate>2010-02-28 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Drug id="16545">delamanid</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>SUDOCU</ProtocolAcronym><ProtocolTitle>PanACEA Sutezolid Dose-finding and Combination Evaluation</ProtocolTitle><Sponsor>Ludwig-Maximilians University of Munich</Sponsor><StudyType>Interventional</StudyType><Trial id="381674"/><TrialStartDate>2019-08-31 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="16545">delamanid</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>MDR-END</ProtocolAcronym><ProtocolTitle>Treatment Shortening of MDR-TB Using Existing and New Drugs</ProtocolTitle><Sponsor>Seoul National University Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="247456"/><TrialStartDate>2016-01-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="16545">delamanid</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>A 6-Month Safety, Efficacy and PK Trial of Delamanid in Pediatric Patients With Multidrug Resistant Tuberculosis</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="133567"/><TrialStartDate>2013-07-20 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>4+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="51310">bedaquiline</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>NC-003</ProtocolAcronym><ProtocolTitle>Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With Clofazimine (C)-TMC-207 (J)-PA-824 (Pa)-Pyrazinamide (Z)</ProtocolTitle><Sponsor>TB Alliance</Sponsor><StudyType>Interventional</StudyType><Trial id="92275"/><TrialStartDate>2012-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="51310">bedaquiline</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>TMC207TBC1003 - A Study in Healthy Volunteers Investigating the Effect of Single-Dose TMC-207 on the QT/QTc Interval Under Fed Conditions</ProtocolTitle><Sponsor>Janssen Diagnostics BVBA</Sponsor><StudyType>Interventional</StudyType><Trial id="74529"/><TrialStartDate>2011-02-28 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>5+</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="51310">bedaquiline</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>endTB-Q</ProtocolAcronym><ProtocolTitle>Evaluating Newly Approved Drugs in Combination Regimens for Multidrug-Resistant TB With Fluoroquinolone Resistance</ProtocolTitle><Sponsor>Médecins Sans Frontières France</Sponsor><StudyType>Interventional</StudyType><Trial id="375499"/><TrialStartDate>2019-06-30 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="51310">bedaquiline</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>InDEX</ProtocolAcronym><ProtocolTitle>The Individualized M(X) Drug-resistant TB Treatment Strategy Study</ProtocolTitle><Sponsor>Centre for the AIDS Program of Research in South Africa</Sponsor><StudyType>Interventional</StudyType><Trial id="307654"/><TrialStartDate>2017-06-14 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="51310">bedaquiline</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Early Bactericidal Activity and Pharmacokinetics of the Diarylquinoline TMC-207 in Treatment of Pulmonary Tuberculosis</ProtocolTitle><Sponsor>Johnson &amp; Johnson</Sponsor><StudyType>Interventional</StudyType><Trial id="150059"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="53019">GX-70</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Safety and Immunogenicity Study of GX-70 in TB Patient</ProtocolTitle><Sponsor>Yonsei University</Sponsor><StudyType>Interventional</StudyType><Trial id="298965"/><TrialStartDate>2018-03-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="53784">Ag85B-ESAT-6 vaccine (IC31 adjuvant, tuberculosis), SSI/ Valneva</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>THYB-04</ProtocolAcronym><ProtocolTitle>THYB-04</ProtocolTitle><Sponsor>Statens Serum Institut</Sponsor><StudyType>Interventional</StudyType><Trial id="285704"/><TrialStartDate>2012-08-27 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="53975">AERAS-402</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Safety and Immunogenicity of AERAS-402 in HIV-infected, Bacillus Calmette-Guerin (BCG)-Vaccinated Adults</ProtocolTitle><Sponsor>Aeras Global TB Vaccine Foundation</Sponsor><StudyType>Interventional</StudyType><Trial id="62096"/><TrialStartDate>2009-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="55317">MVA-85A</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Safety, Immunogenicity and Impact of MVA-85A, on the Immunogenicity of the EPI Vaccines</ProtocolTitle><Sponsor>University of Oxford</Sponsor><StudyType>Interventional</StudyType><Trial id="52375"/><TrialStartDate>2006-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="55317">MVA-85A</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>MVA-85A Aerosol Versus Intramuscular Vaccination in Adults With Latent Mycobacterium Tuberculosis (M tb) Infection</ProtocolTitle><Sponsor>University of Oxford</Sponsor><StudyType>Interventional</StudyType><Trial id="238674"/><TrialStartDate>2015-09-30 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="55317">MVA-85A</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Safety Study of ChAdOx1-85A Vaccination With and Without MVA-85A Boost in Healthy Adults</ProtocolTitle><Sponsor>University of Oxford</Sponsor><StudyType>Interventional</StudyType><Trial id="120744"/><TrialStartDate>2013-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="55569">VPM-1002</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Phase II/III Study To Check The Efficacy And Safety Of Recombinant BCG Vaccine In TB Patients In India</ProtocolTitle><Sponsor>Serum Institute of India Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="292836"/><TrialStartDate>2017-04-01 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="68617">ID93 vaccine (GLA-SE adjuvant, TB), IDRI/ Quratis</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Phase I Clinical Trial of ID93 + GLA-SE Vaccine in BCG-vaccinated Healthy Adolescent</ProtocolTitle><Sponsor>Quratis Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="366672"/><TrialStartDate>2019-04-02 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Drug id="68617">ID93 vaccine (GLA-SE adjuvant, TB), IDRI/ Quratis</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Phase IIa ID93 + GLA-SE Vaccine Trial in TB Patients After Treatment Completion</ProtocolTitle><Sponsor>Infectious Disease Research Institute</Sponsor><StudyType>Interventional</StudyType><Trial id="231367"/><TrialStartDate>2015-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Drug id="70581">GSK-3036656</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>An Early Bactericidal Activity, Safety and Tolerability of GSK-3036656 in Subjects With Drug-sensitive Pulmonary Tuberculosis</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="343050"/><TrialStartDate>2019-03-27 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="71323">Ad5Ag85A</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Study of the Safety and Immunogenicity of an Adenovirus-based Tuberculosis Vaccine</ProtocolTitle><Sponsor>McMaster University</Sponsor><StudyType>Interventional</StudyType><Trial id="77668"/><TrialStartDate>2009-06-30 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="71323">Ad5Ag85A</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Phase I Clinical Trial of the Safety and Immunogenicity of an Adenovirus-based TB Vaccine Administered by Aerosol</ProtocolTitle><Sponsor>McMaster University</Sponsor><StudyType>Interventional</StudyType><Trial id="219950"/><TrialStartDate>2017-09-05 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>4</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="82091">ethambutol hydrochloride + rifampicin + isoniazid (fixed dose combination, tuberculosis), Shenyang Hongqi Pharmaceutical</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Appropriate course of the treatment of tuberculous pleurisy</ProtocolTitle><Sponsor>Capital Medical University</Sponsor><StudyType>Interventional</StudyType><Trial id="309137"/><TrialStartDate>2015-06-01 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="88505">ethambutol hydrochloride (150 mg) + pyrazinamide (300 mg) + rifampicin (90 mg) + isoniazid (60 mg) (oral tablet, tuberculosis), Shenyang Hongqi Pharmaceutical/Liaoning Hongwuxing Pharmaceutical</Drug><Endpoint>Bioequivalence,Bioavailability</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Ethylamine pyrazine Lifestyle Isonicotinic piece IV bioequivalence trials</ProtocolTitle><Sponsor>Shenyang Hongqi Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="177165"/><TrialStartDate>2013-11-30 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="90231">DAR-901</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Phase I Trial of DAR-901</ProtocolTitle><Sponsor>Dartmouth-Hitchcock Medical Center</Sponsor><StudyType>Interventional</StudyType><Trial id="173446"/><TrialStartDate>2014-02-28 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="95442">ESAT-6CFP10</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Clinical Study of Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10 on Healthy People Aged 18 to 65 years (III-healthy)</ProtocolTitle><Sponsor>Anhui Zhifei Longcom Biopharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="262931"/><TrialStartDate>2016-05-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="95442">ESAT-6CFP10</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Clinical Study of Recombinant Mycobacterium Tuberculosis ESAT-6CFP10 Allergen</ProtocolTitle><Sponsor>Anhui Zhifei Longcom Biopharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="247763"/><TrialStartDate>2015-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="PNA">Phase Not Applicable</DevStatus><Drug id="104447">OPC-167832</Drug><Endpoint>Safety</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>A multiple-ascending-dose and early-bactericidal-activity study to assess OPC-167832 in drug susceptible TB patients</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="327016"/><TrialStartDate>2018-12-31 00:00:00</TrialStartDate><TrialStatus>Planned</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="107803">GamTBvac</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Phase II Clinical Trial of Safety and Immunogenicity of Recombinant Subunit Tuberculosis Vaccine GamTBvac</ProtocolTitle><Sponsor>Gamalei Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation Collaborator</Sponsor><StudyType>Interventional</StudyType><Trial id="373676"/><TrialStartDate>2018-12-01 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="107803">GamTBvac</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>GamTBvac</ProtocolAcronym><ProtocolTitle>Evaluation of the Safety and Immunogenicity of the Recombinant Subunit Vaccine 'GamTBvac' Against the Tuberculosis</ProtocolTitle><Sponsor>Gamalei Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation Collaborator</Sponsor><StudyType>Interventional</StudyType><Trial id="309614"/><TrialStartDate>2017-01-15 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="PNA">Phase Not Applicable</DevStatus><Drug id="116061">68Ga-tilmanocept</Drug><Endpoint>Safety</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>A comparative study to evaluate the use of 68Ga-tilmanocept in patients with tuberculosis (TB)</ProtocolTitle><Sponsor>Navidea Biopharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="378644"/><TrialStartDate/><TrialStatus>Planned</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="14493">tenofovir disoproxil fumarate</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>RRHT</ProtocolAcronym><ProtocolTitle>Rifampicin versus Rifabutin in HIV/AIDS Patients Combined With Tuberculosis</ProtocolTitle><Sponsor>Shanghai Public Health Clinical Center</Sponsor><StudyType>Interventional</StudyType><Trial id="334027"/><TrialStartDate>2018-04-15 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>6</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="14681">lopinavir + ritonavir</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>DATiC</ProtocolAcronym><ProtocolTitle>Optimal Dosing of First-Line Antituberculosis and Antiretroviral Drugs in Children (a Pharmacokinetic Study)</ProtocolTitle><Sponsor>University of Cape Town</Sponsor><StudyType>Interventional</StudyType><Trial id="89135"/><TrialStartDate>2012-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>4</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="4481">stavudine</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>N2R</ProtocolAcronym><ProtocolTitle>Efavirenz-Based Versus Nevirapine-Based Antiretroviral Therapy Among HIV-Infected Patients Receiving Rifampin</ProtocolTitle><Sponsor>Bamrasnaradura Infectious Diseases Institute</Sponsor><StudyType>Interventional</StudyType><Trial id="10947"/><TrialStartDate>2007-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="4481">stavudine</Drug><Endpoint>Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Effectiveness of Anti-HIV Therapy (HAART) in HIV-Infected Patients With Tuberculosis</ProtocolTitle><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><StudyType>Interventional</StudyType><Trial id="10646"/><TrialStartDate>2000-02-25 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>1+</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="44309">ranitidine</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>SURE</ProtocolAcronym><ProtocolTitle>Short Intensive Treatment For Children With Tuberculous Meningitis</ProtocolTitle><Sponsor>University College London</Sponsor><StudyType>Interventional</StudyType><Trial id="360104"/><TrialStartDate>2018-01-02 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry>African Ancestry</Ancestry><ArmCount>1+</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="53724">artenimol + piperaquine (malaria), Sigma-Tau</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>ARTEM-TB STUDY</ProtocolAcronym><ProtocolTitle>Evaluating Pharmacokinetic Interactions Between Artemisinin-Based Therapies and Rifampacin-Based Tuberculosis Treatment in African Patients</ProtocolTitle><Sponsor>Infectious Diseases Institute of Makerer University</Sponsor><StudyType>Interventional</StudyType><Trial id="142485"/><TrialStartDate>2013-01-31 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="2935">didanosine</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>SAPIT</ProtocolAcronym><ProtocolTitle>A Study to Compare Three Existing Starting Points of Antiretroviral Therapy (ART) Initiation in HIV/Tuberculosis (TB) Co-infected Patients</ProtocolTitle><Sponsor>Centre for the AIDS Program of Research in South Africa</Sponsor><StudyType>Interventional</StudyType><Trial id="201474"/><TrialStartDate>2005-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="3474">lamivudine</Drug><Endpoint>Safety,Efficacy,Bioavailability</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>PK-TB-HAART</ProtocolAcronym><ProtocolTitle>Bioavailability of the Fixed Dose Formulation Rifafour Containing Isoniazid, Rifampicin, Pyrazinamide, Ethambutol and the World Health Organization (WHO) Recommended First Line Antiretroviral Drugs Zidovudine, Lamivudine, Efavirenz Administered to New Tuberculosis (TB) Patients at Different Levels of Immunosuppression</ProtocolTitle><Sponsor>World Health Organization</Sponsor><StudyType>Interventional</StudyType><Trial id="136052"/><TrialStartDate>2006-05-29 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="3474">lamivudine</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>IPEC-EFV</ProtocolAcronym><ProtocolTitle>Randomized Clinical Trial to Assess the Efficacy and Safety of Concomitant Use of Rifampicin and Efavirenz 600 X  800 mg</ProtocolTitle><Sponsor>Fundacao Oswaldo Cruz (Fiocruz)</Sponsor><StudyType>Interventional</StudyType><Trial id="11181"/><TrialStartDate>2007-01-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="11458">Menitorix</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>BAM</ProtocolAcronym><ProtocolTitle>A Study of the Interaction Between BCG And MenC Immunization</ProtocolTitle><Sponsor>University of Oxford</Sponsor><StudyType>Interventional</StudyType><Trial id="162886"/><TrialStartDate>2014-06-20 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="5369">ribavirin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Antivirus Therapy for Population with HIV, HCV and TB Co-infection Clinical Trial</ProtocolTitle><Sponsor>Guangzhou eighth People's Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="162528"/><TrialStartDate>2009-05-01 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="4728">emtricitabine</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>Pred-ART</ProtocolAcronym><ProtocolTitle>Preventing TB-IRIS in High-risk Patients: a Randomized, Placebo-controlled Trial of Prednisone</ProtocolTitle><Sponsor>University of Cape Town</Sponsor><StudyType>Interventional</StudyType><Trial id="150793"/><TrialStartDate>2013-08-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7017">gatifloxacin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Multicenter, controlled clinical study of the safety, tolerability and efficacy of clofazimine in the treatment of drug-resistant tuberculosis</ProtocolTitle><Sponsor>Beijing Chest Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="328802"/><TrialStartDate>2009-12-01 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7017">gatifloxacin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Thrice-Weekly, 4- Months Moxifloxacin or Gatifloxacin Regimens for Pulmonary TB</ProtocolTitle><Sponsor>Indian Council of Medical Research</Sponsor><StudyType>Interventional</StudyType><Trial id="150332"/><TrialStartDate>2004-05-14 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="12543">ertapenem</Drug><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>PK/PD of Ertapenem in Patients with TB</ProtocolTitle><Sponsor>University Medical Center Groningen</Sponsor><StudyType>Interventional</StudyType><Trial id="98848"/><TrialStartDate>2017-01-26 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="10172">efavirenz</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>ANRS 1295 CAMELIA</ProtocolAcronym><ProtocolTitle>Early versus Late Introduction of Antiretroviral Therapy in HIV-infected Patients With Tuberculosis</ProtocolTitle><Sponsor>French National Agency for Research on AIDS and Viral Hepatitis</Sponsor><StudyType>Interventional</StudyType><Trial id="145651"/><TrialStartDate>2006-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="3700">nevirapine</Drug><Endpoint>Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Population Pharmacokinetics of Nevirapine in Combination With Rifampicin-Based Short Course Chemotherapy in HIV- and Tuberculosis-Infected South African Patients</ProtocolTitle><Sponsor>Uppsala University</Sponsor><StudyType>Interventional</StudyType><Trial id="149504"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="3700">nevirapine</Drug><Endpoint>Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Nevirapine Drug Levels in HIV Positive Patients Also Receiving Rifampicin for Tuberculosis</ProtocolTitle><Sponsor>Makerere University</Sponsor><StudyType>Interventional</StudyType><Trial id="11184"/><TrialStartDate>2008-05-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="3616">meropenem</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Phase II Trial to Evaluate the Early Bactericidal Activity, Safety and Tolerability of Meropenem Plus Amoxycillin/CA and Faropenem Plus Amoxycillin/CA in Adult Patients With Newly Diagnosed Pulmonary Tuberculosis</ProtocolTitle><Sponsor>Task Foundation NPC</Sponsor><StudyType>Interventional</StudyType><Trial id="220739"/><TrialStartDate>2014-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="52139">ofloxacin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Randomized Clinical Trial to Study the Efficacy and Tolerability of a 4-Month Regimen Containing Ofloxacin Compared to the Standard 6-Month Regimen in the Treatment of Patients with Superficial Lymphnode Tuberculosis</ProtocolTitle><Sponsor>Indian Council of Medical Research</Sponsor><StudyType>Interventional</StudyType><Trial id="142516"/><TrialStartDate>2012-10-20 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="2587">azithromycin</Drug><Endpoint>Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Azithromycin as Host-directed Therapy for Pulmonary Tuberculosis</ProtocolTitle><Sponsor>University Medical Center Groningen</Sponsor><StudyType>Interventional</StudyType><Trial id="298743"/><TrialStartDate>2018-02-01 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="11036">linezolid</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Safety, Tolerability, Pharmacokinetics And Measurement Of Whole Blood Activity (WBA) Of PNU-100480 After Multiple Oral Doses In Healthy Adult Volunteers</ProtocolTitle><Sponsor>Sequella Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="60906"/><TrialStartDate>2009-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="11036">linezolid</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>DRAMATIC</ProtocolAcronym><ProtocolTitle>Efficacy and Tolerability of Bedaquiline, Delamanid, Levofloxacin, Linezolid, and Clofazimine for Treatment of Patients With MDR-TB</ProtocolTitle><Sponsor>Boston University</Sponsor><StudyType>Interventional</StudyType><Trial id="368916"/><TrialStartDate>2020-01-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="11036">linezolid</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>A Phase III Study Assessing the Safety and Efficacy of Bedaquiline Plus PA-824 Plus Linezolid in Subjects With Drug-Resistant Pulmonary Tuberculosis</ProtocolTitle><Sponsor>TB Alliance</Sponsor><StudyType>Interventional</StudyType><Trial id="219499"/><TrialStartDate>2015-03-31 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="11036">linezolid</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Linezolid Instead of Ethambutol in Treatment of Drug-susceptible Tuberculosis</ProtocolTitle><Sponsor>Seoul National University Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="161831"/><TrialStartDate>2014-01-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="11036">linezolid</Drug><Endpoint>Safety</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>LiMiT</ProtocolAcronym><ProtocolTitle>Pilot Study Examining the Safety and Tolerability of Low Dose Linezolid in the Treatment of Multi-Drug Resistant Tuberculosis</ProtocolTitle><Sponsor>Centers for Disease Control and Prevention, Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="11219"/><TrialStartDate>2009-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="16696">lamivudine + zidovudine, GlaxoSmithKline</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>"NVP"</ProtocolAcronym><ProtocolTitle>Efficacy and Safety of Concomitant Use of Nevirapine and Rifampicin With HIV-TB</ProtocolTitle><Sponsor>All India Institute of Medical Sciences</Sponsor><StudyType>Interventional</StudyType><Trial id="114300"/><TrialStartDate>2007-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="3365">Actimmune</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>A phase III study to evaluate the safety and efficacy of aerosolized Actimmune for the treatment of pulmonary multidrug-resistant tuberculosis (MDR-TB) in patients who have failed a treatment regimen of anti-tuberculosis therapy</ProtocolTitle><Sponsor>InterMune Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="14945"/><TrialStartDate>2000-08-01 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>13</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="3492">levofloxacin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>A Prospective Study of Multidrug Resistance and a Pilot Study of the Safety of and Clinical and Microbiological Response to Levofloxacin in Combination With Other Antimycobacterial Drugs for Treatment of Multidrug-Resistant Pulmonary Tuberculosis (MDRTB) in HIV-Infected Patients</ProtocolTitle><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><StudyType>Interventional</StudyType><Trial id="8776"/><TrialStartDate>1998-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="3492">levofloxacin</Drug><Endpoint>Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>A study to evaluate the pharmacokinetics of levofloxacin in children who received levofloxacin-based tuberculosis preventive therapy</ProtocolTitle><Sponsor>Interactive Research and Development</Sponsor><StudyType>Interventional</StudyType><Trial id="380303"/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="3492">levofloxacin</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>TRUNCATE-TB</ProtocolAcronym><ProtocolTitle>A 2 Month Regimens Using Novel Combinations to Augment Treatment Effectiveness for Drug-Sensitive Tuberculosis</ProtocolTitle><Sponsor>Syneos Health Inc, University College London</Sponsor><StudyType>Interventional</StudyType><Trial id="333435"/><TrialStartDate>2018-03-21 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="3492">levofloxacin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Study of Adjunctive Recombinant Human Interleukin-2 Therapy in Patients With MDR-TB (rhIL-2)</ProtocolTitle><Sponsor>Jiangsu Provincial People’s Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="289837"/><TrialStartDate>2009-06-01 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="3492">levofloxacin</Drug><Endpoint>Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Population Pharmacokinetics and Pharmacodynamics Modeling to Optimize Dosage Regimen of Levofloxacin</ProtocolTitle><Sponsor>Prince of Songkla University</Sponsor><StudyType>Interventional</StudyType><Trial id="254949"/><TrialStartDate>2013-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="3492">levofloxacin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Optimization of MDR-TB Treatment Regimen Based on the Molecular Drug Susceptibility Results of Pyrazinamide</ProtocolTitle><Sponsor>Huashan Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="183613"/><TrialStartDate>2014-04-30 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="3492">levofloxacin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Is Levofloxacin Better Than Rifampicin in the Treatment of Tuberculous Meningitis- a Randomized, Control Study</ProtocolTitle><Sponsor>Sanjay Gandhi Postgraduate Institute of Medical Sciences</Sponsor><StudyType>Interventional</StudyType><Trial id="129005"/><TrialStartDate>2009-10-01 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="4229">rifabutin</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>EARNEST Rifabutin Pharmacokinetics (PK) Substudy</ProtocolTitle><Sponsor>Joint Clinical Research Centre, Medical Research Council</Sponsor><StudyType>Interventional</StudyType><Trial id="90175"/><TrialStartDate>2012-05-03 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="4229">rifabutin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Raltegravir + ABC/3TC in HIV/TB Co-Infected Patients</ProtocolTitle><Sponsor>Central Research Institute of Epidemiology</Sponsor><StudyType>Interventional</StudyType><Trial id="63729"/><TrialStartDate>2010-10-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="4229">rifabutin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>A self-controlled, single-center Taiwanese study to assess the efficacy and tolerability of rifabutin for re-treating chronic cases of multidrug-resistant pulmonary tuberculosis</ProtocolTitle><Sponsor>Pharmacia &amp; Upjohn AB</Sponsor><StudyType>Interventional</StudyType><Trial id="15897"/><TrialStartDate>1996-12-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>3+</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="4229">rifabutin</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>RIFART</ProtocolAcronym><ProtocolTitle>RIFART</ProtocolTitle><Sponsor>Azienda Ospedaliera Spedali Civili di Brescia</Sponsor><StudyType>Interventional</StudyType><Trial id="131240"/><TrialStartDate>2005-03-15 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="8658">rifalazil</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>A randomized, multiple-dose, open-label, phase II clinical study to evaluate the early bactericidal activity of rifalazil (PA-1648) and isoniazid (INH), as compared with INH alone or INH plus rifampin in patients with tuberculosis</ProtocolTitle><Sponsor>Chiron PathoGenesis</Sponsor><StudyType>Interventional</StudyType><Trial id="20175"/><TrialStartDate>1997-10-20 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="9490">MTB72F vaccine (tuberculosis), GSK/ IAVI</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Safety and Immunogenicity of GSK Biological's Candidate Tuberculosis Vaccine Mtb72F/AS02A in Healthy PPD-Positive Adults</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="9528"/><TrialStartDate>2005-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="9490">MTB72F vaccine (tuberculosis), GSK/ IAVI</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Immunogenicity and Safety of a Candidate Tuberculosis (TB) Vaccine Given to Healthy Adults in a TB-Endemic Region</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="11563"/><TrialStartDate>2008-02-29 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>TMC207TBC1003 - A Study in Healthy Volunteers Investigating the Effect of Single-Dose TMC-207 on the QT/QTc Interval Under Fed Conditions</ProtocolTitle><Sponsor>Janssen Diagnostics BVBA</Sponsor><StudyType>Interventional</StudyType><Trial id="74529"/><TrialStartDate>2011-02-28 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>RESWMEN</ProtocolAcronym><ProtocolTitle>Using econazole to attempt to shorten the duration of treatment in MDR tuberculosis</ProtocolTitle><Sponsor>Indian Council of Medical Research</Sponsor><StudyType>Interventional</StudyType><Trial id="374838"/><TrialStartDate>2019-05-01 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><Endpoint>Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>A prospective, single-centre pharmacokinetic study to develop population pharmacokinetic models for second-line drugs in patients with multi-drug-resistant tuberculosis, evaluate the recommended dosage regimens and, if necessary, suggest new dosage regimens</ProtocolTitle><Sponsor>Ministry of Health &amp; Welfare, Korea</Sponsor><StudyType>Interventional</StudyType><Trial id="304264"/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>STREAM</ProtocolAcronym><ProtocolTitle>The Evaluation of a Standard Treatment Regimen of Anti-Tuberculosis Drugs for Patients With MDR-TB</ProtocolTitle><Sponsor>International Union Against Tuberculosis and Lung Diseases</Sponsor><StudyType>Interventional</StudyType><Trial id="228190"/><TrialStartDate>2016-04-30 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="12978">moxifloxacin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>An open-label, comparative, multicenter trial to evaluate long-term tolerance and effectiveness of moxifloxacin therapy for tuberculosis</ProtocolTitle><Sponsor>Ospedale Ninetto Melli</Sponsor><StudyType>Interventional</StudyType><Trial id="113726"/><TrialStartDate>2003-02-28 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="13323">pretomanid</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="PR">Pre-registration</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Effect of PA-824 and of PA-824 Plus Moxifloxacin on the QTc Interval in Healthy Volunteers</ProtocolTitle><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><StudyType>Interventional</StudyType><Trial id="90512"/><TrialStartDate>2012-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="13323">pretomanid</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="PR">Pre-registration</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>ZeNiX</ProtocolAcronym><ProtocolTitle>Safety and Efficacy of Various Doses and Treatment Durations of Linezolid Plus Bedaquiline and Pretomanid in Participants With Pulmonary TB, XDR-TB, Pre-XDR-TB or Non-responsive/Intolerant MDR-TB</ProtocolTitle><Sponsor>TB Alliance</Sponsor><StudyType>Interventional</StudyType><Trial id="293734"/><TrialStartDate>2017-10-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="15102">rifapentine</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>TBTC S29B</ProtocolAcronym><ProtocolTitle>Pharmacokinetics, Safety and Tolerability of Escalating Rifapentine Doses in Healthy Volunteers</ProtocolTitle><Sponsor>Johns Hopkins University</Sponsor><StudyType>Interventional</StudyType><Trial id="68204"/><TrialStartDate>2010-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="15102">rifapentine</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Study of Daily Rifapentine for Pulmonary Tuberculosis</ProtocolTitle><Sponsor>Johns Hopkins University</Sponsor><StudyType>Interventional</StudyType><Trial id="39550"/><TrialStartDate>2010-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="15102">rifapentine</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Rifapentine-containing tuberculosis treatment shortening regimens (S31/A5349)</ProtocolTitle><Sponsor>Centers for Disease Control and Prevention</Sponsor><StudyType>Interventional</StudyType><Trial id="347338"/><TrialStartDate>2018-07-20 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="15102">rifapentine</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Taima TB: 3-HP Study</ProtocolTitle><Sponsor>Ottawa Hospital Research Institute</Sponsor><StudyType>Interventional</StudyType><Trial id="254050"/><TrialStartDate>2016-04-30 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="15102">rifapentine</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Intervention study in rural residents (50 to 70 years old) with latent Mycobacterium tuberculosis infection</ProtocolTitle><Sponsor>Chinese Academy of Medical Sciences &amp; Peking Union Medical College</Sponsor><StudyType>Interventional</StudyType><Trial id="243294"/><TrialStartDate>2014-01-01 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="15102">rifapentine</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Rifapentine-containing Tuberculosis Treatment Shortening Regimens</ProtocolTitle><Sponsor>Centers for Disease Control and Prevention</Sponsor><StudyType>Interventional</StudyType><Trial id="226815"/><TrialStartDate>2016-01-25 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="15102">rifapentine</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>TBTC-22</ProtocolAcronym><ProtocolTitle>TBTC Study 22: Efficacy of Once-Weekly Rifapentine and Isoniazid in Treatment of Tuberculosis</ProtocolTitle><Sponsor>Centers for Disease Control and Prevention</Sponsor><StudyType>Interventional</StudyType><Trial id="10650"/><TrialStartDate>1995-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="16545">delamanid</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Pharmacokinetic and Safety Trial to Determine the Appropriate Dose for Pediatric Patients With Multidrug Resistant Tuberculosis</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="132087"/><TrialStartDate>2013-06-14 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Drug id="31010">SQ-109</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Evaluation of SQ-109 Plus PPI in Urea Breath Test-Positive Volunteers</ProtocolTitle><Sponsor>Sequella Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="72716"/><TrialStartDate>2012-03-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="49162">LL-3858</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>A phase I study to evaluate the safety and pharmacokinetics of LL-3858</ProtocolTitle><Sponsor>Lupin Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="8931"/><TrialStartDate>2005-04-01 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="51310">bedaquiline</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>A Study to Evaluate the Efficacy and Safety of TMC-207 in Patients With Pulmonary Infection With Multi-drug Resistant Mycobacterium Tuberculosis</ProtocolTitle><Sponsor>Janssen Research &amp; Development LLC</Sponsor><StudyType>Interventional</StudyType><Trial id="87533"/><TrialStartDate>2014-03-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="51310">bedaquiline</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Early Access of TMC-207 in Patients With Extensively Drug Resistant or Pre-XDR Pulmonary Tuberculosis</ProtocolTitle><Sponsor>Janssen Diagnostics BVBA</Sponsor><StudyType>Interventional</StudyType><Trial id="82132"/><TrialStartDate>2011-09-16 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="51310">bedaquiline</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis</ProtocolTitle><Sponsor>TB Alliance</Sponsor><StudyType>Interventional</StudyType><Trial id="71046"/><TrialStartDate>2010-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="51310">bedaquiline</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>A Study to Investigate Pharmacokinetics, Safety and Tolerability of TMC-207 in Patients With Moderately Impaired Hepatic Function</ProtocolTitle><Sponsor>Janssen Diagnostics BVBA</Sponsor><StudyType>Interventional</StudyType><Trial id="61895"/><TrialStartDate>2010-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="51310">bedaquiline</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>A phase II, randomized, placebo-controlled study assessing the safety and efficacy of TMC-207 in patients with multidrug-resistant tuberculosis</ProtocolTitle><Sponsor>Johnson &amp; Johnson Pharmaceutical Research &amp; Development LLC</Sponsor><StudyType>Interventional</StudyType><Trial id="57685"/><TrialStartDate>2009-06-03 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="51310">bedaquiline</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>TMC207-TiDP13-C117: Interaction Study in Human Immunodeficiency Virus-type 1 (HIV-1) Infected Patients With Nevirapine (NVP)</ProtocolTitle><Sponsor>Janssen Diagnostics BVBA, Johnson &amp; Johnson</Sponsor><StudyType>Interventional</StudyType><Trial id="56959"/><TrialStartDate>2009-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="51310">bedaquiline</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>TMC207-TiDP13-C110: Interaction Study With Lopinavir/Ritonavir in Healthy Volunteer</ProtocolTitle><Sponsor>Janssen Diagnostics BVBA</Sponsor><StudyType>Interventional</StudyType><Trial id="42128"/><TrialStartDate>2009-02-28 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="51310">bedaquiline</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Study on Tuberculosis Resistant to Treatment</ProtocolTitle><Sponsor>Indian Council of Medical Research, Tuberculosis Research Centre</Sponsor><StudyType>Interventional</StudyType><Trial id="369747"/><TrialStartDate>2019-02-01 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="51310">bedaquiline</Drug><Endpoint>Safety,Bioequivalence,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>BDQ Crush</ProtocolAcronym><ProtocolTitle>TASK-002: Bioequivalence of Bedaquiline 400 mg Administered in Crushed Form Compared to Tablet Form in Healthy Male and Female Adults Under Fed Conditions</ProtocolTitle><Sponsor>International Maternal Pediatric Adolescent AIDS Clinical Trials Group</Sponsor><StudyType>Interventional</StudyType><Trial id="286376"/><TrialStartDate>2016-11-10 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="51310">bedaquiline</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>A study to investigate the safety and efficacy of bedaquiline and linezolid chemotherapy for extensively drug-resistant pulmonary tuberculosis within 6 months period</ProtocolTitle><Sponsor>Russian Academy of Sciences</Sponsor><StudyType>Interventional</StudyType><Trial id="280303"/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>2+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="51310">bedaquiline</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>An Exploratory Study of TMC-207 in Japanese Participants with Pulmonary Multi-Drug Resistant Tuberculosis (MDR-TB)</ProtocolTitle><Sponsor>Janssen Pharmaceutical KK</Sponsor><StudyType>Interventional</StudyType><Trial id="222400"/><TrialStartDate>2015-02-18 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>4+</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="51310">bedaquiline</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Pharmacokinetic Interaction Between Rifapentine or Rifampicin and a Single-dose of TMC-207 in Healthy Subjects</ProtocolTitle><Sponsor>TB Alliance</Sponsor><StudyType>Interventional</StudyType><Trial id="208141"/><TrialStartDate>2010-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="53975">AERAS-402</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Safety Study of Tuberculosis Vaccines AERAS-402 and MVA-85A</ProtocolTitle><Sponsor>University of Oxford</Sponsor><StudyType>Interventional</StudyType><Trial id="91280"/><TrialStartDate>2012-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="53975">AERAS-402</Drug><Endpoint>Safety</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>A phase I study to determine the safety of AERAS-402 in healthy adults, all of whom have been previously vaccinated with the Bacille Calmette-Guerin (BCG) vaccine and a subset of whom have evidence of having been exposed to tuberculosis</ProtocolTitle><Sponsor>Aeras Global TB Vaccine Foundation, Crucell NV, Kenya Medical Research Institute</Sponsor><StudyType>Interventional</StudyType><Trial id="59617"/><TrialStartDate>2008-10-17 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="53975">AERAS-402</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>A phase II, dose escalation study to determine the safety of AERAS-402 in adults who have had active tuberculosis</ProtocolTitle><Sponsor>South African Tuberculosis Vaccine Initiative, University of Cape Town</Sponsor><StudyType>Interventional</StudyType><Trial id="59557"/><TrialStartDate>2008-10-17 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="55173">cadi-05</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Efficacy and Safety of Immunomodulator as an Adjunct Therapy in New Pulmonary Tuberculosis (Category I) Patients</ProtocolTitle><Sponsor>Ministry of Science and Technology, India</Sponsor><StudyType>Interventional</StudyType><Trial id="10866"/><TrialStartDate>2007-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="55317">MVA-85A</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>A BCG Challenge Model Study to Assess Anti-mycobacterial Immunity Induced by BCG and a Candidate TB Vaccine, MVA-85A</ProtocolTitle><Sponsor>University of Oxford</Sponsor><StudyType>Interventional</StudyType><Trial id="69926"/><TrialStartDate>2010-05-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry>African Ancestry</Ancestry><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="55317">MVA-85A</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Efficacy Against TB Disease, Safety, and Immunogenicity of MVA-85A/AERAS-485 in HIV-Infected Adults</ProtocolTitle><Sponsor>Aeras Global TB Vaccine Foundation</Sponsor><StudyType>Interventional</StudyType><Trial id="67841"/><TrialStartDate>2011-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="55317">MVA-85A</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Study Evaluating Aerosol and Intradermal Administration of a Candidate Tuberculosis (TB) Vaccine, MVA-85A, as a Way to Increase Immune Response and Avoid Anti-Vector Immunity</ProtocolTitle><Sponsor>University of Oxford</Sponsor><StudyType>Interventional</StudyType><Trial id="156675"/><TrialStartDate>2013-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Drug id="57308">RUTI</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Safety of RUTI Vaccination in MDR-TB Patients</ProtocolTitle><Sponsor>Archivel Farma SL</Sponsor><StudyType>Interventional</StudyType><Trial id="256039"/><TrialStartDate>2019-01-01 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="61340">S-004992</Drug><Endpoint>Safety</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>A phase I study to evaluate S-004992 in patients with tuberculosis</ProtocolTitle><Sponsor>Shionogi &amp; Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="348025"/><TrialStartDate/><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Drug id="76307">delpazolid</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>A clinical trial of RMX-2001 in multidrug-resistant tuberculosis (MDR-TB) in USA</ProtocolTitle><Sponsor>HaiHe Pharmaceuticals Co Ltd, LegoChem Bioscience Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="370698"/><TrialStartDate/><TrialStatus>Planned</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="81363">AEC/BC02</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="PR">Pre-registration</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Freeze-dried recombinant tuberculosis vaccine (AEC/BC02) phase I clinical human tolerance test</ProtocolTitle><Sponsor>Anhui Zhifei Longcom Biopharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="329497"/><TrialStartDate/><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="85970">telacebec</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Open, phase I clinical trial to evaluate the safety, tolerability and pharmacokinetic parameters of Q-203 after single and multiple doses in healthy volunteers</ProtocolTitle><Sponsor>Infectex</Sponsor><StudyType>Interventional</StudyType><Trial id="255234"/><TrialStartDate>2016-01-12 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="87251">Perchlozone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Multicenter, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy and safety of the drug Perhlozone in the treatment of patients with pulmonary MDR MBT, including the presence of HIV infection</ProtocolTitle><Sponsor>Pharmasyntez</Sponsor><StudyType>Interventional</StudyType><Trial id="183939"/><TrialStartDate>2014-04-08 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="91861">clofazimine (oral, tuberculosis), Novartis</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>RESWMEN</ProtocolAcronym><ProtocolTitle>Using econazole to attempt to shorten the duration of treatment in MDR tuberculosis</ProtocolTitle><Sponsor>Indian Council of Medical Research</Sponsor><StudyType>Interventional</StudyType><Trial id="374838"/><TrialStartDate>2019-05-01 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="91861">clofazimine (oral, tuberculosis), Novartis</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Clofazimine treatment of multidrug-resistant tuberculosis (MDRTB)</ProtocolTitle><Sponsor>Novartis AG</Sponsor><StudyType>Interventional</StudyType><Trial id="284370"/><TrialStartDate>2016-03-01 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>4</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="98013">isoniazid + rifampicin + pyrazinamide + ethambutol</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Using electronic monitors and a smartphone app to improve treatment adherence of new pulmonary tuberculosis patients in Tibet, China</ProtocolTitle><Sponsor>The Chinese Centre for Disease Control and Prevention</Sponsor><StudyType>Interventional</StudyType><Trial id="359917"/><TrialStartDate>2018-09-01 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="14681">lopinavir + ritonavir</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>EARNEST Rifabutin Pharmacokinetics (PK) Substudy</ProtocolTitle><Sponsor>Joint Clinical Research Centre, Medical Research Council</Sponsor><StudyType>Interventional</StudyType><Trial id="90175"/><TrialStartDate>2012-05-03 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="14681">lopinavir + ritonavir</Drug><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>A Bioavailability Study of Rifabutin and Lopinavir/Ritonavir in Healthy Adult Subjects</ProtocolTitle><Sponsor>Abbott Laboratories</Sponsor><StudyType>Interventional</StudyType><Trial id="25327"/><TrialStartDate>2008-08-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="12132">albendazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Deworming Against Tuberculosis</ProtocolTitle><Sponsor>Linkoping University</Sponsor><StudyType>Interventional</StudyType><Trial id="48176"/><TrialStartDate>2009-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>8</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="12132">albendazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>TB-LION</ProtocolAcronym><ProtocolTitle>Tuberculosis - Learning the Impact of Nutrition</ProtocolTitle><Sponsor>Boston Medical Center Corp</Sponsor><StudyType>Interventional</StudyType><Trial id="347635"/><TrialStartDate>2019-06-30 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="4481">stavudine</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>ANRS 1295 CAMELIA</ProtocolAcronym><ProtocolTitle>Early versus Late Introduction of Antiretroviral Therapy in HIV-infected Patients With Tuberculosis</ProtocolTitle><Sponsor>French National Agency for Research on AIDS and Viral Hepatitis</Sponsor><StudyType>Interventional</StudyType><Trial id="145651"/><TrialStartDate>2006-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="3474">lamivudine</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>REFLATE TB</ProtocolAcronym><ProtocolTitle>Efficacy and Safety of Two Raltegravir Doses in Naive HIV-1-Infected Patients Receiving Rifampin for Active Tuberculosis</ProtocolTitle><Sponsor>French National Agency for Research on AIDS and Viral Hepatitis</Sponsor><StudyType>Interventional</StudyType><Trial id="40948"/><TrialStartDate>2009-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="3474">lamivudine</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>REFLATE TB2</ProtocolAcronym><ProtocolTitle>Raltegravir Versus Efavirenz in Naive HIV-1-infected Patients Receiving Rifampin for Active Tuberculosis</ProtocolTitle><Sponsor>INSERM</Sponsor><StudyType>Interventional</StudyType><Trial id="214156"/><TrialStartDate>2015-09-30 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="44406">imipenem + cilastatin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>InDEX</ProtocolAcronym><ProtocolTitle>The Individualized M(X) Drug-resistant TB Treatment Strategy Study</ProtocolTitle><Sponsor>Centre for the AIDS Program of Research in South Africa</Sponsor><StudyType>Interventional</StudyType><Trial id="307654"/><TrialStartDate>2017-06-14 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="49219">tenofovir disoproxil fumarate + emtricitabine (fixed dose), Gilead Sciences</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>TEMPRANO</ProtocolAcronym><ProtocolTitle>Early Antiretroviral Treatment and/or Early Isoniazid Prophylaxis Against Tuberculosis in HIV-Infected Adults</ProtocolTitle><Sponsor>French National Agency for Research on AIDS and Viral Hepatitis</Sponsor><StudyType>Interventional</StudyType><Trial id="195741"/><TrialStartDate>2008-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="4728">emtricitabine</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>IMPAACT4TB</ProtocolAcronym><ProtocolTitle>Safety, Tolerability DDI Short Course Treatment of LTBI Infection With High-dose Rifapentine Isoniazid in HIV+ Patients</ProtocolTitle><Sponsor>Aurum Institute</Sponsor><StudyType>Interventional</StudyType><Trial id="329251"/><TrialStartDate>2018-01-18 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C0">Phase 0 Clinical</DevStatus><Drug id="4728">emtricitabine</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>TasP in Correctional Facilities</ProtocolTitle><Sponsor>University of North Carolina</Sponsor><StudyType>Interventional</StudyType><Trial id="280225"/><TrialStartDate>2016-02-01 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="12813">Rotarix</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>BAM</ProtocolAcronym><ProtocolTitle>A Study of the Interaction Between BCG And MenC Immunization</ProtocolTitle><Sponsor>University of Oxford</Sponsor><StudyType>Interventional</StudyType><Trial id="162886"/><TrialStartDate>2014-06-20 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="44370">clindamycin</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>Staph</ProtocolAcronym><ProtocolTitle>Pharmacokinetics of Antistaphylococcal Antibiotics in Infants</ProtocolTitle><Sponsor>Duke University</Sponsor><StudyType>Interventional</StudyType><Trial id="98566"/><TrialStartDate>2013-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="13624">BCG vaccine, Organon</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>A Clinical Challenge Study of BCG in Healthy Volunteers</ProtocolTitle><Sponsor>University of Oxford</Sponsor><StudyType>Interventional</StudyType><Trial id="177982"/><TrialStartDate>2014-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3+</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="10172">efavirenz</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>BRIEF TB</ProtocolAcronym><ProtocolTitle>Brief Rifapentine-Isoniazid Evaluation for TB Prevention</ProtocolTitle><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><StudyType>Interventional</StudyType><Trial id="79741"/><TrialStartDate>2012-05-23 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="10172">efavirenz</Drug><Endpoint>Safety</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>TIME</ProtocolAcronym><ProtocolTitle>Appropriate Timing of HAART in Co-infected HIV/TB Patients</ProtocolTitle><Sponsor>Bamrasnaradura Infectious Diseases Institute</Sponsor><StudyType>Interventional</StudyType><Trial id="61991"/><TrialStartDate>2009-10-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C0">Phase 0 Clinical</DevStatus><Drug id="10172">efavirenz</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>TasP in Correctional Facilities</ProtocolTitle><Sponsor>University of North Carolina</Sponsor><StudyType>Interventional</StudyType><Trial id="280225"/><TrialStartDate>2016-02-01 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="10172">efavirenz</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>PrOMPT</ProtocolAcronym><ProtocolTitle>Prevention of Early Mortality by Presumptive Tuberculosis (TB) Treatment</ProtocolTitle><Sponsor>University of Amsterdam</Sponsor><StudyType>Interventional</StudyType><Trial id="182316"/><TrialStartDate>2011-08-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="10172">efavirenz</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>RIFAVIRENZ</ProtocolAcronym><ProtocolTitle>Interaction Between High-Dose Rifampicine and Efavirenz in Pulmonary Tuberculosis and HIV Co-infection</ProtocolTitle><Sponsor>INSERM</Sponsor><StudyType>Interventional</StudyType><Trial id="161096"/><TrialStartDate>2013-12-31 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="10172">efavirenz</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>HIV-TB Pharmagene</ProtocolAcronym><ProtocolTitle>Optimization of Tuberculosis and HIV Co-treatment in Africa</ProtocolTitle><Sponsor>Karolinska Institutet</Sponsor><StudyType>Interventional</StudyType><Trial id="131419"/><TrialStartDate>2008-01-09 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>4+</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="10172">efavirenz</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Once-Daily Dose of Nevirapine (400 mg) Versus Twice Daily Dose (200 mg) of Nevirapine in HIV and Tuberculosis Infection</ProtocolTitle><Sponsor>National AIDS Control Organization</Sponsor><StudyType>Interventional</StudyType><Trial id="126486"/><TrialStartDate>2012-09-01 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>4+</ArmCount><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="44384">ceftriaxone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>EMPIRICAL</ProtocolAcronym><ProtocolTitle>Empirical Treatment Against Cytomegalovirus and Tuberculosis in HIV-infected Infants With Severe Pneumonia</ProtocolTitle><Sponsor>Hospital Universitario 12 de Octubre</Sponsor><StudyType>Interventional</StudyType><Trial id="377163"/><TrialStartDate>2020-01-01 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="3700">nevirapine</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Efficacy of Thrice Weekly Directly Observed Treatment, Short-course (DOTS) in HIV-associated Tuberculosis</ProtocolTitle><Sponsor>All India Institute of Medical Sciences</Sponsor><StudyType>Interventional</StudyType><Trial id="161275"/><TrialStartDate>2006-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="44284">amoxicillin + clavulanate potassium, GSK</Drug><Endpoint>Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Whole Blood Bactericidal Activity (WBA) Against Mycobacterium Tuberculosis of Faropenem Plus Amoxicillin/Clavulanic Acid in Healthy Volunteers</ProtocolTitle><Sponsor>National University Hospital (Singapore) Pte Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="224811"/><TrialStartDate>2015-02-28 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>5+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="44284">amoxicillin + clavulanate potassium, GSK</Drug><Endpoint>Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Trial of Faropenem and Cefadroxil (in Combination With Amoxicillin/Clavulanic Acid and Standard TB Drugs) in Patients With Pulmonary Tuberculosis: Measurement of Early Bactericidal Activity and Effects on Novel Biomarkers</ProtocolTitle><Sponsor>National University Hospital (Singapore) Pte Ltd, Syneos Health Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="224111"/><TrialStartDate>2018-12-31 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="4567">etanercept</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Risk of Tuberculosis and Other Infections in Patients of Spondyloarthritis Treated With Tofacitinib in Bangladesh</ProtocolTitle><Sponsor>Bangabandhu Sheikh Mujib Medical University</Sponsor><StudyType>Interventional</StudyType><Trial id="337163"/><TrialStartDate>2018-01-16 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Drug id="3616">meropenem</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Early Bactericidal Activity of Rifampin + Meropenem + Amoxicillin/Clavulanate in Adults With Pulmonary TB</ProtocolTitle><Sponsor>Johns Hopkins University</Sponsor><StudyType>Interventional</StudyType><Trial id="300655"/><TrialStartDate>2017-08-23 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>5+</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="11036">linezolid</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>endTB-Q</ProtocolAcronym><ProtocolTitle>Evaluating Newly Approved Drugs in Combination Regimens for Multidrug-Resistant TB With Fluoroquinolone Resistance</ProtocolTitle><Sponsor>Médecins Sans Frontières France</Sponsor><StudyType>Interventional</StudyType><Trial id="375499"/><TrialStartDate>2019-06-30 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="11036">linezolid</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>TRUNCATE-TB</ProtocolAcronym><ProtocolTitle>A 2 Month Regimens Using Novel Combinations to Augment Treatment Effectiveness for Drug-Sensitive Tuberculosis</ProtocolTitle><Sponsor>Syneos Health Inc, University College London</Sponsor><StudyType>Interventional</StudyType><Trial id="333435"/><TrialStartDate>2018-03-21 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="11036">linezolid</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>DAZZLE</ProtocolAcronym><ProtocolTitle>Efficacy and Tolerability of Delamanid, Linezolid, Pyrazinamide and Levofloxacin</ProtocolTitle><Sponsor>Boston University</Sponsor><StudyType>Interventional</StudyType><Trial id="280651"/><TrialStartDate>2017-08-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="11036">linezolid</Drug><Endpoint>Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>LINEZOLIDE</ProtocolAcronym><ProtocolTitle>Pharmacokinetic and Therapeutic Adaptation of Linezolid in the Treatment of Multi-Resistant Tuberculosis</ProtocolTitle><Sponsor>Groupe Hospitalier Paris Saint-Joseph</Sponsor><StudyType>Interventional</StudyType><Trial id="261481"/><TrialStartDate>2015-11-04 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="11036">linezolid</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Drug Interaction Study Between Linezolid and Clarithromycin in Tuberculosis Patients</ProtocolTitle><Sponsor>University Medical Center Groningen</Sponsor><StudyType>Interventional</StudyType><Trial id="182646"/><TrialStartDate>2011-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="34281">Prevnar 13</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>BAM</ProtocolAcronym><ProtocolTitle>A Study of the Interaction Between BCG And MenC Immunization</ProtocolTitle><Sponsor>University of Oxford</Sponsor><StudyType>Interventional</StudyType><Trial id="162886"/><TrialStartDate>2014-06-20 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="54488">raltegravir</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym>REFLATE TB2</ProtocolAcronym><ProtocolTitle>Raltegravir Versus Efavirenz in Naive HIV-1-infected Patients Receiving Rifampin for Active Tuberculosis</ProtocolTitle><Sponsor>INSERM</Sponsor><StudyType>Interventional</StudyType><Trial id="214156"/><TrialStartDate>2015-09-30 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="12420">rosuvastatin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Effect of rosuvastatin on HIV TB coinfection</ProtocolTitle><Sponsor>Armed Forces Medical College</Sponsor><StudyType>Interventional</StudyType><Trial id="292154"/><TrialStartDate>2017-04-01 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>5+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="4492">faropenem</Drug><Endpoint>Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>Trial of Faropenem and Cefadroxil (in Combination With Amoxicillin/Clavulanic Acid and Standard TB Drugs) in Patients With Pulmonary Tuberculosis: Measurement of Early Bactericidal Activity and Effects on Novel Biomarkers</ProtocolTitle><Sponsor>National University Hospital (Singapore) Pte Ltd, Syneos Health Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="224111"/><TrialStartDate>2018-12-31 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7310">ritonavir</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="221">Mycobacterium tuberculosis infection</Indication><ProtocolAcronym/><ProtocolTitle>A prospective, open-label, pilot study to evaluate the pharmacokinetics (PK)/safety/efficacy of an adjusted dose of indinavir/ritonavir (IDV/r) 600/100 mg plus two nucleoside reverse transcriptase inhibitors (NRTIs) in HIV/TB-coinfected Thais receiving rifampicin-based anti-TB treatment</ProtocolTitle><Sponsor>Thai Red Cross AIDS Research Centre</Sponsor><StudyType>Interventional</StudyType><Trial id="100728"/><TrialStartDate>2012-01-17 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row></Rowset>